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Abstract
Lung cancer is the leading cause of cancer related deaths worldwide. Major
contributing factors include asymptomatic disease progression and a high level of intra-
and intertumour genomic, molecular, and microenvironmental heterogeneity. Large lung
cancer sequencing efforts have identified clear histopathology-specific genetic alteration
patterns,  which  in  the  cases  of  lung  adenocarcinomas  (ACs)  are  applied  in  clinics  to
direct treatment. Unfortunately, in most patients acquired resistance to targeted treatment
often develops within months. Recently, lung cancer immunotherapy approaches have
shown promising results in clinical trials. However, a need for further development and
accurate patient stratification to better counter the variability seen in the lung cancer
immune microenvironment exists. Hence, a deeper understanding of the functional
importance of novel lung cancer genes as well as the lung cancer-related niche and cell
type specific propensities leading to molecular and microenvironmental tumour
heterogeneity would be beneficial.
The first part of this thesis work concentrated on the functional in vitro and in vivo
investigation of putative tumour suppressive characteristics of the EPH receptor A3
(EPHA3), a gene commonly mutated in human lung cancers. Our finding that silencing
of EPHA3 induces cellular senescence, a cell intrinsic mechanism for tumour
suppression, prompted us to further validate its tumour suppressive characteristics. An in
vitro kinase assay-based investigation of EPHA3 cancer point mutations indicated that
EPHA3-mediated tumour suppression was specifically dependent on its kinase activity.
However, we found that constitutive loss of EphA3 did not co-operate with two known
genetic alterations of human lung cancer, namely conditional oncogenic Kras or Trp53-
loss, in murine lung tumourigenesis. Moreover, we did not find any defects in lung
morphogenesis due to EphA3-loss, despite its expression being detected in developing
murine lung mesenchyme. Hence, we conclude that our study demonstrates how
functional validation of putative cancer genes can be challenged by biological
complexity, which may result in acquired compensation or different functional roles in
human and mice.
The second part of this thesis work investigated the propensities of the in vivo lung
proximal and peripheral niche and lung epithelial cell types to respond to known lung
cancer genetic alterations, namely conditional oncogenic Kras combined with loss of a
tumour suppressor Lkb1 (KL).  Our  results  showed  that  cells  in  the  airways  of  mouse
lungs had a higher propensity to develop faster growing and progressing lung tumours
than the cells in the alveolar space. These lung tumours, which were predominantly
classified as adenosquamous carcinomas (ASCs), showed elevated levels of immune
related genes, suggesting an ASC-specific immunosuppressive microenvironment. This
conclusion was further supported by a notable ASC-specific immune cell infiltration
12
with an increase in the amount of myeloid cells, possibly representing a subpopulation of
myeloid-derived suppressor cells (MDSCs) and decrease in the amount of tumour-
infiltrating T-cells. The KL ASC model may thus represent a relevant preclinical model
for the study of anti-MDSC immune therapy as a treatment for ASCs, which in humans
represent a rare but aggressive type of lung cancer.
Thus, the findings presented in this thesis highlight the importance of the functional
niche in the progression of lung cancer and, therefore, possibly affecting a response to
treatment. Niche-specific investigation of lung cancer genetic alterations thus leads to a
more accurate stratification of the preclinical in vivo models, simultaneously revealing
relevant molecular mechanisms underlying lung cancer heterogeneity.
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Tiivistelmä
Keuhkosyöpä on maailmanlaajuisesti eniten kuolemaan johtava syöpäsairaus, jonka
hoito on aina yksilöllistä riippuen muun muassa syövän tyypistä ja levinneisyydestä.
Huolimatta uusimmista keuhkosyövän hoitomuodoista, joilla pyritään vaikuttamaan
kohdennetusti tiettyjen geenimutaatioiden aiheuttamaan pahalaatuisen syöpäkudoksen
kasvuun, ei riittävän hyviä potilaan parantumiseen johtavia hoitoja ole vielä keksitty.
Tämän ajatellaan johtuvan muun muassa yksittäisen syöpäkudoksen sisäisestä tai
syöpäkasvainten välillä olevasta heterogeenisyydestä eli siitä, että syöpäsolut poikkeavat
toisistaan ja reagoivat siksi eritavalla syöpähoitoihin. Laajat keuhkosyövän DNA-
sekvensointitutkimukset ovat tunnistaneet valtavan määrän uusia mutaatiota, jotka ovat
oletettavasti vaikuttaneet tutkittujen syöpien kehittymiseen. Näiden geneettisten
muutosten syvempi toiminnallinen ymmärtäminen on tärkeää, jotta voimme paremmin
käyttää hyväksi tätä suurta määrää uutta tietoa kehittäessämme uusia hoitomuotoja
syöpiin.
Keuhkosyövät luokitellaan histopatologisesti kahteen pääluokkaan, ei-pienisoluisiin
ja pienisoluisiin keuhkosyöpiin. Ei-pienisoluisten keuhkosyöpien, joiden esiintyvyys on
noin 85% kaikista keuhkosyövistä, kaksi yleisintä alaluokkaa ovat adenokarsinooma
(~60%) ja levyepiteelikarsinooma (~30%), joiden diagnostiset tutkimukset ja hoitolinjat
poikkeavat toisistaan. Potilaan oman immuunipuolustuksen valjastaminen
syöpäkasvainta vastaan on syövän hoitomuotona keksitty jo 1900-luvun alussa, mutta
vasta viimeaikaiset tutkimukset ovat selvittäneet immuunipuolustukseen liittyvää
kasvaimen mikroympäristön ja molekyylisäätelyn taustaa.
Tämän väitöskirjatyön tavoitteena oli selvittää useissa keuhkosyövissä
mutatoituneen EPH-reseptori A3- (EPHA3) geenin osuutta keuhkosyövän synnyssä ja
etenemisessä, sekä tutkia kyseisen geenin toimintaa keuhkon kehityksessä.
Tutkimustuloksemme osoittavat, että EPHA3-geenin ilmentymisen väheneminen
soluissa johtaa senesenssiin eli solun palautumattomaan lepotilaan. Tämän mekanismin
on osoitettu toimivan solujen luontaisena keinoina puolustautua normaalista poikkeavaa
kasvua vastaan. Jatkotutkimuksemme osoittivat, että keuhkosyöpäsoluista löytyneet
EPHA3-geenin mutaatiot vähentävät EPHA3-proteiinin kinaasiaktiivisuutta, tukien
EPHA3-geenin syövän kasvua estävää eli tuumorisuppressivista tehtävää soluissa.
Keuhkosyöpähiirimalleilla saadut tuloksemme eivät kuitenkaan tukeneet EPHA3-geenin
tuumorisuppressivista toimintaa. Lisäksi, vaikka EPHA3-proteiinin osoitettiin
ilmentyvän hiiren alkion keuhkojen mesenkymaalisissa soluissa, EphA3-poistogeenisten
hiirten alkioiden keuhkojen havaittiin kehittyvän normaalisti. Näiden in vivo hiirimallista
saatujen tulosten perusteella teimme johtopäätöksen, että hiiren EphA3- geenin poisto
voi esimerkiksi johtaa saman geeniperheen geenien ilmentymisen aikaansaamaan
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kompensaatioon ja/tai EPHA3-geenin poistolla voi olla eri merkitys hiirelle kuin
ihmiselle.
Toinen tämän väitöskirjatyön tavoite oli tutkia eri keuhkosolutyyppien alttiutta
kehittyä ei-pienisoluisen keuhkosyövän eri histopatologiatyypeiksi.
Tutkimustuloksemme keuhkosyöpähiirimallilla, jossa tunnettujen keuhkosyöpägeenien,
KRAS ja LKB1, muutokset aikaansaavat ei-pienisoluisen keuhkosyövän synnyn,
osoittivat, että keuhkojen kahdella eri solutyypillä on erilainen alttius kehittyä
adenoskvamoosi karsinoomaksi. Ihmisellä adenoskvamoosi karsinooma on harvinainen,
mutta aggressiivinen keuhkosyöpätyyppi. Tutkimustuloksemme osoittivat, että
keuhkosyöpähiirimallin adenoskvamooseissa karsinoomissa, joiden havaittiin kasvavan
nopeammin kuin adenokarsinoomien, on immuunipuolustuksen vaimentamiseen
viittaava immuunisoluympäristö. Tämän on osoitettu liittyvän syövän huonoon
ennusteeseen. Tulevaisuudessa kyseistä hiirimallia voidaan mahdollisesti käyttää uusien
potilaan omaa immuunipuolustusta hyväksi käyttävien hoitomuotojen kehityksessä.
Tämä väitöskirjatyö on tuottanut merkittävää uutta tietoa EPHA3-geenin
toiminnallisesta tehtävästä syövässä, jonka valossa kyseiseen geeniin liittyvää
syöpätutkimusta pystytään ohjaamaan tulevaisuudessa oikeaan suuntaan. Lisäksi tämä
väitöskirjatyö avasi uusia näkökulmia keuhkosyövän heterogeenisyyteen johtavista
tekijöistä sekä osoitti aggressiivisen keuhkosyöpätyypin mahdollisesti omaavan erityisen




Cancer is a disease caused by rapid and abnormal expansion of cells growing
beyond their normal tissue boundaries. Cancer can affect any part of the body, invade
neighbouring tissues, and/or spread to distant organs via a process called metastasis.
Cancer is among the leading cause of morbidity and mortality worldwide (Stewart et al.,
2014).
Cancerous growth of cells is caused by genetic errors in genes normally regulating
tissue homeostasis. These errors can be inherited or occur sporadically due to exposure
to environmental agents, such as ultraviolet radiation, components of tobacco smoke,
and infections by specific viruses. Cancer-causing genetic alterations functionally either
promote cellular growth or inhibit it and are referred to as oncogenes and tumour
suppressor genes, respectively. The multistep process that leads to development of
malignant cancer is composed of acquired biological capabilities of the cancer cells,
generally referred to as ‘hallmarks of cancer’. These capabilities include sustaining
proliferative signalling, evading growth suppression and cell death, enabling replicative
immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming
of energy metabolism, and evading immune destruction (Hanahan and Weinberg, 2000,
2011).
Cellular senescence is a cell-intrinsic mechanism to arrest cell growth, and its bypass
is considered one of the cancer hallmarks (Hanahan and Weinberg, 2000, 2011). In
embryonic development and normal physiology, senescence takes part in tissue
remodelling and removal of damaged cells (Munoz-Espin et al., 2013; Munoz-Espin and
Serrano, 2014; Storer et al., 2013). Replicative senescence, which acts as a mechanism
to protect cells from unlimited proliferation, is triggered by DNA damage to allow DNA
repair during the DNA damage response (DDR) (Campisi and d'Adda di Fagagna, 2007;
Evan and d'Adda di Fagagna, 2009). The mechanisms that lead to cellular senescence are
context-dependent. In general, induction of cellular senescence is mediated by up-
regulation of cell cycle inhibitors including cyclin-dependent kinase inhibitors (CDKIs)
p21 (encoded by CDKN1A) and p16INK4a (encoded by CDKN2A), and often up-
regulation and activation of transcription factor p53 (encoded by TP53 in humans and
Trp53 in mice) (Munoz-Espin and Serrano, 2014). Recently, it has been also reported
that senescent cells acquire a pro-inflammatory senescence-associated secretory
phenotype (SASP), which can affect neighbouring cells in a paracrine manner and
trigger responses including inflammation. This response leads to elimination of
senescent cells as well as promotion of cell growth (Munoz-Espin and Serrano, 2014;
Rodier and Campisi, 2011). Thus, cellular senescence has pleiotropic effects on tissue
homeostasis.
The tumour suppressive role of cellular senescence is demonstrated both in vitro and
in vivo. Expression of the constitutively active, oncogenic small guanosine
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triphosphatase HRAS (harvey rat sarcoma viral oncogene homolog) in murine and
human cells induces cellular senescence (Serrano et al., 1997). This process is named
oncogene-induced senescence (OIS). In vivo, OIS is detected in lung lesions induced by
oncogenic Kras (Kirsten rat sarcoma viral oncogene homolog) and oncogenic BRAF, a
downstream effector of Ras (Collado et al., 2005; Dankort et al., 2007). In both cases,
OIS, characterised by expression of p16INK4a and senescence-associated β-galactosidase
(SA-β-gal) positivity, is bypassed in the more progressed AC lesions or by introduction
of p53- or p16INK4a-loss. Additionally, loss of the tumour suppressor phosphatase and
tensin homologue (Pten) in mouse prostate induces p53-dependent cellular senescence,
which is bypassed with inactivation of p53 (Chen et al., 2005). Taken together, OIS acts
as  a  mechanism  to  suppress  tumourigenesis,  initiated  by  an  oncogene  or  by  loss  of  a
tumour suppressor gene. Furthermore, acquired bypass of OIS with alterations in genes
such as TP53 and CDKN2A may be needed for cancers to progress.
The development of malignant cancer is characterised by aberrant activation or
deactivation of molecules generally regulating embryonic development. An example is
observed with the members of the EPH receptor family (Nievergall et  al., 2012).
Specifically, concepts gained with studies exploring mechanisms of developmental
biology can be crucial in understanding the functional importance of cancer-promoting
genetic alterations. Furthermore, the tissue-specific niches in adult organs, which are
composed of cells specialised to control physiologically distinct processes, are crucial
determinants of cancer heterogeneity (Leeman et al., 2014). In lungs, different parts of
the proximo-distal axis are highly specialised for maintenance of organ homeostasis,
enabling uninterrupted respiration providing oxygen to and removing carbon dioxide
from the body. The lung injury model-based identification of lung epithelial stem and
progenitors cells and following progenitor cell specific modulation of genes have
revealed new insights to several lung pathologies including lung cancer (Leeman  et al.,
2014; Sutherland and Berns, 2010; Sutherland et al., 2014).
Lung cancer is the leading cause of cancer-related deaths worldwide (Ferlay et al.,
2015). It is characterised by high levels of genetic, epigenetic, and histopathological
tumour heterogeneity within and between the lung tumours. In addition to heterogeneity
detected in the epithelial tumour cell compartment, cancer heterogeneity is also detected
within the tumour microenvironment, which includes tumour-infiltrating innate immune
cells, such as natural killer cells, macrophages, and neutrophils, as well as adaptive
immune cells including B- and T-lymphocytes (de Visser et  al., 2006; Hanahan and
Coussens, 2012). Recently, much progress has been made applying  cancer
immunotherapy approaches in which the patient’s own immune system is harnessed
against the cancer cells (Wolchok and Chan, 2014). Inhibition of molecules which
cancer cells use to escape from an immune attack, in combination with standard
chemotherapy treatment, is being pursued in clinical trials and showing promising results
(Creelan, 2014). Thus, there is a need for a deeper understanding of the functional
importance of novel lung cancer genes as well as the molecular and microenvironmental
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tumour heterogeneity caused by factors including lung cancer related niche and cell type
specific propensities.
This thesis work concentrated on the in vitro and in vivo investigation of the
functional tumour suppressor role of the EPH receptor A3 (EPHA3) gene, a result from a
cellular senescence screen executed to identify novel putative tumour suppressors. Since
EPHA3 is commonly mutated in human lung cancers, the work presented in this thesis
focused on the in vivo role of EPHA3 in lung cancer development. Considering the well-
established roles of EPH receptors in embryonic development, the possible role of
EphA3 in mouse lung morphogenesis was addressed with the aim to gain biological
insight into its putative function during lung cancer progression. Finally, this thesis work
established the differential contributions of in vivo lung proximal and peripheral niches,
and specific epithelial cell progenitor types, to growth of murine NSCLC. Using a
murine NSCLC model driven by known lung cancer drivers, namely oncogenic Kras and
loss of the tumour suppressor Lkb1, the investigation of lung progenitor cell niche-
specific tumour heterogeneity analysed lung lesion-specific immunosuppressive
mechanisms and established a link between the tumour histopathology spectrum and the
immune microenvironment.
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2 Review of the literature
2.1 The lung
The lung is a complex organ with a primary function to provide oxygen and remove
carbon dioxide from the body. Different parts of the lung are highly specialized for
maintaining organ homeostasis and enabling uninterrupted flow of gasses.  The lung
belongs to the group of organs that have a low steady-state cell turnover but can robustly
respond to injury and repair damaged tissue. During recent years excellent progress has
been made through murine studies to gain information about the composition and
organization of the distinct epithelial cell populations of mouse lung, (Leeman et al.,
2014) which in many aspects resemble the composition of the cells in human lung (Rock
et al., 2010). Much work has focused on the identification of lung epithelial stem and
progenitors cells, key players of normal lung tissue homeostasis.  Dysfunction of these
cells is likely the cause of several lung pathologies such as chronic obstructive
pulmonary disease (COPD), asthma, and lung cancer (Leeman et al., 2014) (for literature
review of lung cancer see section 2.3.1.4). Therefore, current mechanistic studies are
focusing on the functional differences between the distinct epithelial stem and progenitor
cells of the lung to better understand the aetiology of these lung diseases.
2.1.1 Structure and cell types of the lung
The lung consists of conducting proximal airways and gas-exchanging distal
alveolar space that is surrounded by a dense capillary network. The proximal airways are
composed of cartilaginous trachea, which in mice is lined by pseudostratified columnar
epithelial cells and noncartilaginous bronchioles, made of simple columnar epithelium.
The epithelial cells in the distal alveolar space form the gas-exchanging alveolar
structures. The epithelial cell types in the proximo-distal axis of the lungs vary and are
highly specialised to carry out functions needed for the maintenance of the tissue
homeostasis and/or defence against inhaled harmful gases, particulates, and
microorganisms, as well as the gas-exchanging process (Figure 1). Lung cell types with
mesenchymal origin and resident to the epithelial and endothelial cells, take part in
respiration and contribute to the maintenance of the airway, alveolar structures, and stem
cell  niches,  as  well  as  support  the  formation  of  a  capillary  network (Barkauskas et al.,
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2013; Hogan et al., 2014). The importance of these non-epithelial cell types to lung
tissue homeostasis is axiomatic. However, this thesis work concentrated on lung cancers
of epithelial origin (carcinomas), and thus the following sections describe the known
epithelial cell types of mammalian lung and their properties as progenitor cells and thus
possible contributors to lung carcinomas.
The epithelial cell types within the proximal part of the lung vary in its different
regions (Figure 1). The basal cells, which are found in the trachea in mice, but
interestingly, all along the airway to distal bronchioles in humans, are a population of
multipotent stem cells that take care of both homeostasis of the normal epithelium as
well as its regeneration after injury. These cells divide symmetrically and
asymmetrically in the steady state murine lung, thus are capable of self-renewal as well
as production of luminal ciliated and Clara cells (Watson et al., 2015). Furthermore,
basal cells, marked with cytokeratin 14 (CK14) expression, serve as progenitor cells for
Clara and ciliated cells (see sections below) after naphthalene treatment-induced Clara
cell selective injury (Ghosh et al., 2011; Hong et al., 2004). Basal cells can be identified
by expression of markers including nerve growth factor receptor (NGFR), tumour
protein 63 (p63), cytokeratin 5 (CK5), and CK14 (Rock et al., 2010).
Nonciliated columnar secretory cells, which are the source of secretoglobins, such as
Clara cell 10 kDa secretory protein (CC10, also known as CCSP) encoded by the
Scgb1a1 gene, are a heterogeneous population of cells generally referred to as Clara (or
club) cells. They are capable of self-renewal and are found toward the distal parts of
airways in increasing numbers (Rawlins et al., 2009b). Specific CC10+ Clara cells in the
neuroepithelial body (NEB) microenvironment represent a naphthalene-resistant
subpopulation of Clara cells indicating variety among the CC10+ cells and pointing out a
possible Clara cell progenitor population (Hong et al., 2001). Functionally, Clara cells
have been linked to the lung inflammatory response. Specifically, Clara cell depletion, as
well as CC10 deficiency, increases the lung inflammatory response induced by both
pseudomonas aeruginosa lipopolysaccharide (Snyder et al., 2010) and adenovirus
(Harrod et al., 1998).
Clara cells are progenitors for at least two other cell types of the lung airways,
namely ciliated cells and goblet cells, both of which take part in mucociliary clearance,
the process by which inhaled microorganisms and particulates are cleared from the lung.
Multiciliated cells expressing the forkhead transcription factor (FOXJ1) are not capable
of self-renewal (Rawlins et al., 2007). During normal regeneration of the epithelium, as
well as in response to tracheal sulfur dioxide (SO2) ciliated cell injury, ciliated cells
originate from Clara cells (Rawlins et al., 2009b). Mucin, which is composed of large
glycoproteins, is produced by MUC5AC-expressing goblet cells. In comparison to
humans, the amount of goblet cells in in adult mice, which are maintained under
laboratory conditions, is low.  However, the number increases in response to
inflammation. For example, the differentiation of Clara cells into mucin-producing
goblet cells, which are not capable of self-renewal, increases in ovalbumin-induced
allergen inflammation in the mouse lungs (Chen et al., 2009; Rock et al., 2009).
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Columnar pulmonary neuroendocrine cells (PNECs), which secrete calcitonin gene-
related peptide 1 (CALCA also known as CGRP), sense stimuli within the airway lumen,
including hypoxia and nicotine (Fu et al., 2002; Schuller et al., 2003). PNECs are found
either as single cells in proximal airways or in clusters called neuroepithelial bodies
(NEBs) closer to the distal alveolar space.
Figure 1. Structure and epithelial cell types of mouse lung. Adapted from Leeman et al.
2014.
The most distal parts of the bronchioles, which are called the terminal bronchioles,
lead to the distal alveolar space. This peripheral part of the lungs consists of alveolar
surface tension-reducing surfactant-associated protein C (SPC)-secreting alveolar type II
(AT2) cells and gas-exchanging, alveolar type I (AT1) cells characterised with
podoplanin (PDPN, also known as T1α) (Leeman et al., 2014) (Figure 1). The self-
renewing and proliferating AT2 cells are progenitors of AT1 cells (Desai et al., 2014;
Evans et al., 1972). Interestingly, low levels of CC10 expression, which expression is
high in airway Clara cells, have been detected in mouse AT2 cells (Rawlins et al.,
2009b). The region between the terminal bronchioles and the alveolar space is called the
bronchioalveolar duct junction (BADJ) where rare cells, positive for both CC10 and SPC
and identified as bronchioalveolar stem cells (BASCs), are capable of differentiation to
both Clara and alveolar cells (Kim et al., 2005).
Taken together multiple epithelial cell types have been identified of which five,
namely basal, Clara, ciliated, goblet, and neuroendocrine cells, are described here. Two
of these, basal and Clara cells, are capable of self-renewing and functioning as
progenitors. Of the two types of alveolar epithelial cells, namely AT1 and AT2 cells, the
latter  have  been  shown  to  act  as  progenitors.  Additionally,  BASCS  at  the  BADJ  are
shown to function as progenitors for both Clara and alveolar cells. As shown for the
Clara cells, variety among within these defined cell type clusters may exist and more
research is needed to characterise this possible, yet undefined heterogeneity.
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2.1.2 Lung development
Lung development starts around embryonic (E) day 9.5 in mice and around 4–5
weeks gestation in humans when two primary lung buds appear in a region of the ventral
wall of the anterior foregut.  These primary lung buds express the transcription factor
Nkx2-1 (also known as Titf1) (Lazzaro et al., 1991; Morrisey and Hogan, 2010). NKX2-
1 is one of the key molecules in lung morphogenesis. Lungs of Nkx2-1-null mice do not
branch and show decreased expression levels of respiratory-system-specific genes Sftpc
and the Scgb1a1-encoding SPC and CC10, respectively (Kimura et al., 1996; Minoo et
al., 1999). The ventral side of the foregut tube develops into trachea, making a
connection with the lung buds. Simultaneously, the dorsal side of the single foregut tube
starts to separate and form the oesophagus, leading to the stomach. The two primary lung
buds are composed of a simple endodermal epithelium, which is surrounded by
mesoderm and a vascular plexus. These tissues are further surrounded by a thin layer of
mesothelium, which also gives rise to a proportion of the mesenchymal cells (Dixit et al.,
2013).
The branching morphogenesis, which follows the bud initiation phase (embryonic
stage E9.5-E12.5), continues until E16.5 in mice, generating a tree-like structure with
thousands of branches (Morrisey and Hogan, 2010) (Figure 2). This period is called the
pseudoglandular stage of lung development due to the glandular looking structures that
eventually form the airways. The branching follows an organised program of three
branching modes, called domain branching, planar bifurcation, and orthogonal
bifurcation (Metzger et al., 2008). Tracing of the different modes during branching has
indicated specific functions for the different modes. The central architecture of each lobe
is formed by domain branching, whereas the planar bifurcation and orthogonal
bifurcations  form  the  thin  edges  of  lobes,  create  lobe  surfaces,  and  fill  the  interior
(Metzger et al., 2008). The tip of the epithelial bud is composed of inhibitor of DNA
binding 2 (Id2)-expressing multipotent progenitor cells which give rise to cell types in
the bronchi and bronchioles (Hogan et al., 2014; Rawlins et al., 2009a). The airway
epithelial cell differentiation creates multiple specialized cell types in the proximal
airways starts at this stage (Morrisey and Hogan, 2010). One of the crucial determinants
of airway epithelial cell differentiation is Notch signalling, which has been shown to
control the balance between ciliated and secretory cell fate by silencing the ciliated cell
program (Tsao et al., 2009).
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Figure 2. The branching morphogenesis of murine lungs. Dotted lines at embryonic day
(E) 16 show the right cranial (RCr), right middle (RMd), accessory (RAc), right caudal
(RCd) and left (L) lobes. Scale bar, 500 mm. Adapted from Metzger et al. 2008.
The pseudoglandular stage of lung development is followed by the canalicular
(E16.5-E17.5) and saccular (E18.5-postnatal day (P) 5) stages which are part of the
alveologenesis, a critical stage in preparing the structures for gas exchange. During the
canalicular stage, when the canalisation of the lung parenchyma occurs, a population of
columnar progenitor cells of the epithelial tips starts to become either flat AT1 cells
specialized for gas exchange or cuboidal AT2 cells expressing surfactant proteins which
are needed for reduction of surface tension.  The saccular phase involves the generation
of tiny peripheral sacs separated by primary septa. The development of alveoli continues
postnatally as the number and surface area increase.  Development continues for weeks
after birth in mice and months in humans (Hogan et al., 2014). In support of the
bipotential alveolar progenitor cell type, a single cell transcriptomic analysis of the
developing mouse lung at E18.5 identified cells expressing markers for both AT1 and
AT2 cells (Treutlein et  al., 2014). This observation was further supported by another
study that identified cells expressing a subset of AT1 and AT2 markers giving rise to
either AT1 or AT2 cells by shutting off the expression of specific cell type markers
(Desai et  al., 2014). Throughout the whole process of lung development, dynamic and
reciprocal signalling between the branching epithelium and the surrounding
mesenchyme is needed for correct assembly of the formed organ. This assembly results
in four right lobes (cranial, medial, caudal, and accessory) in humans and one left lobe in
mice (Morrisey and Hogan, 2010).
2.1.2.1 Regulation and signalling networks of branching
morphogenesis
Distinct genes along the axis of the developing lung have been identified to regulate
the controlled process of lung branching. Examples of the dynamic control of branching
morphogenesis are regulation mediated by the transcription factors SRY (sex
determining region Y)-box 2 (Sox2) and -9 (Sox9). Sox2 is  a  key  regulator  of  cell
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differentiation in the ventral early foregut. Its expression is detected in proximal and
non-branching regions and is switched off in branch initiation sites (Gontan et al., 2008;
Ishii et al., 1998). Conditional loss of Sox2 expression in the ventral side of the early
anterior foregut results in abnormal differentiation of the epithelium in the conducting
airways with an increase in the amount of mucus-producing cells and decrease in the
amount of basal, ciliated and Clara cells, indicating a role for Sox2 in regulation of cell
differentiation (Que et al., 2009). In contrast to Sox2, Sox9 is expressed in the tips of the
branching epithelia, and deletion of Sox9 in developing lung epithelium impairs
branching morphogenesis resulting in smaller lungs with dilated airway branches (Chang
et al., 2013). Furthermore, Sox9 expression is suggested to suppress alveolar
differentiation during the pseudoglandular stage of lung development (Chang et al.,
2013).
The key signalling molecules regulating the lung branching process include
members of the fibroblast growth factor (Fgf), bone morphogenic protein (Bmp),
transforming growth factor beta (Tgfb), and sonic hedgehog (Shh) families in addition to
retinoic acid (RA). The dynamic and reciprocal signalling between these molecules in
branching epithelia and surrounding mesenchyme and mesothelium is needed for proper
development (Morrisey & Hogan, 2010) (Figure 3).
Distal mesenchymal fibroblast growth factor 10 (encoded by Fgf10) and fibroblast
growth factor receptor 2 (encoded by Fgfr2) in the branching epithelial tip (De
Moerlooze et al., 2000; Min et al., 1998; Sekine et al., 1999) are two key signalling
molecules in lung branching morphogenesis. The Fgf10-/- mouse embryos display
complete absence of lungs leading to perinatal lethality (Min et al., 1998; Sekine et al.,
1999). Furthermore, the lung phenotype of embryos expressing the IIIb-isoform specific
mutation of Fgfr2 and fusion chimera embryos of homozygous Fgfr2 mutants resemble
closely that of Fgf10-null mouse lungs (Arman et al., 1999; De Moerlooze et al., 2000),
strongly indicating an important role for FGF10-FGFR2 signalling in the initiation of
branching morphogenesis. Interestingly, recent data suggest that the level, rather than the
localized expression, of Fgf10 surrounding the distal epithelial bud controls the correct
formation of a new branch point in developing lung (Volckaert et al., 2013).
The Fgf10-positive distal mesenchyme acts as an organizing and signalling centre
working together with the epithelium- and mesothelium via reciprocal interactions
between specifically expressed signalling molecules to coordinate epithelial branching
(Figure 3). This section describes selected genes encoding signalling molecules which
have been shown to control lung branching morphogenesis often by regulating Fgf10
expression. Fibroblast growth factor 9 (Fgf9), is expressed first in the epithelium and
mesothelium during embryonic stage (Colvin et al., 1999), and later, during the
pseudoglandular stage, its expression is mostly restricted to the epithelium (del Moral et
al., 2006a). Fgf9-null embryonic lungs are hypoplastic, showing thinning of the
mesenchyme and lack Fgf10 expression at E13.5-E14.5, indicating FGF10-FGF9-
dependent regulation of mesenchymal proliferation (Colvin et al., 2001). Also, the
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reciprocal interplay between mesenchymal Fgf10 and epithelial Shh is linked to the
control of mesenchymal cell proliferation as well as to alveolar differentiation in
embryonic lungs. Overexpression of Shh in the developing lung epithelium leads to
hyperproliferation of mesenchyme and absence of normal alveoli, and, interestingly, to
decreased expression of mesenchymal Fgf10 (Bellusci et al., 1997a; Bellusci et al.,
1997b; Pepicelli et al., 1998). Similarly, epithelial overexpression of Bmp4, which is
normally expressed in the branching epithelial tip of the developing lung, causes reduced
epithelial cell proliferation, a small increase in mesenchymal cell proliferation but
simultaneous increased cell death leading to dilated terminal buds incompatible with
normal lung function (Bellusci et al., 1996). Addition of BMP4 to an embryonic lung
epithelial culture system inhibits FGF10-induced epithelial budding and cell
proliferation (Weaver et al., 2000), suggesting that BMP4, and possibly also SHH,
function as a negative feedback loop for an FGF10-induced epithelial branching process.
Fgf10 is also linked to retinoic acid (RA)-dependent lung branching initiation. In a
foregut explant culture system, pan-retinoic acid receptor (RAR) antagonist (BMS493)
treatment, results in failure of the induction of Fgf10 expression and epithelial bud
formation (Desai et al., 2004). This result was later confirmed in vivo using  a
retinaldehyde dehydrogenase 2 (Raldh2)-null mouse model that furthermore linked the
RA-FGF10 axis to regulation of TGFB signalling (Chen et al., 2007). Thus, multiple
signalling molecules in the developing lung mesenchyme, epithelium, and mesothelium
contribute to the lung branching morphogenesis often via regulation of mesenchymal
Fgf10.
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Figure 3. Multiple signalling pathways control lung branching morphogenesis. The
diagram represents expression and known interplay between selected signalling
molecules in the branching epithelium and surrounding mesenchyme during lung
development. These include members of Fgf, Tgfb, Shh, Bmp, and Wnt families as well
as  RA  and  transcription  factors Sox2, Sox9, and Nkx2-1. Also the signalling interplay
between Fgf and Ras is shown.
Epidermal growth factor receptor (Egfr) and Kras, genes which both harbour key
human lung cancer driver mutations (see section 2.2.3), have been functionally
implicated in murine lung morphogenesis (Figure 3). Egfr-null embryos show impaired
lung branching morphogenesis and deficient alveolisation and septation, resulting in
significant reduction of alveolar volume and leading to reduced epithelial surface for gas
exchange (Miettinen et al., 1997). Expression of constitutively active oncogenic Kras
results in reduced cell differentiation in developing lung epithelia. Furthermore,
developing lung expressed oncogenic Kras leads to abnormal localization of mitogen-
activated protein kinase (MAPK) cascade activity and reduced expression levels of
ciliated and Clara cell markers resulting in defects in lung branching morphogenesis
(Shaw et al., 2007). In contrast, silencing of Spry2, an antagonist of MAPK, rescues
oncogenic Kras-induced lung morphogenesis defects (Shaw et al., 2007). Interestingly,
the  combined  loss  of Spry1 and Spry2 results in defects in lung morphogenesis,
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resembling the effect of oncogenic Kras.  Furthermore,  the  defects  in  lung
morphogenesis caused by the loss of Spry1 and Spry2 are rescued both with MAPK
signalling cascade effector MEK1/2 inhibitor treatment and partial loss of Fgf10
expression (Tang et al., 2011). Taken together, these results indicate a dynamic control
as well as a need for accurately localised, timed or dosed EGFR, RAS-MAPK and FGF
signalling to achieve homeostasis in the growing epithelial lung.
2.1.2.2 Development of the pulmonary mesenchyme and vasculature
As described above, lung morphogenesis is dependent on paracrine signalling
between the branching endoderm and the surrounding mesoderm. Contrary to the
extensive knowledge of the origins of epithelial cell lineages, little is known about the
pulmonary mesodermal cells and their origins. Only recently have lineage-tracing assays
begun to explore these cells and shed light on their mesenchyml origin.  . Multipotent
cardiopulmonary mesoderm progenitors (CPPs) that express Wnt2, Gli1 and Isl1,
function as progenitors of both cardiac and lung mesodermal cells (Peng et al., 2013).
CPPs, which are located in the posterior pole of the heart, can generate pulmonary
vascular and airway smooth muscle, as well as pericyte-like cells. Furthermore, the
Fgf10 expressing embryonic lung mesenchymal cells are reported to function as
progenitors of several cell types in the embryonic and postnatal lung mesenchyme
including vascular smooth muscle cells and lipofibroblasts (El Agha et al., 2014).
  The generation of a capillary network surrounding the distal epithelial structures of
the lung is crucial for the exchange of gases, i.e. to provide oxygen to the tissues and for
the removal of carbon dioxide. During the development of the pulmonary vascular
network, precursor cells of the network undergo cellular maturation and patterning to
form a vascular entity connecting airways and linking to the arterial and venous poles of
the heart. Pulmonary endothelial cells are formed by two co-existing processes, namely
vasculogenic and angiogenic process (Peng and Morrisey, 2013). Vasculogenesis is a de
novo process of blood capillary formation, whereas angiogenesis is a process of
formation of blood capillaries from the existing ones (deMello et al., 1997). The Wnt2,
Gli1 and Isl1-expressing multipotent CPPs function as vasculogenic progenitors of the
proximal veins in the developing murine lung (Peng et al., 2013). The vascular
endothelial (VE) cadherin-expressing endothelial progenitors, which exist already at
E8.5, act as the angiogenic source of the distal alveolar capillaries (Peng et al., 2013).
Vascular endothelial growth factor-A (encoded by Vegfa) is an important signalling
molecule both in vasculogenesis and angiogenesis. Overexpression of Vegfa in the distal
lung epithelium of the mouse lung leads to increased vascular density visualised at E17
with the expression of platelet endothelial cell adhesion molecule (PECAM1, also
known as CD31). VEGFA and its receptor kinase insert domain receptor (encoded by
Kdr also known as VEGFR2)-mediated epithelial-to-endothelial crosstalk in branching
morphogenesis has been evidenced using an embryonic lung ex vivo culture system (Del
Moral et al., 2006b).
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Taken together, pulmonary mesenchyme acts as an important signalling centre
during lung morphogenesis and functions as an essential source of non-epithelial
pulmonary cells. However, more work is needed characterize the various mesodermal
cell linages and their contribution to tissue homeostasis.
2.2 Lung cancer
Lung cancer is the leading cause of cancer deaths worldwide with 1,82 million new
cases diagnosed and 1,6 million deaths annually (Figure 4) (Ferlay et al., 2015). Due to
the asymptomatic disease progression and lack of systematic screening programs, lung
cancer is typically diagnosed at a late and advanced stage of disease (Gridelli et al.,
2015). The late diagnosis as well as the high level of heterogeneity within and between
lung tumours caused by exposure to damaging agents, such as tobacco smoke, pollution,
and micro-organisms, make the treatment of lung cancer challenging. Intratumour
heterogeneity (ITH) rises during tumour progression via an evolutionary process where
cancer cells with different fitness levels are subjected to selection, resulting in clonal
evolution (Gerlinger et al., 2014). Clonal populations are thought to cooperate with one
another, influencing cancer progression (Tabassum and Polyak, 2015). Recent advances
in the generation of targeted therapies, which are designed to hit specific genetic drivers,
have taken lung cancer diagnostics closer to a personalized level of treatment (Gridelli et
al., 2015). Nevertheless, the inherent propensity of cancers toward clonal evolution may
be one of the mechanisms cancers use to acquire drug resistance.  Such resistance to
treatment leads to disease relapse as has been observed in lung adenocarcinomas (ACs)
(Zhang et al., 2014).
28
Figure 4. Worldwide incidences and mortalities of  27  major  cancers  in  both  sexes
combined. An age-standardised rate (ASR) is a weighted mean of the age-specific rates
per 100 000 per year. Data from GLOBOCAN 2012 (Ferlay et al., 2015)
(http://globocan.iarc.fr/Default.aspx).
Heterogeneity does not apply only to cancer cells. It is also seen within the tumour
microenvironment, which is composed of extracellular matrix (ECM), vasculature,
fibroblasts, and infiltrating immune cells. The reciprocal interaction between the tumour
and its surrounding stroma modulates tumour progression (Hanahan and Coussens,
2012). Recently, specific interest has been given to the immune microenvironment as a
possible target in cancer treatment. Clinical trials have shown promising results with
drugs targeting the mechanisms by which cancer cells evade immune responses. One
example is programmed death 1 (PD-1) antibody treatment. PD-1 and its ligands, PD-L1
and PD-L2, mediate inhibitory signals which protect normal peripheral tissues from the
adaptive immune system, including the regulation of T-cell activation (Keir et al., 2008).
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By expressing PD-1 or PD-L1, cancer cells escape immune attack. Blocking the PD-1-
PD-L1 interaction with PD-1 antibody results in measurable responses in 20-25% of
patients with advanced NSCLC (Topalian et al., 2012). Thus, use of the patient’s own
immune system to attack cancer cells is one possible way to circumvent the inherent
heterogeneity of tumours.
2.2.1 Epidemiology
Lung cancer is the most common cancer in the world, both in terms of new cases as
well as deaths (Figures 4 & 5) (Ferlay et al., 2015). Women in less developed countries
are exception to the worldwide statistics and among whom lung cancer is the third most
lethal cancer after breast, cervix, and uterine cancers (Ferlay et al., 2015). The low
numbers of lung cancer deaths in Africa is probably a consequence of under-reporting,
rather than an actual low incidence of deaths (Figure 5) (Ferlay et al., 2015).
Interestingly, during the last 30 years there has been a shift in the incidence of specific
lung tumour histopathologies, with an increase in adenocarcinoma diagnoses compared
with squamous cell carcinoma. This difference is most likely due to the change in
smoking behaviours and cigarette manufacture, as filter and light cigarettes have enabled
a deeper aspiration resulting in an exposure of deeper parts of the bronchi and alveoli to
the carcinogens in cigarette smoke (Gridelli et al., 2015).
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Figure 5. Mortality rates due to lung cancer in both sexes combined. An age-
standardised rate (ASR) is a weighted mean of the age-specific rates per 100 000 per
year. Data from GLOBOCAN 2012 (Ferlay et  al., 2015)
(http://globocan.iarc.fr/Default.aspx).
2.2.2 Diagnosis
Lung cancer is diagnosed based on clinical symptoms, such as cough, chest pain,
and dyspnoea and chest radiography and/or a contrast-enhanced computed tomography
(CT) scan, after which pathological diagnosis and identification of genetic alterations are
performed to guide treatment (Gridelli et al., 2015). Cancer stage is determined by
assessment of anatomical extent in three tumour components: the primary tumour (T),
the lymph nodes (N), and the metastases (M). This system is called the Tumour-Node-
Metastasis (TNM) classification (Travis et al., 2015). Pathological diagnosis of lung
tumours is performed using resection samples or small biopsies, both of which have their
own guidelines for classification (Travis et al., 2013).
The two main histopathological classes of lung cancer are non-small-cell lung
cancer (NSCLC), which represents approximately 85% of diagnosed lung cancer cases,
and small-cell lung cancer (SCLC), which constitute the remaining 15%. NSCLC is
further separated into three main histopathologies, namely adenocarcinoma (AC; ~60%
of NSCLC), squamous cell carcinoma (SCC; ~30% of NSCLC) and large cell carcinoma
(LCC; ~10% of NSCLC) (Gridelli et al., 2015). Additional histopathology classes
include adenosquamous carcinoma (ASC; 0,4-4%) and pleiomorphic carcinoma (~2-
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3%), which are both rare but aggressive cancers with poor prognosis (Travis et al.,
2015).
The adenocarcinoma pathological classification system was updated in 2011 by a
multidisciplinary effort that emphasized correlations between pathological, clinical,
radiologic, and molecular characteristics of AC tumours (the IASLC/ATS/ERS
classification) (Travis et al., 2011). Pre-invasive adenocarcinoma in situ (AIS) shows a
hyperproliferative growth pattern, but does not invade the normal alveolar structures.
Invasive ACs, in which invasion of normal tissue structures is seen, are characterised by
glandular differentiation, mucin production, and/or pneumocyte marker expression.
Distinct growth patterns, namely lepidic, acinar, papillary, micropapillary, and solid can
be identified. Classifications are determined according to the predominant subtype after
comprehensive histological subtyping by semiquantitative estimation.
Immunohistochemical (IHC) workups, which guide the pathological diagnoses are
used in everyday clinics to confirm the pathological classifications. The same IHC-based
classification is used in the profiling of lung cancer mouse models (Figure 7 and section
2.3.1.3). Currently used AC markers are NKX2-1 and napsin-A. Both appear to give
comparable sensitivities, although napsin-A has been suggested to better differentiate
SCC from AC (Travis et al., 2015). Mucinous AC phenotype is confirmed with
polysaccharide detecting periodic acid Schiff’s (PAS) staining.
SCCs are characterised by p63 expression, specifically the DNp63 isoform, which
contains an alternative transcriptionally inactive ‘DN’ domain, being preferred over p63,
in up to 30% of ACs express p63 (Bishop et al., 2012). Cytokeratin-5, (CK5, official
gene name type II cytoskeletal keratin 5, KRT5) alone, or in combination with
cytokeratin-6 (CK6, official gene name type II keratin 6A/B, KRT6A/B) is used to
confirm the squamous phenotype and classification (Travis et al., 2015).
SCLCs are distinguished from NSCLCs by their typical small cell morphology
characterised by a smaller cytoplasm and poorly defined cell borders, as well as
dispersed granular nuclear chromatin and absent or indistinguishable nucleoli (Travis et
al., 2015). IHC markers such as a cytokeratin cocktail detecting multiple keratins
(AE1/AE3 cocktail) and neural cell adhesion molecule 1 (NCAM1, also known as
CD56) are used to confirm the epithelial and neuroendocrine nature of the SCLC
tumours. Large cell carcinoma (LCC) is an undifferentiated NSCLC that lacks the
typical characters of SCLC, AC and SCC. Only tumours that are either negative or show
unclear patterns of common IHC markers are considered to be LCC (Travis et al., 2015).
ASC is characterised by both AC and SCC components, each constituting at least 10%
of the tumour. Typical AC and SCC markers, NKX2-1 and napsin-A and p63 and CK5/6
respectively, are used to classify ASCs. Pleiomorphic carcinomas are NSCLCs that
contain at least 10% of spindle and/or giant cells that are diagnosed based on
morphology (Travis et al., 2015).
For all lung cancer cases the prognosis is determined by the TNM classification and
the patient’s performance status. Furthermore, histological analysis and molecular
profiling are used to predict treatment outcomes in a personalized manner (Travis et al.,
2015) (for genetic profiling and targeted treatments see section 2.2.3). SCLCs have
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generally poor prognosis with only 12,7 months of median overall survival time
(Planchard and Le Pechoux, 2011), whereas NSCLCs have a variety of prognoses
depending on the patient’s performance score and the clinical and tumour stage.
Pleiomorphic carcinomas have poor prognosis even in an early stage of the disease.
Similarly, ASCs are reported to have a poorer prognosis when compared to other
NSCLCs (Nakagawa et al., 2003).
The cellular origin of human lung tumours is determined by the location and
expression profiles of the specific tumour histopathology types. SCLCs with clear
expression profiles of NE cells are considered to be developed from NE cells. ACs with
alveolar cell (pneumocyte) expression are considered to have risen from the peripheral
parts of the lungs whereas SCCs with basal cell marker expression are thought to have
developed from airway basal cells (Chen et al., 2014; Travis et al., 2015).  Studies on in
vivo murine lung cancer models support these conclusions (Sutherland et al., 2011;
Sutherland et al., 2014)  and are discussed in more detail in section 2.3.1.3.
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2.2.3 Genetic alterations and targeted treatments
At the genetic level every lung tumour is different. Nevertheless, as a result of recent
major lung cancer sequencing efforts of the most common types of lung cancer, namely
AC, SCC and SCLC, (Cancer Genome Atlas Research, 2012, 2014; George et al., 2015;
Peifer et al., 2012) clear genetic commonalities within the lung tumour histopathology
groups have been identified (Gridelli et al., 2015) (Table 1). Mutations in TP53 are
common in all lung cancer histopathology types, however the incidence is higher in
SCLCs and SCCs than in ACs. (Gridelli et al., 2015). To date, only the genetic profiling
results from lung ACs, the most common and extensively studied lung cancer, are
applied in clinics.  Mutations in epidermal growth factor receptor (EGFR) or
translocations of the anaplastic lymphoma kinase (ALK) gene can be treated with
specific inhibitors (Gridelli et al., 2015) (Table 1). The following sections describe
common lung cancer genetic alterations, approved targeted therapies, as well as selected
therapies under development in lung ACs, SCCs, SCLCs and ASCs.
Table 1. Selected genetic alterations and available targeted treatments for common types
of lung cancer. Adapted from Chen et al. 2014.  Additional and updated information
taken from Cancer Genome Atlas Research, 2012, 2014; George et al., 2015, Tochigi et











EGFR M, C 17-18 9 3,6 13-31 Erlotinib, gefitinib
ALK F 3-5 <1 N/A 0 Crizotinib
ROS1 F 1-2 N/A N/A 0 Crizotinib
TP53 M 52 91 92 38 N/A
KRAS M, C 30-37 4 N/A 13 (M) N/A
STK11 M 15-21 2 1 6-22 N/A
PIK3CA M, C 0,5-9 48 3 19 (M) N/A
CDKN2A M, C 14-24 44 2 (M) 13 (M) N/A
FGFR1 M, C 6 18 1 (M) 0 N/A
PTEN M, C 2-3 11 6 6 N/A
ERBB2 M, C 2-5 5 1 0 N/A
RB1 M, C 4-7 7 75 13 (M) N/A
EPHA3 M, C 6-17 12 3 N/A N/A
*Status: mutation (M), copy number alteration (C) or fusion (F); N/A, not available
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2.2.3.1 Genetic alterations and targeted treatments in AC
Common lung cancer mutations in EGFR,  which  are  mainly  found  in  lung  ACs
(10,4-18,4%) (Cancer Genome Atlas Research, 2014; Cerami et al., 2012; Ding et al.,
2008; Imielinski et al., 2012), include small in-frame deletions and missense
substitutions in exons 18, 19, and 21. The mutations cluster around the active site of the
receptor kinase domain (Lynch et al., 2004; Paez et al., 2004) causing activation of
signalling pathways, including serine-threonine protein kinase AKT and signal
transduction and activator of transcription (STAT) (Sordella et al., 2004). Due to the
clear association between the sensitivity to the EGFR tyrosine kinase inhibitor (TKI),
gefitinib (Iressa) and EGFR mutation status in AC cases (Lynch et al., 2004; Paez et al.,
2004; Pao et al., 2004), gefitinib is now approved as a targeted first-line monotherapy for
the treatment of patients with advanced or metastatic EGFR mutation-positive NSCLC.
Another inhibitor, erlotinib, also targeting EGFR mutant NSCLC (Pao et al., 2004), is
also approved as a first-line treatment for EGFR mutation-positive NSCLC following a
phase-III clinical trial in European lung cancer patients (Rosell et al., 2012).
Small inversions in chromosome 2p resulting in the formation of a fusion gene of
the echinoderm microtubule-associated protein-like 4 (EML4) and ALK genes were first
identified in NSCLC patient tumours, at an incidence of approximately 7% (Soda et al.,
2007). Since the identification of the EML4-ALK fusion gene, multiple variants have
been  found,  and  their  incidence  appears  to  be  mainly  restricted  to  ACs  (Sasaki  et  al.,
2010). The small-molecule inhibitor PF-2341066, which was developed to inhibit ALK
and hepatocyte growth factor receptor encoded by MET proto-oncogene (MET) (Zou et
al., 2007), has been further developed as the targeted therapy crizotinib (Cui et al.,
2011).  Crizotinib is currently approved for treatment of EML4-ALK positive NSCLC
based on clinical trial studies (Kwak et al., 2010). Recently, crizotinib was shown to also
target rearrangements of the receptor tyrosine kinase ROS proto-oncogene 1 (ROS1).
The kinase domain of ROS1 shows 77% amino acid identity with ALK, and crizotinib is
now assigned as a potential treatment of patients with rearrangements (Shaw et al.,
2014b).
Interestingly, NSCLC patients with exon 20 insertions in EGFR do not respond to
EGFR inhibition, indicating heterogeneity in the cellular sensitivity to the targeted
therapies caused by the specific mutation types (Oxnard et al., 2013). Moreover, EGFR
mutation positive tumours, responsive to targeted therapies, acquire resistance by
mechanisms including secondary mutations in EGFR, such as the gatekeeper mutation
T790M, responsible for about half of the acquired resistance cases (Arcila et al., 2011;
Choi et al., 2010; Kobayashi et al., 2005). Furthermore, activation of other kinases such
as MET, insulin-like growth factor 1 receptor (IGF1R), serine/threonine-protein kinase
B-raf (BRAF) or downstream pathway signalling molecules such as mitogen-activated
protein kinases (ERK1/2) have been shown to mediate resistance to EGFR inhibition
(Cortot et al., 2013; Engelman et al., 2007; Ercan et al., 2012; Ohashi et al., 2012).
Novel irreversible EGFR inhibitors including AZD9291 developed by AstraZeneca and
WZ4002 developed by Jänne and colleagues can target the gatekeeper mutation
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(T790M)- harbouring lung tumours (Cross et al., 2014; Finlay et al., 2014; Zhou et al.,
2009). 50% of patients with tumours harboring EGFR T790M mutation were shown to
respond to AZD9291 treatment in a phase-I clinical trial (Jänne et al., 2014). Moreover,
targeting the downstream signalling pathways reactivated due to the targeted treatment
appears effective, as combined inhibition of ERK1/2 by the MEK inhibitor trametinib
and EGFR TKI WZ4002 can prevent both T790M- and non–T790M-mediated drug
resistance (Tricker et al., 2015). Similarly, NSCLC patients with disease progression
after initial treatment with crizotinib have shown good response to a more specific ALK
inhibitor LDK378 (ceritinib), which is now approved as a treatment for NSCLC
(Friboulet et al., 2014; Shaw et al., 2014a).
One potentially targetable lung cancer gene is KRAS, in which the first lung cancer
mutations were identified in 1984 (Santos et al., 1984). With a mutation incidence up to
37% in lung ACs, KRAS is  one  of  the  most  mutated  genes  in  lung  cancers  (Pao  and
Hutchinson, 2012). However, no direct inhibitors of RAS oncoproteins have yet been
applied in the clinic (Cox et al., 2014). Nevertheless, recent progress in mutant-specific
inhibitor development has shown promising results, for example with a covalently-
binding inhibitor developed against the KRAS G12C mutation (Ostrem et al., 2013). In
addition to direct RAS inhibitors, other approaches such as blocking the membrane
association, targeting of downstream effector signalling, finding synthetic lethal
interactors with mutant RAS, and targeting of RAS-mediated changes in cell metabolism
are all being investigated (Cox et al., 2014).
2.2.3.2 Genetic alterations in SCC and SCLC
Genetic profiling has also identified potent targets in SCC and SCLC, the second
most common types of lung cancers. Members of the erythroblastic leukaemia viral
oncogene homologues (ERBBs), fibroblast growth factor receptors (FGFRs) and Janus
kinases (JAKs) were found to be genetically altered in 64% of 178 lung SCCs studied in
the The Cancer Genome Atlas research network sequencing effort (Cancer Genome
Atlas Research, 2012). Furthermore, therapeutically targetable cellular pathways,
including members of phosphatidylinositol-3-OH kinase (PI3K)/AKT, receptor tyrosine
kinase  (RTK)  and  RAS  pathways  were  found  to  be  altered  in  69%  of  the  178  cases
(Cancer Genome Atlas Research, 2012). Targeted therapies against these alterations are
under development.
Loss of TP53 encoding p53 transcription factor and RB1 encoding retinoblastoma-
associated protein, a negative regulator of cell cycle, are frequent events in SCLCs.
Recent comprehensive genetic profiling of SCLC manifested the loss of TP53 and RB1
as an obligatory event in SCLC (George et al., 2015). Thus far, therapies restoring these
master regulators have not been translated to clinics even though preclinical evidence
suggests stage-specific effects. Restoration of Trp53 (mouse ortholog for TP53)
expression in latent mutant Kras driven adenocarcinoma mouse model showed clear
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reduction in tumour progression accompanied with signs of cellular senescence (Feldser
et al., 2010).
2.2.3.3 Genetic alterations and targeted treatments in ASC
Microdissection-based molecular profiling of lung ASCs analysing the AC and SCC
components separately has identified EGFR mutations in ASCs with frequencies ranging
from 13% to 31% (Tochigi et al., 2011; Vassella et al., 2015). The detected EGFR
mutations are trunk mutations, as they are found in both the AC and SCC components.
This finding corroborates clinical evidence that EGFR TKIs gefitinib and erlotinib are as
effective in ASCs as in lung ACs (Song et al., 2013). Mutations in KRAS are found less
frequently in ASCs than in ACs (up to 13%), and these appear to be trunk mutations
(Tochigi et al., 2011). In support of ASC clonal tumour evolution, branch mutations
have been detected in these tumours, separating the AC and SCC components. A
targeted next-generation sequencing analysis of frequently mutated human cancer genes
in 16 microdissected ASCs identified branch mutations in TP53, CDKN2A, PIK3CA,
RB1, and PTEN. Of the mutations affecting the PI3K pathway, only one PIK3CA trunk
mutations was identified. Two other PIK3CA mutations and one mutation in PTEN,  a
regulator of PI3K pathway, were branch mutations in the SCC component (Vassella et
al., 2015). Interestingly, even though PIK3CA mutations in lung SCCs are as common as
in ACs (10,1% and 6,1% respectively) the PIK3CA gene amplifications are much more
frequent in SCCs than in ACs (44,9% and 1,7% respectively) (Cancer Genome Atlas
Research, 2012, 2014; Cerami et al., 2012), indicating a possible role for PI3K pathway
activation in the SCC component of ASCs. Mutations in LKB1 (STK11), APC, JAK3,
TP53, RB1 and KIT were found in both the AC and SCC components, suggesting their
founder role (Vassella et al., 2015).
Genetic landscapes of lung tumours can predict response to targeted therapies.
Nevertheless, genetic ITH created by tumour evolution leading to clones with common
early (trunk) and distinct late (branch) mutations has been suggested to affect treatment
outcomes. De Bruin and colleagues sequenced altogether 25 spatially different regions
from seven NSCLC tumours including four AC, one SCC, one ASC, and one
undifferentiated NSCLC tumour and found evidence of branched evolution within the
tumours (de Bruin et al., 2014). Similarly, whole-exome sequencing of 11 localized lung
ACs identified clear ITH and possible association with increased likelihood of
postsurgical relapse (Zhang et al., 2014).
A deeper understanding of the genetic factors and their role in specific lung cancer
histopathologies and interaction with the tumour microenvironment are important for the
design of individualized treatment options. Furthermore, understanding of the normal
physiological functions of these factors is prerequisite for discerning their roles in




KRAS belongs to the large Ras superfamily of small guanosine triphosphatases
(GTPases) which, with its 150 members, regulate processes including cell cycle
progression, cell survival, actin cytoskeletal organisation, cell polarity and movement,
and vesicular and nuclear transport (Wennerberg et al., 2005). RAS oncogenes were first
identified in retroviruses of leukemic rats, which were able to induce tumours in
newborn rodents (Harvey, 1964; Kirsten and Mayer, 1967). Later, three separate studies
discovered that the genes in Kirsten and Harvey sarcoma viruses had human homologues
found in cancer cell lines, and capable of transforming mouse embryonic fibroblast
NIH/3T3 cells (Der et al., 1982; Parada et al., 1982; Santos et al., 1982).
The name RAS comes from the ability of the first two identified members of the
super family, HRAS and KRAS, to cause rat sarcomas. These two members are
distinguished by the names of their discoverers Harvey and Kirsten (Cox and Der, 2010).
The third member of the Ras family was identified in neuroblastoma-derived DNA, and
therefore named NRAS (Hall et al., 1983). The molecular basis underlying RAS
oncogenic functions were shown to be single point mutations detected in both the cancer
cell lines and the viruses (Capon et al., 1983; Reddy et al., 1982; Tabin et al., 1982;
Taparowsky et al., 1982). The three founding members of the Ras superfamily, namely
HRAS, KRAS, and NRAS together comprise one of the most frequently mutated oncogene
families in human cancers, and interestingly show tissue specificity in the distribution of
distinct RAS gene mutations (Cox et al., 2014).
Interestingly, only KRAS has been shown to be essential for embryonic
development. Kras-null mouse embryos die before birth due to defects in developing
heart myocardial cell proliferation and increased neuronal programmed cell death,
whereas Hras and Nras embryos develop normally (Koera et al., 1997).
2.2.3.4.1 RAS signalling
The members of the Ras superfamily of GTPases are divided into five major
families on the basis of their sequence and functional similarities. These families are
Ras, Rho, Rab, Ran, and Arf (Colicelli, 2004; Wennerberg et al., 2005).
The activity of GTPases depends on their GTP-bound state, which is modulated by
two classes of regulatory proteins, guanine nucleotide exchange factors (GEFs) that
stimulate the exchange of GDP to GTP and GTPase-activating proteins (GAPs) that
terminate the active state by stimulating GTP hydrolysis (Bos et al., 2007; Wennerberg
et al., 2005). Once activated, Ras family proteins interact with multiple distinct
downstream signalling effectors. The best characterised Ras signalling cascade is the
pathway initiated by EGFR activation that leads to Ras activation and subsequent
activation of mitogen-activated protein kinase (MAPK) signalling:  RAF, MEK1/2 and
ERK1/2, finally leading to phosphorylation of Ets transcription factors (Wennerberg et
al., 2005). Ets transcription factors regulate expression of genes involved in cell
differentiation, proliferation, apoptosis, and tissue remodelling (Kar and Gutierrez-
Hartmann, 2013). The link between EGFR and RAS was first noted following EGFR-
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induced increases in Ras-GTP binding (Kamata and Feramisco, 1984). Almost a decade
later, the connection to the MAPK-pathway was discovered in a study using
immunoprecipitates of MAP kinase from the rat brain in a kinase assay which used
immobilized Ras bound to the non-hydrolyzable GTP analog GMP-PNP (Moodie et al.,
1993).
During the last 20 years, multiple other downstream effectors of RAS have been
identified, including the class I phosphoinositide 3‑kinases (PI3Ks) (Rodriguez-Viciana
et al., 1994) and the Ral guanine nucleotide-dissociation stimulator (RalGDS) and
RalGDS-like protein (RGL) GEFs for the Ras-like small GTPases RalA and RalB
(Karnoub and Weinberg, 2008; Spaargaren and Bischoff, 1994). Consistent with the
functions of RAS, RalA and RalB GTPases regulate cellular proliferation as well as
apoptosis (Chien and White, 2003). Early studies showed PI3K-dependent activation of
AKT and protection from programmed cell death (Khwaja et al., 1997). Later, the more
precise molecular mechanism of AKT activation was shown to require both translocation
to the plasma membrane and phosphorylation at sites Thr308 and Ser473 (Vivanco and
Sawyers, 2002). PI3K-AKT activation regulates multiple hallmarks of tumourigenesis,
including cell proliferation by preventing cyclin D1 degradation (Diehl et al., 1998) and
cell growth by targeting the mammalian target of rapamycin (mTOR) (Nave et al.,
1999), and protection from apoptosis (Khwaja et al., 1997). Taken together, RAS acts as
a  signalling  centre  by  switching  its  form  between  the  GDP-  and  GTP-bound  stages  in
response to cellular stimuli and thus mediates several signals, which regulate multiple
cellular processes including growth and movement.
2.2.3.4.2 KRAS and lung cancer
The human KRAS gene at chromosome location 12p12.1 is mutated in up to 37% of
lung ACs. In contract, KRAS mutations in SCCs and SCLCs are rare (0,6-1,1%, 3,6%
respectively; Table 1 and Figure 6) (Cancer Genome Atlas Research, 2012, 2014;
Cerami et al., 2012; Ding et al., 2008; Imielinski et al., 2012; Peifer et al., 2012; Rudin et
al., 2012). Interestingly, lung cancer mutations are mainly found in KRAS, but not HRAS
or NRAS isoforms (incidence <1%) (Cox et al., 2014).
The majority of mutations in KRAS observed in lung cancer result in a single amino
acid missense mutation at residue glycine (G) 12, G13, or glutamine (Q) 61, of which
G12 is the most frequent mutation. The amino G12 residue is observed most frequently
changed to cysteine (G12C), but also valine (G12V) or aspartic acid (G12D) (Cox et al.,
2014). Point mutation in RAS proteins impair intrinsic GTP hydrolysis and render them
GAP insensitive, and thus continuously GTP-bound and active. Thus, this results an
uncoupling of downstream signalling from activation by upstream regulators (Baines et
al., 2011; Karnoub and Weinberg, 2008).
Downstream RAS effectors are also mutated in lung cancers, supporting RAS-
dependent signalling in tumour growth. PIK3CA,  which  encodes  one  of  the  PI3Ks,  is
mutated in all three main lung cancer subclasses AC (0,6-6,1%), SCC (6,1%) and SCLC
(4,8%). Interestingly, gene amplifications of PIK3CA are detected more often in SCCs
(32,6-44,9%) than for example in ACs (1,1-2,2%), suggesting histopathology-specific
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functions. Similar mutation patterns are seen in the phosphatase and tensin homologue
(PTEN) tumour suppressor gene, a negative regulator of AKT kinase, for which
mutations are more frequently detected in lung SCCs (7,9%) and SCLCs (4,8-13,8%)
compared to lung ACs (1,3-2,2%) (Cancer Genome Atlas Research, 2012, 2014; Ding et
al., 2008; Imielinski et al., 2012; Peifer et al., 2012; Rudin et al., 2012).
Activation of the most common lung cancer mutations in KRAS, G12C, G12V and
G12D, have all been shown to initiate lung tumourigenesis in mice, leading to
development of ACs (Fisher et al., 2001; Floyd et al., 2005; Jackson et al., 2001;
Mainardi et al., 2014; Meuwissen et al., 2001). Of these, the most studied is the G12D
mutation.
2.2.3.5 TP53
The transcription factor (TF) p53, encoded by the TP53 gene (Trp53 gene in mouse),
belongs to a gene family that also includes TP63 and TP73, encoding the p63 and p73
transcription factors (Nedelcu and Tan, 2007). The p63 and p73 TFs share similar but
not identical structures with p53, and interestingly, whereas mice deficient for Trp53 are
developmentally normal, loss of Trp63 and Trp73 (mouse orthologs of TP63 and TP73)
results in embryonic lethality (Donehower et al., 1992; Mills et al., 1999; Yang et al.,
2000). Trp53-null mice develop spontaneous tumours, primarily lymphomas
(Donehower et al., 1992), highlighting the role of p53 in tumourigenesis. P53 was
initially identified in simian virus (SV40)-induced tumours in hamsters as a cellular
protein binding to SV40 large T antigen. It was found to accumulate in the nuclei of
cancer cells (Linzer and Levine, 1979), and thus initially thought to function as an
oncogene. However, the later finding that only the mutated, not the wild-type form of
p53, cooperates with RAS in cellular transformation established a tumour suppressive
role for the protein (Finlay et al., 1989; Hinds et al., 1989). Furthermore, it was found
that p53 forms tetramers, which recognise specific responsive elements in the DNA, and
that  mutant  forms  of  p53  are  able  to  act  in  a  dominant  negative  fashion  to  inhibit  the
function of the wild-type protein (Friedman et al., 1993; Lane, 1992; Riley et al., 2008;
Wagner et al., 1991).
2.2.3.5.1 Cellular functions of p53
P53 is a cellular stress sensor that is activated by multiple types of cellular stress,
including DNA damage, hypoxia, oncogene expression, nutrient deprivation, and
ribosome dysfunction (Bieging et al., 2014; Hu et al., 2012). Functionally, p53 has been
linked to cell cycle arrest, senescence, apoptosis, DNA repair, autophagy, metabolic
reprogramming, cellular stem-ness as well as to tumour invasion and metastasis (Bieging
et al., 2014). The mechanisms of action of p53 include transcriptional activation,
transcriptional repression, regulation of translation, and homologous recombination
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(Bertrand et al., 2004; Ewen and Miller, 1996; Harris, 1996; Ho and Benchimol, 2003;
Lane, 1992).
The classical cellular functions regulated by p53, cell cycle arrest, senescence, and
apoptosis are mediated through p53-dependent transcriptional activation of specific
genes. The transcriptional coactivator function of p53 is indeed the best-characterised
function of p53 (Beckerman and Prives, 2010; Bieging et al., 2014). In adult cells not
facing stress, p53 is kept inactive through MDM2, an E3 ubiquitin ligase that binds to
p53 and targets it for proteosomal degradation. When cells face stress, the inhibition is
released, and p53 target gene expression is activated. The p53 pathway is regulated by
the activities of other signal transduction pathways, which define the outcome of p53
activation. For example, introduction of oncogenic RAS in normal cells leads to p53-
mediated senescence (Yang et al., 2006). This observation has been further validated in
vivo in an oncogenic BRAF-driven lung cancer mouse model, where deletion of p53
together with expression of BRAFV600E led to progression of benign lung lesions to lung
AC (Dankort et al., 2007).
2.2.3.5.2 TP53 and lung cancer
The human TP53 gene at chromosomal location 17p13.1 is the most commonly
mutated gene in human lung cancers. Its mutational incidence in the main
histopathological subclasses of lung cancers ranges from 50% in lung ACs to nearly
100% in SCLC (Figure 6) (Cancer Genome Atlas Research, 2012, 2014; Cerami et al.,
2012; Ding et al., 2008; Imielinski et al., 2012; Peifer et al., 2012; Rudin et al., 2012).
The majority of lung cancer mutations in p53 are found within the DNA binding domain
(Olivier et al., 2002).
Conditional loss of Trp53 (mouse ortholog for TP53) expression in mouse lungs
results in AC development with a long latency (350–530 days) (Meuwissen et al., 2003).
Trp53-loss together with oncogenic Kras expression  in  mouse  lung (referred  to  as  KP
from now on) results in ACs with a shorter latency and accelerates malignant
progression when compared to Trp53-loss or oncogenic Kras expression alone (Jackson
et al., 2005). Interestingly, the combined loss of Rb1 together with Trp53 gene
expression results in development of SCLC (Meuwissen et al., 2003). Thus, co-occuring
mutations with Trp53-loss define the murine lung tumour histopathology accurately
correlating with the mutational spectrum detected in human cancers. Mutations in TP53
are common in both lung ACs and SCLCs, but KRAS mutations are almost exclusively
detected in lung ACs (up to 37%), while RB1 mutations are common in SCLCs (45,2-
65,5%) but not in ACs (Cancer Genome Atlas Research, 2012, 2014; Cerami et al.,
2012; Ding et al., 2008; Imielinski et al., 2012; Peifer et al., 2012; Rudin et al., 2012). In
vivo studies have also investigated the effect of p53 point mutations on lung
tumourigenesis. The contact mutation p53R270H (homologous to human p53 R273H
mutation) and structural mutation p53R172H (homologous to human p53 R175H mutation)
combined with activation of oncogenic Kras accelerates malignant progression similar to
total loss of p53. Interestingly, only the contact mutation p53R270H showed a dominant-
negative effect in heterozygous mice (Jackson et al., 2005).
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2.2.3.6 LKB1/ STK11
The liver kinase B1 (LKB1, official gene name serine/threonine kinase 11, STK11) is
a serine/threonine kinase with tumour suppressor functions in a variety of cancers
(Alessi et al., 2006; Vaahtomeri and Makela, 2011). The LKB1 gene was initially
identified in a search for causative germline mutations for Peutz-Jeghers syndrome (PJS)
(Hemminki et al., 1998; Jenne et al., 1998). PJS (OMIM:175200) is an autosomal
dominant disorder characterised by intestinal polyps classified as hamartomas concurrent
with pigmented macules on the skin and mouth (Hemminki, 1999). PJS patients have a
significantly increased risk of developing cancer (Giardiello et al., 1987; Hearle et al.,
2006). The functional role of LKB1 in PJS has been further supported by the phenotypic
similarity of Lkb1-null mice with PJS patients (Wei et al., 2005). The incidence of LKB1
mutations in sporadic cancers is most frequent in NSCLC tumours and cervical cancers
(Sanchez-Cespedes et al., 2002; Wingo et al., 2009).
2.2.3.6.1 LKB1 signalling
The LKB1 kinase has been indicated to regulate cell polarity, metabolism, cell
differentiation, and proliferation via its at least 14 downstream kinases (Vaahtomeri and
Makela, 2011). Activation of LKB1 occurs via heterotrimerisation with pseudokinase
ste20-related adaptor protein (STRAD) and calcium-binding protein 39 (CAB39, also
known as mouse protein 25, MO25) (Baas et al., 2003; Boudeau et al., 2003). The
formation of the heterotrimer regulates LKB1 stability and cellular localisation (Boudeau
et al., 2003; Dorfman and Macara, 2008).
One of the most studied LKB1 substrate kinases is AMP-activated protein kinase
(AMPK), which is the master regulator of cellular and organismal metabolism and acts
as a cellular energy sensor (Alexander and Walker, 2011). The catalytic subunit AMPKα
and the two regulatory subunits AMPKβ and AMPKγ form a heterotrimer which is
activated when the cellular AMP:ATP ratio rises, resulting in allosteric binding of AMP
to the AMPKγ subunit (Alexander and Walker, 2011). AMPK activation also requires
phosphorylation of AMPKα by LKB1 or calcium/calmodulin-dependent protein kinase
kinase 2 (CAMKK) (Alexander and Walker, 2011). To adjust the cellular conditions to
the reduction in ATP, AMPK inhibits protein synthesis by inhibiting mTOR signalling.
mTOR inhibition occurs via AMPK-mediated phosphorylation of the tuberculosis
sclerosis (TSC2/TSC1) complex and raptor, a component of the mTORC1 complex
(Gwinn et al., 2008; Inoki et al., 2003).
The role of LKB1 in regulation of cell polarity has been evidenced in C. elegans,
Drosophila as well as in mammalian cells. PAR-4, the C. elegans orthologue of LKB1,
is required for anterior-posterior polarity of C. elegans embryo (Kemphues et al., 1988).
In Drosophila oocytes, LKB1 loss leads to disruption of anterior-posterior cell polarity
(Martin and St Johnston, 2003). LKB1 is also linked to regulation of cell polarity in
mammalian cells, including intestinal epithelial and pancreatic acinar cells (Baas et al.,
2004; Hezel et al., 2008). Interestingly, the LKB1-dependent regulation of cell polarity
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has also been linked to its role in AMPK-mediated energy sensing. In Drosophila, both
Lkb1- and AMPK-null mutants showed disruption of apico-basal cell polarity when the
cells were exposed to sugar deprivation (Mirouse et al., 2007). The LKB1-dependent
regulation of cell polarity is also mediated by additional LKB1 targets, AMPK-related
kinases, namely microtube affinity-regulating kinases (MARK1-MARK4) and synapses
of the amphid-defective kinases (SAD-A and SAD-B) (Hezel and Bardeesy, 2008).
2.2.3.6.2 LKB1 and lung cancer
The human LKB1 gene at chromosomal location 19p13.3 is among the most
frequently mutated genes in lung ACs and ASCs (6-22%), whereas in lung SCCs the
mutations are rare (1,7-3,9%) and in SCLCs absent (Table 1 and Figure 6) (Cancer
Genome Atlas Research, 2012, 2014; Cerami et al., 2012; Ding et al., 2008; Imielinski et
al., 2012; Ji et al., 2007a; Koivunen et al., 2008; Peifer et al., 2012; Rudin et al., 2012;
Sanchez-Cespedes et al., 2002; Vassella et al., 2015). Lung cancer mutations in LKB1
are distributed mainly along the kinase domain of the protein. Multiple types of somatic
lung cancer mutations in LKB1 have been identified, including nonsense, indel
frameshift mutations, large deletions, and intronic mutations in splicing conserved sites.
A large proportion of the mutations lead to protein truncations and thus inactive LKB1
(Sanchez-Cespedes, 2007). Interestingly, loss of LKB1 has been found to co-occur with
KRAS mutations in NSCLC with an overall incidence of 30%. Moreover, the combined
loss of LKB1 and mutation in KRAS was shown to be associated with a poorer prognosis
in advanced NSCLC (Calles et al., 2015).
Mouse lung-specific Lkb1 deletion on its own does not lead to a discernible
phenotype (Ji et al., 2007a). However, the combined loss of Lkb1 with expression of
oncogenic BRAFV600E bypasses induction of BRAFV600E-induced cellular senescence in
mouse lung, promoting malignant carcinomas (Gonzalez-Sanchez et al., 2013). In
addition, combined conditional loss of Lkb1 with expression of oncogenic Kras
exacerbates lung tumour progression, switches tumour histopathologies from AC to a
mixed spectrum of three main NSCLC histopathologies including the more rare ASC,
and promotes metastasis in 61% of KrasLSL-G12D/+; Lkb1fl/fl or KrasLSL-G12D/+; Lkb1fl/-
(from here on referred to as KL) (Ji et al., 2007a). Mechanistically, the Lkb1 mediated
lung tumour suppression in the KL model is linked to reduction of AMPK activation.
Whereas KrasLSL-G12D/+ ACs are positive for phosphorylated AMPK and acetyl-CoA
carboxylase (ACC), an enzyme functioning in the biosynthesis and oxidation of fatty
acids, the KL ACs show clear reduction in both phospho-AMPK and phospho-ACC (Ji
et  al.,  2007a).   Interestingly,  metastases  in  KL  mice  were  reported  to  be  AC-like  and
SCC-like metastases were not detected. Moreover, the KL ACs but not SCCs showed
elevated expression of angiogenesis and/or metastasis genes, such as Nedd9, Vegfc,
Loxl1, Pdgf receptor and Mmp2, suggesting that the metastases detected in the KL model
are primarily disseminated from ACs (Ji et al., 2007a).
Subsequent studies have suggested that KL ACs transdifferentiate via an ASC
intermediate to SCCs. Expression of lysyl oxidase (Lox) and the Hippo pathway
transcriptional coactivator YAP1 where shown to maintain the KL AC histopathology,
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concomitant with their reduction in KL SCCs. Furthermore, pharmacological LOX
inhibition or genetic Yap1 ablation promoted the transdifferentiation detected as an
increased number of SCC lesions (Gao et al., 2014; Han et al., 2014). These studies
linked the AC-ASC-SCC transdifferentiation to collagen disposition and ECM
remodelling, as well as regulation of cell growth and apoptosis. In addition, also reactive
oxygen species (ROS) accumulation was shown to modulate transdifferentiation, with
KL ACs showing higher amounts of ROS, and treatments with the ROS scavenger N-
acetyl cysteine reducing the amount of SCCs (Li et al., 2015). Lentiviral introduction of
a constitutively active AMPK mutant (caAMPK) in KL mice decreased the amount of
ROS in ACs and reduced SCC numbers, thus directly linking the AMPK pathway to
both regulation of ROS and transdifferentiation. Moreover, pentose phosphate pathway
(PPP) deregulation and impaired fatty acid oxidation were both shown to affect ROS and
transdifferentiation. Specifically, glucose-6-phosphate dehydrogenase (G6PD), a
regulator of PPP activity, showed lower enzymatic activity and protein expression in KL
ACs compared with SCCs, and in vivo G6pd shRNA treatment increased the incidence
of ACs (Li et al., 2015). Interestingly, conditional lung-specific Lkb1-loss in
combination with Pten-loss or overexpression of Sox2 leads to generation of pure lung
SCCs without apparent transdifferentiation from AC (Mukhopadhyay et al., 2014; Xu et
al., 2014a). Taken together, these results indicate that the loss of Lkb1 contributes to
SCC development, either during the process of tumour progression or directly triggering
squamous differentiation upon tumour initiation.
2.2.3.7 EPHA3
The EPH receptor tyrosine kinase A3 (EPHA3) is a member of the EPH receptor
tyrosine kinase (RTK) family, which is the largest family of RTKs, containing altogether
14 members in humans (Gucciardo et al., 2014; Pasquale, 2008). The name EPH is
derived from the erythropoietin-producing hepatocellular carcinoma cell line from which
the first member of the family, EPHA1,  was  cloned  (Hirai  et  al.,  1987).  EPHA3  was
identified on the cell surface of a pre-B acute lymphoblastic leukemia cell line, LK63,
using the IIIA4 monoclonal antibody (Boyd et al., 1992).
In vivo studies have indicated a crucial role for EphA3 in embryonic heart
development. The null mouse model of EphA3 was initially generated to study the
potential functional role of EphA3 in the developing medial motor column. Contrary to
the hypothesis, derived from its expression pattern, no effect on motor axon direction to
muscle targets was detected in EphA3-null mice (Vaidya et al., 2003). Instead, 75% of
the EphA3-null mice died at birth due to cardiac abnormalities including defects in the
development of their atrial septa and atrioventricular endocardial cushions. These defects
were caused by defective endothelial-to-mesenchymal transition (EndMT), a specific
form of mesenchymal conversion that generates progenitors of the atrioventricular
valves. Endocardial cushion explants from E10.5 wt and EphA3-null embryos showed
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fewer migrating cushion cells in a type I collagen matrix, indicating that this specific
type of EMT process is altered in EphA3-null embryos (Stephen et al., 2007).
2.2.3.7.1 EPH/EPHA3 signalling
EPH receptor-mediated signalling has been shown to regulate cellular processes
including modulation of the actin cytoskeleton, cell-substrate adhesion, intercellular
junctions, cell shape and movement, as well as cell proliferation, survival,
differentiation, and secretion (Gucciardo et al., 2014; Pasquale, 2008). EPH receptor
signalling typically functions in cell sorting and tissue patterning, primarily during
embryogenesis, through mechanisms linked to cell attraction and repulsion (Nievergall
et al., 2012; Pasquale, 2005).
The EPHs are transmembrane proteins which interact with their ligands via an
extracellular ligand-binding domain (LBD) in cell-cell contacts. EPH receptor ligands,
the  ephrins,  are  classified  into  two subgroups,  class  A and B,  based on their  sequence
similarities and affinities. The EPHA receptors typically interact with ephrin-A ligands,
while EPHB receptors interact with ephrin-B ligands, although exceptions have been
found (Grunwald et al., 2004; Himanen et al., 2004; Qin et al., 2010; Smith et al., 1997).
A ligand for EPHA3, ephrin-A5, was purified using a biosensor-based affinity detection
approach (Lackmann et al., 1996) and later shown to be one of the preferred ligands for
EPHA3 (Lackmann et al., 1997). In addition to ephrin-A5, also ephrin-A1 (encoded by
Efna1 gene) is indicated as a ligand for EPHA3, as it is expressed in the endothelial
lining adjacent to the EphA3-positive endocardial cushions in the developing heart
(Stephen et al., 2007). Interestingly, Efna1-null mice exhibit impaired cardiac function
with increase in the amount of atrioventricular endocardial cushions indicating excess in
the amount of cell which undergo EndMT during heart valve development (Frieden  et
al., 2010). Unlike EphA3-null mice, Efna1-null mice do not die prenatally, suggesting
additional and possibly compensating mechanisms for ephrin-A1 function. Indeed,
ephrin-B2 is expressed in the epithelial layer of the developing heart valve leaflets and
mice homozygous for a carboxy-terminal cytoplasmic domain mutant of ephrin-B2 show
thickened cardiac valves similar to Efna1-null mice (Cowan et al., 2004). These results
suggest that multiple ephrin ligands function together with EPHA3 in a context and
tissue dependent manner.
Unlike RTK signalling in general, EPH receptor and ephrin ligand signalling occurs
in a bidirectional manner, both in the receptor-expressing cell (forward signalling) and in
the ligand-expressing cell (reverse signalling) (Pasquale, 2008). As a consequence of
ligand binding, the EPH receptors are autophosphorylated at two tyrosine residues within
the juxtamembrane domain and one tyrosine residue within the activation segment of the
kinase domain. The conformational changes resulting from autophosphorylation release
the inhibition of the receptor kinase domain, triggering downstream signalling. The
glycosylphosphatidylinositol (GPI)-linked ephrin-As use lipid raft-mediated interaction
with transmembrane protein complexes and recruit signalling adaptor molecules such as
the Src family kinase Fyn (Davy et al., 1999).
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The EPH-ephrin interaction generally results in activation of downstream signalling
pathways including the PI3K-AKT, RAS-MAPK, Janus kinase/Signal transducer and
activator of transcription (JAK-STAT), as well as the focal adhesion kinase (FAK) and
SRC kinase-mediated RhoA signalling. Also EPHA3 has been shown to signal through
some of these pathways. Ephrin-A5-induced EPHA3 signalling can lead to changes in
cell adhesion mediated by RhoA signalling in human epithelial kidney 293T, melanoma,
and rhabdomyosarcoma cells (Clifford et al., 2008; Lawrenson et al., 2002). In addition,
overexpression of wild-type EPHA3 in the human lung cancer cell line H1299 leads to
both ephrin-A5- and ephrin-A1-induced reduction of phospho-AKT levels (Zhuang et
al., 2012). Similarly, EPHA2 has been shown to function via a feedback loop to regulate
Ras-Raf-MAPK (Macrae et al., 2005) and Ras–PI3K–AKT (Menges and McCance,
2008) pathways.
In addition to the traditional receptor-ligand interaction in cell-cell contacts, ephrin
ligands interact with EPH receptors also laterally, in cis in the same cell. This interaction
occurs independently of the N-terminal LBD of the receptor and inhibits the activation
of the receptor by the trans-expressed ephrins (Carvalho et al., 2006; Falivelli et al.,
2013). Additionally, the actual levels of EPH receptor expression can regulate their
activity. Clusters formed by the EPH receptors within the cell membrane, induced by
high abundance of the receptors rather than ligand interaction, lead to activation of the
receptors (Wimmer-Kleikamp et al., 2004). Another mode of EPH receptor regulation
was evidenced for EPHA7. The truncated form of EPHA7, encoded by an alternative
splice variant of EPHA7, was shown to suppress tyrosine phosphorylation of the full-
length EPHA7 (Holmberg et al., 2000). This shorter soluble form of EPHA7 was later
shown to act as a tumour suppressor in follicular lymphoma by binding to EPHA2,
thereby inhibiting oncogenic signals including ERK and SRC kinases (Oricchio et al.,
2011). Moreover, an increasing number of studies reveal new mechanisms explaining
regulation of EPH-ephrin signalling.  Disintegrin and metalloprotease 10 (ADAM10)-
mediated cleavage of membrane-bound ephrin-A5 ligand interacting with EPHA3 has
been shown to lead to Eph-ephrin internalisation into the EPH expressing cell (Janes et
al., 2005). Additionally, membrane type-1 matrix metalloproteinase (MT1-MMP)-
mediated cleavage of EPHA2 has been shown to occur subsequently to ephrin binding.
EPHA2 cleaved by MT1-MMP at the fibronectin type-III domain in cis translocates
inside the cell, leading to SRC activation as well as an increase in RhoA activity and cell
junction disassembly (Sugiyama et al., 2013).
2.2.3.7.2 EPHA3 and cancer
The human EPHA3 gene at chromosomal location 3p11.2 is a putative lung cancer
gene, mutated in 6-16% of lung ACs, approximately 6% of lung SCCs and in 2-3% of
SCLCs. Both deletions and amplifications in the genetic locus of EPHA3 are found,
respectively in 0,5% and 2% of ACs, or 2% and 4% of SCCs. (Table 1 and Figure 6)
(Cancer Genome Atlas Research, 2012, 2014; Cerami et al., 2012; Ding et al., 2008;
Imielinski et al., 2012; Peifer et al., 2012; Rudin et al., 2012). The lung cancer mutations
in EPHA3 are located along the protein and they are mostly composed of missense
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mutations. The effect of the mutations has been studied in vitro using transient
transfection and in vitro kinase assay methods using 293T cells. Selected cancer point
mutations in the extracellular domains of EPHA3 can affect ephrin ligand binding and/or
the level of receptor cell surface localization, and selected kinase domain mutations
impair the kinase activity of EPHA3 (Lisabeth et al., 2012).
One of the reported mechanisms of EPHA3 tumour suppression is its ephrin-A5- or
ephrin-A1-induced activation of cellular apoptosis via reduction of phospho-AKT, and
subsequent reduced phosphorylation of FOXO3A. These signaing activities are specific
to wildtype EPHA3, as overexpression of EPHA3 G187R or G766E cancer mutation
variants do not trigger a similar effect. Moreover, EPHA3 cancer mutations leading to
receptor inactivation were shown to act in a dominant negative manner via inhibiting the
activity of the wildtype receptor (Zhuang et al., 2012).
In addition to tumour-suppressing effects, EPHA3 has been indicated to possess
tumour-promoting functions. EPHA3 is highly expressed in the most aggressive
mesenchymal subtype of glioblastoma, where its expression is particularly detected in
undifferentiated, tumour-initiating cells. shRNA- mediated downregulation of EPHA3
leads to increased ERK/MAPK pathway activation, increased cell differentiation and
reduced capacity of sphere formation in primary glioblastoma cell cultures (Day et al.,
2013). EPHA3-mediated control of the ERK/MAPK pathway has also been shown in
neural precursor cells, where ephrin-A1 stimulation leads to ERK activation and
increased neurogenesis, and therefore increased differentiation (Aoki et al., 2004).
Interestingly, glioblastoma primary cell cultures expressing high levels of EPHA3 show
low levels of EPHA3 kinase activity (Day et al., 2013). Activation of EPHA3 with a
monoclonal antibody in the EPHA3 positive glioblastoma cell line U251 leads to rapid
EPHA3 activation and reduction of cell proliferation (Day et al., 2013). These results
suggest that high expression of EPHA3 in glioblastoma cells maintains the
undifferentiated status of the cells, but in a kinase-independent fashion via control of
ERK/MAPK pathway. Interestingly, normal physiological function of EphA3 is also
linked to mesenchymal cell identity in mice as loss of EphA3 leads to reduced
endothelial-to-mesenchymal transition during heart development (Stephen et al., 2007).
In a recent study, activation of EPHA3 has also been linked to tumour suppression,
via disruption of the tumour microenvironment (TME) (Vail et al., 2014). This study
reported EPHA3 overexpression in the microenvironment of a range of human cancers
and mouse tumour xenografts. EPHA3 expression was detected in mouse bone marrow–
derived cells with mesenchymal and myeloid phenotypes. Activation of mesenchymal–
stromal/stem cells (MSCs) with EPHA3 agonist led to MSC contraction, and apoptosis
in vitro, and disruption of the stromal tumour architecture leading to tumour growth
inhibition in vivo (Vail et al., 2014). Together, these studies indicate both tumour
suppressing, as well as tumour promoting, roles for EPHA3. However, thus far no
studies have addressed the in vivo functional role of EphA3 using murine genetically
engineered models.
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Figure 6. Genetic alterations of KRAS, TP53, LKB1 (STK11) and EPHA3 in the three
main lung cancer histopathologies adenocarcinoma (AC), squamous cell carcinoma
(SCC), and small-cell lung cancer (SCLC). Data exported from cBioportal and based on
results from TCGA (Cancer Genome Atlas Research, 2012, 2014) and George et al.,
2015.
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2.3 Modelling lung cancer
Lung tumourigenesis is a multifactorial process, which over time creates tumours
consisting of subclones of regionally-separated genetic alterations and different levels of
genomic instability (de Bruin et al., 2014). Models that mimic the biological, genetic,
etiological, immunological, and therapeutic properties of human lung cancer are a
prerequisite for understanding the determinants of its biology, and for predictive testing
of new therapeutic molecules.
Currently, the best characterised and most frequently used platform for preclinical
testing of cancer therapeutics is the US National Cancer Institute 60 human tumour cell
line panel (NCI-60), used for in vitro drug screening and development (Abaan et al.,
2013). These cell lines have been valuable for early discoveries in cancer research.
Examples start from the discovery of oncogenes, such as RAS (Der et al., 1982), and
continue to the development of targeted therapies which block cell-autonomous
pathways such as EGFR activation (Wakeling et al., 2002). Yet, the in vitro and in vivo
(xenograft) testing of these cell lines, when compared with results from phase II trials,
has shown good predictability only of compounds with anti-proliferative activity
(Johnson et al., 2001a). Moreover, it has been shown that their continued cultivation
facilitated their adaptation to two dimensional (2D) conditions. Additionally, all cell
lines showed a higher resemblance to each other, regardless of the tissue-of-origin, than
to their clinical source samples, likely due to culture-acquired properties such as gain or
loss of genetic information, alterations in growth and invasion, and/or selective loss of
cell populations (Gillet et al., 2011).
The interest in developing and using more sophisticated preclinical models has led
to the creation of more advanced models, such as patient derived xenografts (PDX) and
genetically engineered mouse models (GEMMs). PDX models have been shown to
recapitulate the heterogeneity and intrinsic properties of human primary tumours
(Hidalgo et al., 2014). Moreover, lung cancer PDX models have shown molecular
characteristics of the primary tumours and correlation with clinical response to cytotoxic
agents (Fichtner et al., 2008; Fiebig et al., 1985). GEMMs, on the other hand, are
particularly useful if tumour-stromal interactions are taken into account. A study using a
mouse model of Burkitt’s lymphoma showed that paracrine factors in the tumour
microenvironment can affect lymphoma cell survival after genotoxic chemotherapy
administration (Gilbert and Hemann, 2010) showing the importance of the physiological
tumour microenvironment in cancer treatment testing. Moreover, more and more studies
have reported on the role of the tumour immune microenvironment in cancer
progression. For example, in a breast cancer mouse model driven by conditional loss of
Cdh1 and Trp53, tumour expressed IL1B was shown to induce expression of IL17 in
gamma delta (γδ) T-cells, which induced granulocyte colony-stimulating factor (G-
CSF)-dependent infiltration of myeloid derived suppressor cells (MDSCs) to the tumour
site.  The  infiltration  of  the  MDSCs  was  shown  to  suppress  CD8+ T-cells and promote
metastasis (Coffelt et al., 2015).
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Additionally, a recent study underlined the importance of carcinogen-induced
models in the study of lung tumourigenesis. Murine lung tumours, initiated either by
carcinogens or transgene expression, resulted in different cancer genomic landscapes.
Methyl-nitrosourea (MNU) carcinogen-induced lung tumours carried numerous non-
synonymous point mutations in contrast to the tumours induced by genetic activation of
mutant Kras, which were enriched with copy number alterations (Westcott et al., 2015).
Thus, the researchers concluded that these two models recapitulate genetic versus
epigenetic features of cancers, predominantly representing mutations or copy number
changes (Ciriello et al., 2013).
The following sections describe lung cancer GEMMs with specific concentration on
genetic alterations, tumour histopathologies, cell-of-origin, and immune cell contexts
relevant to this thesis work.
2.3.1 Genetically engineered mouse models of lung cancer
Genetic engineering of the murine genome is a powerful tool to address the
functional importance of lung cancer genes in disease initiation and progression (Kwon
and Berns, 2013). Genetic engineering started with traditional knock-out technology
with microinjection of embryonic stem cells with vectors executing target genome
homologous recombination (Capecchi, 2005; Schwartzberg et al., 1989). Tumour studies
using full knock out mice have often been limited by the embryonic lethality of the mice
due to the importance in embryonic development of the genes studied (Jacks et al., 1992;
Koera et al., 1997). Use of conditional allelic systems, such as Cre–loxP or Flp–FRT,
have permitted modulation of genetic loci in tissue and time-specific manners and have
thus enabled in vivo study of cancer genes in a way which mimics the sporadic human
cancer genetic alterations (Jackson et al., 2001; Meuwissen et al., 2003; Sadowski, 1995;
Sauer and Henderson, 1988; Sternberg and Hamilton, 1981). Moreover, new state-of-
the-art technologies including the use of the prokaryotic type II CRISPR- (clustered
regularly interspaced short palindromic repeats) Cas9- (CRISPR-associated protein-9
nuclease) system, which enables simultaneous introduction of genetic alterations in
single embryonic cells, is accelerating the process of in vivo genetic manipulation to
functionally test single or combined genetic alterations (Sanchez-Rivera and Jacks,
2015; Sanchez-Rivera et al., 2014).
2.3.1.1 Genetic mutations
The first generations of lung cancer GEMMs used overexpression of putative
oncogenes such as c-Myc or EGF, leading to the development of ACs (Ehrhardt et al.,
2001). One of the earliest studies used expression of simian virus large T-antigen (SV40
Tag) under an SPC-promoter. The SV40 Tag binds to both p53 and RB1 in an inhibitory
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manner, resulting in uncontrolled cellular proliferation. In contrast to results showing
that combined loss of Trp53 and Rb1 drives development of SCLC (Meuwissen et al.,
2003), SV40 Tag- induced tumours were classified as adenocarcinomas with papillary
and lepidic growth (Wikenheiser et al., 1992), suggesting differences between SV40 Tag
and direct mutation-mediated suppression of p53 and RB1.
A number of studies have generated in vivo evidence for the cancer driver roles of
the most common genetic alterations of lung cancer, including mutant EGFR and EML4-
ALK translocations. Expression of conditional human EGFR exon 19 deletion and exon
21 L858R mutation in mouse lung CC10-expressing cells leads to ACs with local
invasion (Ji et al., 2006; Politi et al., 2006). Similarly, expression of the human EML4-
ALK fusion gene in SPC+ cells leads to hundreds of adenocarcinoma nodules within only
a few weeks after birth (Soda et al., 2008).  Most recently, CRISPR-Cas9-mediated
engineering of the mouse endogenous Eml4-Alk rearrangement resulted in development
of lung tumours resembling human ALK-rearrangement positive NSCLC (Maddaloni et
al., 2015; Soda et al., 2008).
Several GEMM studies have investigated the functional role and possible targetable
features of oncogenic Kras and  loss  of Trp53 and Lkb1 in lung tumourigenesis. Three
studies in year 2001 reported a mouse model carrying Kras G12D mutation, all resulting
in development of lung ACs. Jacks and colleagues created mouse strains carrying
oncogenic Kras G12D activated by a spontaneous recombination event (Kras latent
allele, KrasLA). These mice were highly predisposed to a range of tumour types,
predominantly early onset lung tumours (Johnson et al., 2001b). Two inducible Kras
G12D mouse strains were also created:  one with reverse tetracycline-controlled
transactivator (rtTA) controlled Kras G12D (Fisher et al., 2001) and one with Cre-loxP
sites flanking a stop codon prior to the G12D mutation (KrasLSL-G12D/+) (Jackson et al.,
2001). All of these models have been combined with several other genetic modifications
in studies exploring the effect of co-occurring mutations on lung tumourigenesis. These
studies have clearly shown how loss of a tumour suppressor accelerates tumour
progression initiated by activation of an oncogene. Table 2 lists selected models which
used the conditional KrasLSL-G12D/+ model (Jackson et al., 2001) in combination with
other genetic alterations. These include genes involved in cell cycle regulation and
sensing of oncogenic and genotoxic stress, such as Trp53, Rb1, Rbl2, and Map2k7; genes
in the control of cellular metabolism, such as Lkb1; and genes acting downstream of Ras,
such as Pten (references listed in the table 2). Loss of the transcription factor Nkx2-1,
which has a role in cell differentiation during lung development, accelerates lung
tumourigenesis (Snyder et al., 2013). This acceleration coincides with the conversion of
the cellular transcription profile to a gastric lineage, as well as the development of
mucinous ACs, a histopathology not detected in oncogenic Kras-induced tumours
(Snyder et al., 2013). In addition, loss of the hypoxia-inducible transcriptional regulator
Hif2a as well as Notch2, a gene controlling cell fate decisions during embryonic
development, accelerates oncogenic Kras-driven AC formation (Baumgart et al., 2015;
Mazumdar et al., 2010). Interestingly, in contrast to loss of Notch2, Notch1-loss reduces
the oncogenic Kras-driven AC burden (Baumgart et al., 2015), indicating differential
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roles  for  the  members  of  the  same  signalling  pathway.  Conditional  expression  of  an
activated form of NOTCH1/2 (the NOTCH1/2 intracellular domain, N1/2ICD) in
combination with oncogenic Kras promotes papillary AC formation in CC10+ airway
cells (Xu et al., 2014b), indicating that Notch2-mediated tumour suppression is
dependent on the function of the full length protein. Furthermore, expression of a
dominant negative form of mastermind-like protein (DNMaml1), inhibiting the
transcriptional activation of Notch targets, interferes with oncogenic Kras-driven lung
ACs from CC10+ cells (Xu et al., 2014b). Deletion of RAS downstream effectors such as
Rac1 and Pik3r2 together with Pik3r1 inhibits oncogenic Kras-driven AC development
(Engelman et al., 2008; Kissil et al., 2007). Together, these results indicate a clear
cooperation between Ras and other pathways during lung tumourigenesis. Moreover, the
results highlight the power of mouse models to confirm functional cooperation between
pathways suspected to be key or even essential drivers of human lung cancer.
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Table 2. Selected Kras G12D lung cancer mouse models. Change in tumour burden and






KrasLSL-G12D/+ Ad5-CMV-Cre AC spectrum* (Jackson et al., 2001)
KrasLSL-G12D/+;Spry2fl/fl Ad5-CMV-Cre Increased AC burden (Shaw et al., 2007)
KrasLSL-G12D/+;Dicerfl/fl Ad5-CMV-Cre Increased AC burden (Kumar et al., 2007)
KrasLSL-G12D/+;Trp53fl/fl Ad5-CMV-Cre Progressed AC with lymph node
metastases
(Jackson et al., 2005)
KrasLSL-G12D/+;Trp53LSL-R172H/- Ad5-CMV-Cre Progressed AC with lymph node
metastases
(Jackson et al., 2005)
KrasLSL-G12D/+;Trp53LSL-R270H/- Ad5-CMV-Cre Progressed AC with lymph node
metastases
(Jackson et al., 2005)
KrasLSL-G12D/+;Lkb1fl/fl Ad5-CMV-Cre Progressed tumourigenesis with
broadened tumour histopathology
spectrum (AC, ASC, SCC and LCC)
and metastasis
(Ji et al., 2007a)
KrasLSL-G12D/+;Ptenfl/fl CC10-Cre Progressed AC (Iwanaga et  al.,
2008)
KrasLSL-G12D/+;Rb1fl/fl Ad5-CMV-Cre Increased AC burden (Ho et al., 2009)
KrasLSL-G12D/+;Rbl2fl/fl Ad5-CMV-Cre Increased AC burden (Ho et al., 2009)
KrasLSL-G12D/+;tetO-YapS127A Ad5-CMV-Cre +
rtTA
Increased AC burden and
progressed tumourigenesis
(Lau et al., 2014)
KrasLSL-G12D/+;Nkx2-1fl/fl Ad5-CMV-Cre Increased AC burden and additional
mucinous AC
(Snyder et al., 2013)
KrasLSL-G12D/+;Hif2afl/fl Ad5-CMV-Cre Increased AC burden (Mazumdar et  al.,
2010)
KrasLSL-G12D/+;Map2k7fl/Δ Ad5-CMV-Cre Increased AC burden (Schramek et  al.,
2011)




CC10-CreER Increased AC burden in airways (Xu et al., 2014b)
KrasLSL-G12D/+;Tgfbr2fl/fl K5-CrePR Increased AC burden (Malkoski et  al.,
2012)
KrasLSL-G12D/+;Rac1fl/fl Ad5-CMV-Cre Decreased AC burden (Kissil et al., 2007)
KrasLSL-G12D/+;Pik3r2-/-;
Pik3r1fl/fl
Ad5-CMV-Cre Decreased AC burden (Engelman et  al.,
2008)




CC10-CreER Decreased AC burden (Xu et al., 2014b)
*Epithelial hyperplasia of bronchioles, adenomatous hyperplasia, adenomas, both solid
and papillary adenocarcinomas **Cell-autonomous and ligand-independent Notch
activation by the intracellular domain (ICD) of Notch1. ***Notch inhibition by
dominant-negative Mastermind-like protein (DNMaml1).
The functional consequence of Trp53-loss in lung cancer progression has been
studied in combination with several other genetic alterations (listed in Table 3). In
addition to the cooperation of oncogenic Kras and Trp53-loss, accelerating progression
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of lung ACs (Jackson et al., 2005), the loss of Trp53 cooperates with the loss of Rb1 in
the development of lung SCLCs (Meuwissen et al., 2003). Furthermore, Trp53- and Rb1-
loss-driven SCLC development is accelerated when Rbl2 (also  known as  p130),  a  cell
cycle inhibitor related to RB1, is also deleted (Schaffer et al., 2010). Moreover, in
contrast to results from oncogenic Kras-driven ACs, loss of both Notch1 and Notch2
inhibits SCLC development driven by loss of Trp53, Rb1 and Rbl2 (George et al., 2015),
indicating that Notch pathway activation is a key factor driving SCLC progression.






Trp53fl/fl Ad5-CMV-Cre AC (Meuwissen et al.,
2003)




Trp53fl/fl;Rb1fl/fl;Rbl2fl/fl Ad5-CMV-Cre Increased SCLC burden when






Ad5-CMV-Cre Decreased SCLC burden when
compared to Trp53fl/fl; Rb1fl/fl; Rbl2fl/fl




Ad5-CMV-Cre Decreased SCLC burden when
compared to Trp53fl/fl; Rb1fl/fl; Rbl2fl/fl
(George et al., 2015)
Trp53fl/fl;BrafCA/+ Ad5-CMV-Cre Increased AC burden and progressed




* Conditional expression of an activated form of NOTCH1/2 (NOTCH1/2 intracellular
domain, N1/2ICD)
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In addition, the functional role of Lkb1-loss in lung cancer progression has been
studied in combination with several other genetic alterations. Table 4 lists selected
mouse models that have used the conditional loss of Lkb1 (Bardeesy et al., 2002) to
study lung cancer. Loss of Lkb1 accelerates lung tumourigenesis driven by oncogenic
Kras and Braf (Gonzalez-Sanchez et al., 2013; Ji et al., 2007a; Mukhopadhyay et al.,
2014). Interestingly, rather than merely affecting the tumour progression, Lkb1-loss
switches the tumour histopathology development towards SCC (Ji et al., 2007a;
Mukhopadhyay et al., 2014; Xu et al., 2014a). Lung specific loss of Pten alone leads to
lung hyperplasia or to rare ACs, depending on the used method (Liu et al., 2015;
Malkoski et al., 2014). Similarly, overexpression of Sox2 in the lung promotes
hyperplasia and AC tumourigenesis accompanied with expression of squamous markers
(Lu et al., 2010). Lung specific loss of Lkb1 combined with both Pten-loss and
overexpression of Sox2 leads to an increase in tumour progression and a switch to SCC
development (Mukhopadhyay et al., 2014; Xu et al., 2014a). Nevertheless, LKB1
mutations are rare in human lung SCCs (1,7-3,9%), and it remains to be elucidated if the
molecular events linked to Lkb1-loss in SCC development are different in mice. Another
possibility is that LKB1 loss constitutes only a rare event in human SCC, defining a
small subset of this histopathology.






Lkb1fl/fl Ad5-CMV-Cre No tumour formation (Ji et al., 2007a)
Lkb1fl/fl;BrafCA/CA Tyr::CreERT2 +
Ad5-CMV-Cre
AC, Lkb1-loss bypasses senescence (Gonzalez-Sanchez
et al., 2013)
Lkb1fl/fl;Ptenfl/fl Ad5-CMV-Cre SCC (Xu et al., 2014a)
Lkb1fl/fl Lenti-Sox2-CMV-
Cre
SCC with rare AC (Mukhopadhyay et
al., 2014)
KrasLSL-G12D/+;Lkb1fl/fl Ad5-CMV-Cre Progressed tumourigenesis with
broadened tumour histopathology
spectrum (AC, ASC, SCC and LCC) and
frequent metastases when
compared to KrasLSL-G12D/+
(Ji et al., 2007a)
KrasLSL-G12D/+;Lkb1fl/fl;
SPC-YAPS127A
Ad5-CMV-Cre Decreased incidence of SCC when
compared to KrasLSL-G12D/+; Lkb1fl/fl
(Gao et al., 2014)
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2.3.1.2 Histopathology
The histopathological analysis of lung tumour samples is a standard procedure of
lung cancer diagnosis, and is used to guide treatment decisions. In the case of murine
lung cancer models, an accurate and comparative histopathology analysis can help to
stratify models to mimic specific subsets of cancer patients (Figure 7). Several GEMMs
expressing known human lung AC gene alterations develop a disease similar to that of
humans, thus validating the use of mouse models in the study of human disease. These
include models conferring expression of mutated EGFR (Ji et al., 2006), mutant Kras
(Jackson et al., 2001), loss of Trp53 (Meuwissen et al., 2003) or Eml4-Alk rearrangement
(Maddaloni et al., 2015; Soda et al., 2008). Moreover, expression of mutated Ras
effectors such as BRAF and PIK3CA also drive lung ACs (Engelman et al., 2008; Ji et
al., 2007b), further supporting the role of Ras activation in lung AC development.
Interestingly, loss of the transcription factor Nkx2-1 in combination with oncogenic
Kras, results in development of mucinous ACs, a tumour histopathology not detected in
mice with activation of oncogenic Kras alone (Snyder et al., 2013). Loss of Nkx2-1 alters
differentiation and promotes the metastatic potential of KP ACs which is mechanistically
linked to activation of high mobility group AT-hook 2 (Hmga2) expression (Winslow et
al., 2011). Thus, loss of Nkx2-1 is linked to lung tumours with a lower differentiation
status and increased metastatic potential, such as that seen in some cases of mucinous
AC histopathology.
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Figure 7. Immunohistochemistry-based characterisation is utilised to stratify mouse lung
tumours to show their similarity to human disease. Both human and mouse SCC tumours
are positive for p63 and KRT5 SCC markers and negative for NKX2-1 AC marker.
Scale bars 100 mm. Adapted from Xu et al. 20014a.
Table 5 lists selected lung SCC and ASC GEMMs. The development of murine
squamous cell carcinomas is triggered by lung specific expression of oncogenic Kras
G12D in combination with loss of Lkb1 or Tgfbr2 (Ji et al., 2007a; Malkoski et al.,
2012). As discussed earlier, also conditional loss of Lkb1 in combination with loss of
Pten (Xu et al., 2014a) (Figure 7) or overexpression of Sox2 (Mukhopadhyay  et  al.,
2014) leads to the development of lung SCCs. The Lkb1 loss  is  required  for  these
tumours to develop as SCCs since the conditional loss of Pten or expression of Sox2
alone  only  results  in  lung  hyperplasias  or  ACs  (Liu et al., 2015; Lu et al., 2010;
Malkoski et al., 2014). Interestingly, expression of a kinase-inactive IKKα, a subunit of
the IKK complex regulating NF-κB activation, leads to development of spontaneous
SCCs, which show significantly decreased protein levels of LKB1 expression (Xiao et
al., 2013). Moreover, these SCC tumours are characterised by infiltration of F4/80+
tumour-associated macrophages (TAMs), and depletion of TAMs with liposome
treatment prevents SCC formation (Xiao et al., 2013). Also, the combined loss of Pten
and Tgfrb2 results in SCCs with low incidence (Malkoski et al., 2014). Also Notch
signalling is linked to squamous differentiation. Inhibition of Notch with DNMaml1
expression blocks oncogenic Kras-driven ACs and induces development of SOX2+,
KRT5+, and p63+ squamous hyperplasia from lung alveolar cells (Xu et al., 2014b).
Finally, overexpression of human CK14 in CC10+ progenitor cells leads to hyperplasia
with squamous differentiation and occasional squamous metaplasia (Dakir et al., 2008).
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Currently no targeted inhibitors are available for lung SCCs highlighting the importance
of the development of preclinical models for this lung tumour histopathology.
ASC histopathology tumours are seen following 1) expression of oncogenic Kras
G12D in combination with loss of Lkb1 (Ji et al., 2007a), 2) expression of an in-frame
M774 AYVM insertion of HER2 (Perera et al., 2009), or 3) combined loss of Smad4 and
Pten (Liu  et  al.,  2015).  ASCs,  a  relatively  rare  histopathology  in  humans,  exhibit  a
mutational spectrum similar to lung ACs. As presented previously, studies using the KL
mouse model have shown evidence for ASC being an intermediate histopathology stage
between AC and SCC (Han et al., 2014).






CC10-hK14 * Hyperplasia with SC differentiation and
rare SC metaplasia
(Dakir et al., 2008)
IkkaKA/KA** Spontaneous SCC (LKB1 levels
significantly decreased)
(Xiao et al., 2013)
hHER2YVMA CC10-rtTA ASCs with few ACs (Perera et al., 2009)
KrasLSL-G12D/+;Lkb1fl/fl Ad5-CMV-Cre AC, ASC, SCC, and LCC (Ji et al., 2007a)
KrasLSL-G12D/+;Tgfbr2fl/fl K5-CrePR AC with rare SCC (Malkoski et al.,
2012)
Ptenfl/fl;Smad4fl/fl CCSPiCre ASC (Liu et al., 2015)
Tgfbr2fl/fl;Ptenfl/fl K5-CrePR AC with rare SCC (Malkoski et al.,
2014)
Lkb1fl/fl;Ptenfl/fl Ad5-CMV-Cre SCC (Xu et al., 2014a)
Lkb1fl/fl Lenti-Sox2-
CMV-Cre
SCC with rare AC (Mukhopadhyay et
al., 2014)
*Human CK14 under CC10 promoter, ** Dominant negative, kinase-dead IKKα
Alterations leading to loss of of RB1 and TP53 in human SCLC are obligatory
events for this tumour histopathology (George et  al., 2015). Similarly, the loss of Rb1
and Trp53 appears to be a prerequisite also for murine SCLC development, as no SCLC
develops from NE cells with ectopic expression of Hras, even following carcinogen
nitrosamine treatment (Sunday et al., 1999).
2.3.1.3 Cell-of-origin
As introduced earlier, multiple lung epithelial progenitor cells have been identified
based on their capacity to self-renew and/or differentiate into other lung epithelial cells
(section 2.1.1). These progenitor cell types include basal cells, Clara cells, BASCs and
AT2 cells (Leeman et al., 2014). Interestingly, recent studies comparing tumour
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initiation, progression, and histopathology distribution of murine lung tumours derived
from different cells-of-origin have shown that the site of the oncogenic event impacts on
tumourigenesis, thus affecting tumour heterogeneity (Sutherland et al., 2011; Sutherland
et al., 2014; Xu et al., 2014b; Xu et al., 2012).
Past lung GEMM research mostly utilised specific promoters to drive genetic
alterations in distinct lung epithelial cells. Only recently, these cell sites have been
compared with an aim to identify the relative effect of the cell-of-origin on lung
tumourigenesis (Table 6). Specifically, these studies used promoters including CC10,
SPC  or  CGRP  to  drive  expression  of  Cre-recombinase  in  Clara,  AT2  or  NE  cells,
respectively. In the case of the CC10 promoter, Cre-mediated recombination is not
detected in alveolar cells when adenovirus-mediated delivery is used (Sutherland et al.,
2011). On the other hand, use of the CreER strain achieves Cre-mediated recombination
in alveolar AT2 cells following multiple doses of tamoxifen (Rawlins et  al., 2009b),
indicating a low level of CC10 expression in a subset of AT2 cells.
The progenitor-specific etiologies of lung ACs are relatively well described. Lung
ACs driven by activation of oncogenic Kras with or without Trp53-loss can originate
from Clara cells, AT2 cells, and BASCs (Kim et al., 2005; Sutherland et al., 2014; Xu et
al., 2012). However, the role of BASCs as a cell-of-origin for murine lung ACs at the
BADJ region is still under debate. Ad5-CMV-Cre-induced oncogenic Kras G12D
expression increased the number of BASCs (Kim et al., 2005), but Ad5-SPC-Cre-
infected KrasLSL-G12D/+ mice failed to develop cellular proliferative abnormalities at the
BADJ, accompanied by lack of an increase in the number of CC10/SPC double-positive
cells (Sutherland et al., 2014). Two possible explanations have been suggested; either
expression of SPC promoter-driven Cre via Ad5-SPC-Cre in CC10/SPC double-positive
cells is too low to activate the conditional KrasLSL-G12D/+ allele, or the CC10/SPC cells are
not the cell-of-origin of these lesions (Sutherland et al., 2014).
Interestingly, also the role of CC10+ lung epithelial cells as a cell-of-origin for
murine lung ACs has been shown to be context dependent (Figure 8). The CC10+ lung
airway cells are sensitive to adenovirus-mediated inflammatory responses, which can
accelerate tumour formation (Mainardi et al., 2014). When comparing Cre-ER- and Ad-
CMV-Cre-mediated expression of KrasG12V, Barbacid and colleagues showed that the
microenvironmental inflammatory response in bronchial cells caused by Ad-Cre
supported the progression of lung epithelial hyperplasias to low-grade adenomas, but not
to high grade ACs. The progression of lung epithelial hyperplasias to low-grade
adenomas was not seen following Cre-ER-mediated expression of KrasG12V (Mainardi et
al., 2014). Similar findings were reported combining CC10-CreER and SPC-CreER
strains with the KrasLSL-G12D/+;Trp53+/fl model (Xu et al., 2012). Specifically, Hogan and
colleagues showed that expression of oncogenic KrasLSL-G12D/+ in combination with
heterozygous loss of Trp53 in CC10+ airway cells did not lead to tumourigenesis,
whereas SPC+ cells with identical genetic alterations formed ACs in the alveoli (Xu et
al., 2012). Consistent with these results, adenovirus-mediated cell type-specific
expression of Cre resulted in oncogenic Kras-induced tumourigenesis from CC10-
expressing airway cells when compared to SPC-expressing cells (Sutherland et al.,
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2014). As discussed by Barbacid and colleagues, the inflammatory response caused by
the adenovirus infection may alter the differentiation status of the CC10+ airway cells,
sensitising cells to oncogenic Kras-induced transformation. Alternatively, and as
observed in pancreatic acinar cells, the inflammatory response may inhibit OIS (Guerra
et al., 2011). Indeed, KrasG12V-induced early lesions have been shown to exhibit clear
marks of OIS using markers such as senescence-associated β-galactosidase (SA-β-gal)
and p16INK4A, and this OIS was bypassed in fully developed ACs (Collado et al., 2005).
It is not yet known if OIS explains why CC10+ airway cells fail to progress to tumours in
the case of the CreER models. Either way, the inflammation-promoting
microenvironment might well recapitulate conditions seen in physiological lung airways.
Figure 8. CC10+ lung epithelial cells show a context-dependent propensity to develop
into murine lung ACs. The models presented are based on results reported by Sutherland
et al. 2014, Mainardi et al. 2014, and Xu et al. 2012.
The role of the cell-of-origin has also been shown to affect loss of Trp53- and Rb1-
driven murine SCLC development. Sutherland and colleagues studied the effect of the
cell-of-origin in murine SCLC using cell type-specific adenoviruses driving Cre-
60
mediated recombination in CC10-, SPC- or CGRP-expressing epithelial cells
(Sutherland et al., 2011). While CGRP+ cells  were  shown  to  initiate  NCAM1+ NE
tumours in 25 out of 30 mice, almost no SCLCs developed from CC10-expressing cells.
Interestingly, also SPC+ cells were shown to initiate development of SCLC (Sutherland
et al., 2011).
Taken together, these results indicate variation in the propensity of different lung
epithelial cells to give rise to lung tumours driven by specific genetic alterations.
Moreover, the sensitivity of airway CC10+ cells to inflammation exacerbated
tumourigenesis, implying intricate cooperation between oncogenic events, cellular
identity and microenvironmental factors such as inflammation-inducing pathogens
during lung tumourigenesis.







KrasLSL-G12D/+ Ad5-CC10-Cre AC spectrum with more high grade
tumours than in Ad5-SPC-Cre induced
(Sutherland et al.,
2014)
KrasLSL-G12D/+ Ad5-SPC-Cre AC spectrum (Sutherland et al.,
2014)
Trp53fl/fl;Rbfl/fl Ad5-CGRP-Cre SCLC (Sutherland et al.,
2011)
Trp53fl/fl;Rbfl/fl Ad5-CC10-Cre Bronchiolar hyperplasia, and rare SCLC (Sutherland et al.,
2011)




KrasLSL-G12D/+;Trp53fl/fl Ad5-CC10-Cre Progressive AC with more high grade
tumours than in Ad5-SPC-Cre induced
(Sutherland et al.,
2014)
KrasLSL-G12D/+;Trp53fl/fl Ad5-SPC-Cre Progressive AC (Sutherland et al.,
2014)
KrasLSL-G12D/+;Trp53+/fl CC10-CreER AC spectrum in the alveoli (Xu et al., 2012)
KrasLSL-G12D/+;Trp53+/fl SPC-CreER AC spectrum in the alveoli (Xu et al., 2012)
KrasLSL-G12D/+;Lkb1fl/fl SPC-CreER NSCLC histopathology spectrum with
AC, ASC, SCC and LCC
(Han et al., 2014)
KrasLSL-G12D/+;Lkb1fl/fl Ad5-SPC-Cre NSCLC histopathology spectrum with
AC, ASC, SCC and LCC
(Li et al., 2015)
2.3.1.4 Modelling lung cancer immune contexture
Tumour immune contexture refers to the population of different tumour-infiltrating
immune cell types, each conferring different effects on tumour progression (Fridman et
al., 2012). The cells in the tumour microenvironment are part of the cancer
immunoediting process that modulates cancer progression. The concept of
immunoediting is used to describe three phases by which immunity controls and shapes
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cancer (Dunn et al., 2002). These phases are (1) elimination (also called cancer
immunosurveillance), describing the capacity of the immune system to remove benign
lesions (2) equilibrium, characterised by dormant poorly proliferating cancer cells
maintained by the immune system, and (3) escape, in which cancer cells have acquired a
weakened immunogenicity or capacity to attenuate immune responses (e.g. immune
tolerance via PD1, PD-L1 and/or CTLA-4) and therefore can grow to malignant disease,
a phase when the cancer is usually diagnosed (Fridman et al., 2012; Koebel et al., 2007).
Analyses of the amount, location, and density of immune cell populations can assist
in determining prognosis (Dieu-Nosjean et al., 2008; Halama et al., 2011). Specific
lymphocyte infiltrations in lung NSCLC have been suggested to have positive prognostic
value (Al-Shibli et al., 2008; Dieu-Nosjean et al., 2008; Donnem et al., 2010), clearly
showing a correlation between the presence of CD3+CD4+ T-helper cells or CD3+CD8+
cytotoxic T-cells and good prognosis. In addition, analysis of neutrophil counts and the
neutrophil-to-lymphocyte ratio has indicated an association between accumulation of
neutrophils and poor disease prognosis in NSCLC (Sarraf et al., 2009; Teramukai et al.,
2009). Moreover, a heterogeneous population of cells with myeloid origin and
immunosuppressive activity, known as myeloid-derived suppressor cells (MDSCs), is
shown to contribute to the suppression lymphocyte-mediated immunosurveillance
(Gabrilovich and Nagaraj, 2009). MDSCs are a heterogeneous population of activated
immature myeloid cells (IMCs), which in normal conditions function as progenitor cells
for mature granulocytes, macrophages, or dendritic cells. MDSCs show the morphology
of granulocytes or monocytes, which have been suggested to have different roles in
cancer immunoediting, with granulocytic MDSCs showing more substantial expansion
than the monocytic subset in tumour models (Gabrilovich and Nagaraj, 2009; Youn et
al., 2008). Quantification of MDSCs characterised by CD11b, CD15, and CD33
expression from peripheral blood of lung cancer patients has implied a positive
correlation between the abundance of MDSCs and poor prognosis (Liu et al., 2010).
Additionally, a negative correlation has been found between the abundance of MDSCs
and CD3+CD8+ cytotoxic T-cells, suggesting that active MDSC-mediated
immunosuppression may contribute to the poor prognosis of lung cancer patients (Liu et
al., 2010).
In mice, MDSCs characterised based on positive expression of CD11b (integrin
alpha M) and Gr-1 antigen. Monoclonal Gr-1 antibody also recognises epitopes in
lymphocyte antigen 6 complex, locus G and C (LY6G and LY6C) with preference to
LY6G (Fleming et al., 1993). Epitope-specific antibodies against LY6G and LY6C have
led to the identification of two mouse MDSC subsets, namely granulocytic MDSCs
characterised as CD11b+LY6G+LY6Clow,  and  monocytic  MDSCs  characterised  as
CD11b+LY6G–LY6Chi (Youn et al., 2008).
In vivo studies using pancreatic cancer GEMMs have shown that MDSCs create a
favourable environment for tumour growth and metastasis by secreting molecules which
modulate the extracellular matrix, including matrix metalloproteinase 9 (MMP9) and
cathepsin B (Shchors et al., 2013). The immunosuppressive characteristics of MDSCs,
seen as a negative correlation between the presence of MSDCs and CD3+CD8+ T-cells, is
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mechanistically linked to expression of L-arginase (Arg1) by MDSCs (Gabrilovich and
Nagaraj, 2009). Elevated Arg1 expression by tumour-associated myeloid cells leads to
reduced availability of the amino-acid L-arginine, and therefore decreased proliferation
and/or inhibition of T-cell function in an orthotopic murine lung AC model (Rodriguez
et al., 2004). This observation is supported by human studies showing the amount of
MDSCs, specifically expressing ARG1, to correlate with immunouppressive
characteristics, namely reduced abundance and proliferation of lymphocytes (Liu et al.,
2010; Munder et al., 2006).
The recruitment of MDSCs to tumour sites is linked to several protein factors that
are released by tumour cells, including cytokines. The pro-inflammatory cytokine
interleukin-1b (encoded by Il1b) can mobilise and recruit MDSCs to the stomach,
sensitising the organ for gastric inflammation and carcinoma (Tu et al., 2008).  In a
murine breast cancer model, IL-1B has also been linked to the recruitment of MDSCs to
tumour sites. Importantly, antibody-mediated inhibition of IL-1B can inhibit the
recruitment of CD11b+Ly6G+Ly6C+ MDSCs in a syngeneic murine breast carcinoma
model; depletion of MDSCs with anti-Ly6G antibody reduced the amount of early
metastases to the lungs, which was mechanistically linked to suppression of CD8+ T-cell
activation as also CD8+ T-cell depletion facilitated metastasis (Coffelt et al., 2015).
GEMMs have also been used to study the lung cancer lymphocyte contexture. Using
the CC10-TAg lung adenocarcinoma model, Coussens and colleagues reported that
CD4+ T-lymphocytes comprise the major population of lung adenocarcinoma CD45+
immune cells,  and when compared with normal lung tissue, an increased proportion of
CD4+FOXP3+ regulatory T-cell (Treg) in the total CD4+ population was detected
(Ganesan et al., 2013). Their hypothesis that FOXP3+ Tregs might be enriched within
tumours that suppress CD8+ T-cell responses was confirmed with anti-CD25–depleting
mAb, which reduces the major subset of CD25-expressing Foxp3+ Tregs. This reduction
resulted in an increased infiltration of CD8+ T-cells in the lung parenchyma, and tumour
cell death. Interestingly, also lung squamous cell carcinomas, driven by loss of Pten and
Lkb1, display marks of immunosuppression by expressing PD-L1, and show increased
G-MDSC and FOXP3+ T-cell infiltration (Xu et al., 2014a). Moreover, a mouse model
expressing kinase-dead IKKα, a subunit of the IKK complex, develops spontaneous lung
SCCs accompanied by pulmonary inflammation. Interestingly, SCC tumours in the latter
model also showed a reduction in somatic LKB1 protein expression, further linking the
loss of Lkb1 to both SCC development and tumour inflammation (Xiao et al., 2013).
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The present knowledge of the epidemiological, pathological, molecular, and
microenvironmental details of lung cancer is greater than it has ever been.
Simultaneously, development of sophisticated in vitro and in vivo methodologies has
enabled functional research on the factors contributing to lung tumourigenesis.
Combining this information to the growing amount of knowledge on the regulators of
normal tissue homeostasis and embryonic development, will help to create a better
understanding of lung tumourigenesis and assist its translation to individualized
treatment options.
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3 Aims of the study
Treatment of lung cancer is challenged by a high level of intra- and intertumour
genomic, molecular, and microenvironmental heterogeneity. Despite extensive
knowledge on molecular profiles of lung tumours, validation of their functional
importance is needed to translate this information into the clinic. The first aim of this
thesis work was to validate the functional importance of the putative tumour suppressor
gene EPHA3, which is commonly mutated in human lung cancers and was identified as a
hit in a high-content cellular senescence tumour suppressor screen. Furthermore, this
thesis work aimed to uncover the role of specific progenitor cells in defining the murine
lung tumour spectrum, both with respect to tumour growth and histopathology as well as
immune microenvironments.  This aim was performed by using a murine NSCLC model
driven by two known lung cancer genetic alterations, oncogenic Kras and  loss  of  the
tumour suppressor Lkb1, with no prior knowledge on the lung niche specific contribution
to histopathology or immune microenvironment heterogeneity.
To address these aims, the following specific questions were asked:
1. Does EPHA3, a gene commonly mutated in cancers, show
characteristics of a tumour suppressor (Study I)?
2. Does EphA3 demonstrate a tumour suppressive role in murine
embryonic lungs and NSCLC (Study II)?
3. Does the cell-of-origin impact murine NSCLC development and lesion-
specific immune microenvironments (Study III)?
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4 Materials and methods
4.1 Materials
The following materials were used in this thesis work.
4.1.1 Cell lines
Cell line Description Source or reference Study
293T Flp-In T-
REx
Human embryonic kidney epithelial cell line




hTERT immortalised human retinal pigmented
epithelial cell line, converted also to a Flp-In cell
line by inserting of a FRT site.
Clontech I, II
4.1.2 Plasmids
Plasmid Description Vector Tag Source Study
pgLAP5 Destination vector pgLAP5 CT-GFP-LAP Addgene I
hEPHA3 wt Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3  497C-A Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 807G-A Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 1137T-G Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 1336G-T Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 2183G-T Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 2283G-T Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 2416G-T Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 2798C-T Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
hEPHA3 2297G-A Expression vector pgLAP5 CT-GFP-LAP Verschuren laboratory * I
pgLAP5/puro Destination vector pgLAP5/puro CT-GFP-LAP Addgene I
hEPHA3 wt Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3  497C-A  Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3 807G-A Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3 1137T-G Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
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hEPHA3 1336G-T Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3 2183G-T Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3 2283G-T Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3 2416G-T Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3 2798C-T Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
hEPHA3 2297G-A Expression vector pgLAP5/puro CT-GFP-LAP Verschuren laboratory I
pEGFP-H2B-N1
Human H2B
plasmid CT-EGFP Dr. Matt Summers I




* Used but not cloned by the author.
4.1.3 siRNAs
siRNA Catalogue no. Source or reference Study
Human EPHA1 J-003115-10 GE Healthcare Dharmacon Inc. I
Human EPHA2 J-003116-09 GE Healthcare Dharmacon Inc. I
Human EPHA3 M-003117-03 GE Healthcare Dharmacon Inc. I, II
Human EPHA4 J-003118-09 GE Healthcare Dharmacon Inc. I
Human EPHA5 J-005315-08 GE Healthcare Dharmacon Inc. I
Human CDKN2A  (p16INK4) M-011007-03 GE Healthcare Dharmacon Inc. I
Human EMI1 (FBXO5) L-012434-00 GE Healthcare Dharmacon Inc. I
Human TP53 SI02655170 Qiagen I
siCONTROL D-001810-10-20 GE Healthcare Dharmacon Inc. I, II
4.1.4 Quantitative PCR (Q-PCR) probes and primers
Q-PCR probe Catalogue no. Source or reference Study
Human RPL19 Hs02338565_gH Life Technologies I, II
Human EPHA3 Hs00739096_m1 Life Technologies I, II
Human CDKN2A  (p16INK4) Hs00923894_m1 Life Technologies I
Human EPHA1 Hs00178313_m1 Life Technologies I
Human EPHA2 Hs00171656_m1 Life Technologies I
Human EPHA4 Hs00177874_m1 Life Technologies I
Human EPHA5 Hs00300724_m1 Life Technologies I
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Q-PCR primer Nucleotide sequence Source or
reference
Study
Human EPHA3 fwd 5’GCAGACAAAGACCCTCCAT3’ Verschuren laboratory I
Human EPHA3 rev 5’GTAACATCTTTCCGGCCTC3’ Verschuren laboratory I
Human CDKN2A  (p16INK4)
fwd 5’CCCAACGCACCGAATAGTTAC3’ Verschuren laboratory I
Human CDKN2A  (p16INK4)
rev
5’CCAGCGTGTCCAGGAAG3’ Verschuren laboratory I
Human TP53 fwd 5'GTCCCTTCCCAGAAAACCTA3’ Dr. Sergey Kuznetsov I
Human TP53 rev 5’CTCGGATAAGATGCTGAGGA3’ Dr. Sergey Kuznetsov I
Human RPL19 fwd 5’ACCCCAATGAGACCAATGAA3’ Verschuren laboratory I
Human RPL19 rev 5’CGCAAAATCCTCATTCTCCT3’ Verschuren laboratory I
Mouse EphA1 fwd 5’CAAGATTGCAAGACTGTGGC3’ (Abdul-Aziz et al., 2009) II
Mouse EphA1 rev 5’CCTCCCACATTACAATCCCA3’ (Abdul-Aziz et al., 2009) II
Mouse EphA2 fwd 5’GTCTATAAAGGGACGCTGAAGG3’ Verschuren laboratory II
Mouse EphA2 rev 5’CGCTCCATTCTCCATGTACTC3’ Verschuren laboratory II
Mouse EphA3 fwd 5’GAGACAGTATGCCGCAGTCA3’ Verschuren laboratory II
Mouse EphA3 rev 5’GCCTCTTGCTCTCAAAATGG3’ Verschuren laboratory II
Mouse EphA4 fwd 5’CCGAAGCAGCCTACACTACC3’ (Andersson et al., 2011) II
Mouse EphA4 rev 5’GCCAGCAGTCCAGCATTAAC3’ (Andersson et al., 2011) II
Mouse EphA5 fwd 5’AGTGACAGTGGGAGTCATCT3’ Verschuren laboratory II
Mouse EphA5 rev 5’GCAGTTTAATGTGCCCGTTATG3’ Verschuren laboratory II
Mouse EphA7 fwd 5’CAGCAGACGGGATTAGAGGA3’ Verschuren laboratory II
Mouse EphA7 rev 5’GATGACTCCATTGGGATGCT3’ Verschuren laboratory II
Mouse Efna1 fwd 5’CAGGAATCCCAGTGCTTGAA3’ Verschuren laboratory II
Mouse Efna1 rev 5’CAGCAGTGGTAGGAGCAATAC3’ Verschuren laboratory II
Mouse Efna5 fwd 5’GAGATGTTGACGCTGCTCTT3’ Verschuren laboratory II
Mouse Efna5 rev 5’TTCTGGGACAGAGTCCTCATAG3’ Verschuren laboratory II
Mouse Efnb2 fwd 5’CCAGACAAGAGCCATGAAGAT3’ Verschuren laboratory II
Mouse Efnb2 rev 5’TGCGATCCCTGCGAATAAG3’ Verschuren laboratory II
Mouse Fgf10 fwd 5’GCTGTTCTCCTTCACCAAGTA3’ Verschuren laboratory II
Mouse Fgf10 rev 5’ACTCCGATTTCCACTGATGTT3’ Verschuren laboratory II
Mouse Pecam1 fwd 5’GTGGTCATCGCCACCTTAATA3’ Verschuren laboratory II
Mouse Pecam1 rev 5’TTCTCGCTGTTGGAGTTCAG3’ Verschuren laboratory II
Mouse Nkx2-1 fwd 5’CTACTGCAACGGCAACCTG3’ Verschuren laboratory II
Mouse Nkx2-1 rev 5’CCATGCCACTCATATTCATGC3’ Verschuren laboratory II
Mouse Cdh1 fwd 5’CAGGTCTCCTCATGGCTTTGC3’ Verschuren laboratory II
Mouse Cdh1 rev 5’CTTCCGAAAAGAAGGCTGTCC3’ Verschuren laboratory II
Mouse Il1b fwd 5’TGCCACCTTTTGACAGTGATGAGA3’ Verschuren laboratory III
Mouse Il1b rev 5’CCTGGAAGGTCCACGGGAA3’ Verschuren laboratory III
Mouse Arg1 fwd 5’TCGTGTACATTGGCTTGCGA3’ Verschuren laboratory III
Mouse Arg1 rev 5’GCCAATCCCCAGCTTGTCTA3’ Verschuren laboratory III
Moue H2-D1 fwd 5’CTGAAGAACGGGAACGCGAC3’ Verschuren laboratory III
Moue H2-D1 rev 5’TGTAAGAGTCAGTGGACGGAGG3’ Verschuren laboratory III
Mouse H2-M2 fwd 5’GTGCCTTGGATGGAACAGAT3’ Verschuren laboratory III
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Mouse H2-M2 rev 5’CCAGTCATCCTTTGGATGGT3’ Verschuren laboratory III
Mouse Rpl19 fwd 5’CGGGAATCCAAGAAGATTGA3’ Verschuren laboratory II, III
Mouse Rpl19 rev 5’TTCAGCTTGTGGATGTGCTC3’ Verschuren laboratory II, III
4.1.5 Mouse strains
Mouse strain Description Reference Study
EphA3-/- EphA3-null mice lacking first exon of EphA3 (Stephen et al., 2007;Vaidya et al., 2003) II
KrasLSL-G12D/+ Mice carrying a conditional mutant allele of Kras (Jackson et al., 2001) II, III
p53fl/fl Mice carrying a conditional loss-of-function allele
of Trp53 (Marino et al., 2000) II, III




4.1.6 Probes for in situ hybridization
In situ hybridization probe Fragment Source or reference Study
Mouse EphA3 Nucleotides 658-1474 Prof. Mark Krasnow II
Mouse Efna1 Nucleotides 20-421 Prof. Mark Krasnow II
Mouse Fgf10 Nucleotides 11-579 Prof. Irma Thesleff II
4.1.7 Primary antibodies
Antibody (Cat. no.) Description Source or reference Study
GFP Rabbit polyclonal Verschuren laboratory I, II, III
GFP (A11122) Rabbit polyclonal Invitrogen I
Phosphotyrosine 4G10 (05-321) Mouse monoclonal Millipore I
EEA1 (610457) Mouse monoclonal BD Biosciences I
β-actin (A1978) Mouse monoclonal Sigma-Aldrich I, III
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NKX2-1 (TTF1) (ab133638) Rabbit monoclonal Abcam II, III
p63 (ab53039) Rabbit polyclonal Abcam II, III
EPHA3 (34-8500) Rabbit polyclonal Invitrogen/Thermo Fisher Scientific II
CD31 (PECAM1) (553370) Rat monoclonal Becton, Dickinson and Company II
E-Cadherin (CST 3195) Rabbit monoclonal Cell Signaling Technology II
BrdU Cell Signaling Technology II
Ki67 (RM-9106-S0) Rabbit monoclonal Thermo Fisher Scientific III
Cytokeratin 5 (ab52635) Rabbit monoclonal Abcam III
Gr-1 (Ly6G) (14-5931) Rat monoclonal E-Bioscience III
CD11b (BSB6441) Rabbit monoclonal BioSB III
CD3 (ab5690) Rabbit polyclonal Abcam III
SOX2 (sc-17320) Goat polyclonal Santa Cruz Biotechnology III
LKB1 (D60C5F10) Rabbit monoclonal Cell Signaling Technology III
4.2 Methods
The following methods were used in this thesis work.
4.2.1 Cell culture and cell line generation (I)
hTERT immortalised human retinal pigmented epithelial cells (hTERT-RPE1,
Clontech) were maintained in DMEM:F-12 (Invitrogen) containing 10% FBS (Gibco),
2mM L-Glutamine (Gibco) and 0,348%  sodium bicarbonate (Gibco). Human embryonic
kidney epithelial cells (293T) were maintained in DMEM (Lonza) containing 10% FBS
(Gibco) and 2 mM L-Glutamine (Gibco). A stable H2B-GFP hTERT-RPE1 clonal cell
line was generated by transfection with GFP-tagged human H2B plasmid (pEGFP-H2B-
N1) followed by clonal selection using G418 (Roche). The 293T Flp-In T-Rex cell line
was purchased from Invitrogen. The hTERT-RPE1 cell line was converted to a Flp-In
cell line by the insertion of a FRT site. Stable cell lines were created as previously
described (Torres et al., 2009). Briefly, human EPHA3 cDNA and tumour variants were
synthesised by DNA 2.0 into Gateway compatible pDONR221 entry vectors and cloned
into appropriate pG-LAP5 or pG-LAP5/puro Gateway destination vectors using LR
recombination technology (Invitrogen). pG-LAP constructs encoding proteins of interest
were co-transfected with pOG44 plasmid encoding the Flp recombinase (Invitrogen) into
Flp-In cell lines using Fugene 6 (Roche), followed by selection for stable integrants
using Hygromycin B (pG-LAP5) or Puromycin (pG-LAP5/puro) selection. Pooled lines
were used with 293T cells; clonal cell lines were used with hTERT-RPE1 cells.
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4.2.2 siRNA transfections (I and II)
For gene expression silencing (knockdown), cells were treated with 50 nM pooled
siRNA duplexes (GE Healthcare Dharmacon Inc.) or 30 nM for single siRNAs (Qiagen)
using Oligofectamine reagent (Invitrogen) in 24-well plates.
4.2.3 Live cell imaging (I)
For live cell imaging hTERT-RPE1 cells expressing H2B-GFP protein were treated
with 50 nM pooled siRNA using forward transfection with Oligofectamine reagent
(Invitrogen) on 24-well plates. Transfections were carried out in replicates of four and
imaging was performed using the IncuCyte™ FLR instrument (Essen BioScience) for
five days. Cells from a duplicate plate were harvested at day three to confirm siRNA
knockdown. Object analysis was performed with the IncuCyte default parameters.
4.2.4 Senescence-associated  -galactosidase (SA- -gal)
staining (I)
Cellular senescence was detected in cells transfected with siRNAs in 24-well plates
(Corning), by staining for acidic β-galactosidase as described (Dimri et  al., 1995).
Imaging of cells was performed with the Zeiss Axio light microscope and AxioCam
MRc5 camera using Axio Vision Rel. 4.8 software.
4.2.5 Ligand treatment, in vitro kinase assay and
immunoblotting (I)
For cellular activity measurements, 293T cells stably expressing LAP-tagged
EPHA3 proteins were serum starved for 1 h, and then incubated with 1.5 μg/ml
recombinant human ephrin-A5-Fc or IgG1-Fc proteins (R&D Systems), pre-clustered for
20 min with anti-human Fc antibody (Jackson ImmunoResearch) at 10:1 molar ratio.
Cells were then lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM
NaCl, 0.1 % SDS, 1 % Triton X-100, 0.25 % Na-Deoxycholate, 100 mM β-glycerol-2-
phophate, 15 mM sodiun fluoride, 2.5 mM orthovanadate) containing Protein Inhibitor
Cocktail (Roche) and Phosphatase Inhibitor Cocktail (Roche), and 500 μg of protein
lysate was rotated for 16h with 1 μg of anti-GFP antibody (Invitrogen). Antigen was
captured using Protein G/A Sepharose beads (Sigma). Alternatively, specific antigen was
captured using S-protein agarose beads (Novagen). Samples were immunoblotted using
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anti-phosphotyrosine (PY 4G10; Upstate Biotechnology Inc.) or in-house affinity-
purified anti-GFP antibodies.
For the in vitro kinase assay, 293T Flp-In T-Rex and hTERT-RPE1 Flp-In cells
expressing LAP-tagged EPHA3 proteins were lysed in RIPA buffer containing protease
inhibitors.  500  μg  of  total  protein  was  incubated  for  1h  with  1  μg  of  GFP  antibody
(Invitrogen). Specific antigen was captured using Protein A/G Sepharose beads (Thermo
Scientific), or, alternatively, with S-protein agarose beads (Novagen), and washed using
RIPA and kinase buffer (50 mM NaCl, 20 mM Hepes pH 7.2, 10 mM MgCl2,  2  mM
EDTA, 0.02% Triton X-100). Beads were next incubated in kinase buffer supplemented
with 20 μM adenosine 5'-triphosphate disodium salt hydrate (Sigma). Samples were
immunoblotted using anti-phosphotyrosine or anti-GFP antibodies.
4.2.6 Immunostaining and fluorescence microscopy (I)
hTERT-RPE1 Flp-In cells stably expressing LAP-tagged EPHA3 proteins with or
without ephrin-A5 treatment were fixed on coverslips and immunostained for GFP
(EPHA3-LAP) and EEA1 early endosomal marker (BD Biosciences). Fluorescence
microscopy imaging was performed with the Nikon 90i microscope using 60X objective.
Image handling was done with Adobe Photoshop CS5 software.
4.2.7 Protein variant structural domain analysis (I)
For protein variant structural domain analysis, a PDB file with EPHA3 kinase and
juxtamembrane domain structure information (2QOC)  (Davis et al., 2008) and the
structural information of LKB1 tumour suppressor (2WTK) (Zeqiraj et al., 2009) were
downloaded from the RCSB (Research Collaboratory for Structural Bioinformatics)
protein data bank (http://www.pdb.org/pdb/home/home.do). Mutation analysis, distance
measurements, and alignment analysis were performed using the PyMOL molecular
visualisation system.
4.2.8 RNA expression analysis (I-III)
Normal adult lung and tumour tissue was homogenised using a Precellys
homogenisation kit (Bertin Technologies). Total RNA was extracted using NucleoSpin
RNA II kit (MACHEREY-NAGEL) and quantified using NanoDrop 1000 (Thermo
Fisher Scientific Inc.). Complementary DNA (cDNA) was synthesised from the
extracted RNA using a High-capacity cDNA reverse transcription kit (Life
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Technologies/Thermo Fisher Scientific Inc.). Quantitative PCR (qPCR) analysis was
done for triplicate reactions using iQ™ SYBR® Green Supermix (Bio-Rad) or iQ™
Supermix (Bio-Rad) were run and analysed on a CFX384 TouchTM Real-Time PCR
Detection System (Bio-Rad), using relative quantitation against the housekeeping Rpl19
mRNA. Cycles started with three min. denaturation at 95 °C, followed by 40 cycles of
15 sec at 95°C, and 1 min at 60°C. A melting curve ranging from 57 °C to 95 °C was
included in every analysis to confirm specific amplification. For Arg1, an annealing
temperature  of  58  °C  was  used.  For  the  embryonic  lung  expression  analysis,  an
exponential expression (ΔCq Expression) was obtained with formula ΔCq
Expression=2–ΔCq, where ΔCq=Cq (target) – Cq (reference).
4.2.9 Mouse breeding and recombinant adenovirus
administration (II and III)
All animal studies followed guidelines from the Finnish National Board of Animal
Experimentation and were approved by the Experimental Animal Committee of the
University of Helsinki and the State Provincial Office of Southern Finland (Licence
number ESAVI-2010-04855/Ym-23). EphA3-null mice were bred with KrasLSL-G12D/+ and
Trp53fl/fl mice to generate the study cohorts and were maintained on a mixed genetic
background using littermates as controls. KrasLSL-G12D/+ mice were crossed with Lkb1fl/fl
or Trp53fl/fl mice to generate KrasLSL-G12D/+; Lkb1fl/fl (KL) or Lkb1fl/fl; Trp53fl/fl (KP) mice
on a mixed background. KL mice were crossed with Rosa26mT/mG Cre-reporter mice,
resulting  in  mixed  background  cohorts.  Six  to  ten  wk  old  mice  were  intranasally  or
intratracheally administered with 3,3×107 or with 3,3×108 plaque-forming units (pfu) of
Ad5-CMV-Cre (University of Turku, Finland), 1-20x107 pfu of Ad5-CC10-Cre or 2.5-
7.5x109 pfu of Ad5-SPC-Cre viruses (Viral Vector Core Facility, University of Iowa,
USA) under isoflurane anaesthesia.
4.2.10 Tissue preparation and immunohistochemistry (II and
III)
Immunohistochemistry was performed for formalin fixed and paraffin embedded
lungs that were sectioned (4-5 μm) from two distinct regions representing the surface
and middle regions of the lungs. Sections were dehydrated and antigenic epitopes were
exposed by heating in 10 mM citrate buffer, pH 6.0 (anti-GFP, anti-NKX2-1, anti-p63,
anti-EPHA3, anti-E-Cadherin, anti-Ki67, anti-Cytokeratin 5, anti-CD11b, anti-CD3 and
anti-SOX2) or by incubation in 0.05% trypsin at 37 °C (anti-CD31 and anti-Gr-1).
Tissue sections were blocked with 1% BSA and 10% Normal Goat Serum in 1x PBS.
Primary antibodies were detected using secondary antibody BrightVision poly-HRP anti-
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rabbit (IL ImmunoLogic), or Peroxidase-Goat Anti-Rat IgG (H+L) (Invitrogen
Corporation) for 30 min at ambient temperature. Detection was done with DAB (3,3'-
diaminobenzidine, Bright DAB, IL ImmunoLogic). Immunohistologically stained lung
sections were scanned with a Pannoramic 250 3DHISTECH (3DHISTECH Kft.) digital
slide scanner using a 20x objective. Snapshots from the stained sections were taken with
Pannoramic Viewer software (3DHISTECH Kft.).
4.2.11 Preparation of embryonic lung tissue (II)
For the embryonic lung epithelial and mesenchymal expression analysis, embryonic
lungs were dissected and epithelial and mesenchymal cells separated using a previously
described protocol (del Moral and Warburton, 2010) with minor modifications. Briefly,
pregnant mice were sacrificed to harvest embryos at E11.5, E13.5 and E15.5 by CO2
administration. Collected embryos were dissected under a stereoscopic microscope in a
glass Petri dish immersed in PBS. Isolated lungs were transferred to 24-well plates
containing CO2-independent medium (Gibco by Life Technologies/Thermo Fisher
Scientific Inc.). Epithelial and mesenchymal cells were separated by treating the lungs
with 10 mg/ml collagenase (collagenase from Clostridium histolyticum, Sigma) in CO2-
independent medium at 37°C for 20 min. Enzymatic degradation was stopped by adding
CO2-independent medium supplemented with 5 U/ml RNase-free DNase (RQ1 RNase
free DNase, M6101, Promega), after which mechanical cell separation was performed
under a stereoscopic microscope. Mesenchymal and epithelial cells from one to five
embryos were used to reach high enough RNA yields.
4.2.12 In vivo cell proliferation assay (II)
Cell proliferation in developing lung at E13.5 was assayed by detecting
incorporation of 5-bromo-2-deoxyuridine (BrdU) in S phase of cell cycle. BrdU (Sigma)
was injected into a timed pregnant mouse intraperitoneally. Mice were sacrificed and
embryos were harvested four hours post injection. The embryos were fixed in formalin
overnight and embedded in paraffin. BrdU positive cells were then detected using anti-
BrdU antibody (Cell Signaling Technology).
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4.2.13 Whole-mount immunohistochemistry and optical
tomography scanning (II)
Sample processing and whole-mount immunohistochemistry of dissected embryonic
lungs at E11.5-E15.5 were performed as described previously (Alanentalo et al., 2007).
Briefly, 4% paraformaldehyde fixed lungs were dehydrated with methanol followed by
rehydration and processing to immunohistochemical staining. Localisation of anti-E-
cadherin (Cell Signaling Technology) was detected either by fluorescently labelled
secondary antibody conjugated to Alexa-Fluor-594-conjugated anti-rabbit IgG (Life
Technologies/Thermo Fisher Scientific Inc.) or visualized by using the chromogenic
DAB substrate (Immunologic) following the incubation with poly-HRP-conjugated anti-
rabbit IgG antibody (Immunologic). Fluorescently labelled lungs were processed for
optical projection tomography (OPT) scanning as described previously (Alanentalo et
al., 2007) including sample clearance with mixture of two parts of benzyl benzoate and
one part benzyl alcohol, and scanned using a Bioptonics OPT 3001M Scanner.
Chromogenically-stained samples were imaged using a Leica MZFLIII stereomicroscope
(Leica) and Colorview camera (Software imaging system).
4.2.14 In situ hybridization (II)
The in situ hybridisation assay for the E14.5 embryonic sagittal paraffin sections was
performed according to the standard protocol using probes labelled with 35[S]-UTP. The
mouse EphA3 probe covered an 817-bp fragment ranging from nucleotide 658 to 1474.
The gene-specific fragment was inserted into pGEM-3Zf- vector. The mouse Efna1
probe covered a 402-bp fragment ranging from nucleotide 20 to 421 also inserted into
pGEM-3Zf. After image acquisition dark-field images were inverted, linearly
thresholded and combined with bright field images in Adobe Photoshop CS6 (Adobe
Systems Software).
4.2.15 Image analysis (II, III)
All mouse lung tumour analyses were performed under the guidance of an expert
pathologist. For the tumour burden analysis, whole slide scans of the H&E stained
mouse lung sections were analysed using the structure based detection solution in Tissue
Studio Image Analysis solution of the Definiens Developer XD 64 2.1 software
(Definiens). For the quantitation of PAS or immunohistological stainings whole slide
scans were analysed with marker or nuclear detection solution in the Tissue StudioTM
image analysis solution of the Definiens Developer XD 64 2.1 software (Definiens). The
three-dimensional (3D) visualization and branch end point analysis of the embryonic
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mouse lungs was perfomed with Imaris 3D and 4D data software, using the Filament
analysis function (Bitplane AG).
4.2.16 Comparative gene expression analysis (III)
Differentially expressed genes from the Illumina Mouse WT-6 version 2 expression
array (Illumina, GEO, accession no. GSE69552) were compared with publically
available gene expression data from NCBI-GEO (http://www.ncbi.nlm.nih.gov/geo/)
database. p < 0,01 and logFC > 1 were used as cut-off values in the analysis. Venn
diagrams comparing the lists of differentially expressed genes were generated with
Venny 2.0.2 (http://bioinfogp.cnb.csic.es/tools/venny/) using ENSEMBL GENE IDs
as gene identifiers.
4.2.17 Statistical analysis (I, II, III)
All numerical values are represented as mean +/- standard deviation (s.d.). Statistical
significance was determined using two-tail student’s t-test assuming equal variance
between the datasets in all studies except in the survival curve analysis (study III), where
a Gehan-Breslow-Wilcoxon Test was used.
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5 Results and discussion
5.1 EPHA3 has functions characteristic of a tumour
suppressor (I)
As shown for the PTEN tumour suppressor, to prevent oncogenic transformation,
nontransformed mammalian cells can activate in-built cellular checkpoints in response to
loss of a tumour suppressor (Chen et al., 2005). This concept was used to identify
putative, new tumour suppressors in an siRNA screen for cellular senescence. The screen
utilised retinal pigmented epithelial cells (RPE) immortalised with human telomerase
(hTERT). These cells model key aspects of nontransformed epithelial cells, including
dormancy  and  normal  expression  of  G0  markers,  and  the  presence  of  primary  cilia.
hTERT-RPE1 cells were engineered to express a doxycycline-inducible TP53 shRNA to
identify proteins which specifically relied on the p53 pathway in their mechanism of
action. The primary screen included 862 siRNA pools targeting kinases and proteins
predicted to influence kinase signalling. Using proliferation marker Ki67, nuclei count,
and size as readouts, the screen identified 16 primary candidates as regulators of cellular
senescence (I, Fig. 1A & B).
A secondary screen using SA-β-gal as the readout confirmed 12 out of the initial 16
candidates (I, Fig. 1C). These 12 hits, namely AURKA, CDK1, CSNK1A1, EPHA3,
KSR2, LATS1, MAP2K3, MAP4K1, MYLK, NEK1, PIK3C2A, and SMG1 were studied
further to determine the underlying senescence-associated pathways linked to their loss.
The Arf-p53-p21 pathway was examined by measuring the levels of both p53 and p21
proteins subsequent to the siRNA-mediated gene expression knockdown of the
senescence hits. Results indicated that the senescence phenotype detected after the
silencing of the identified hits indeed correlated with p53-p21 activation (I, Fig. 2A).
Dependency on p53 activation was further supported by the increased total cell numbers
and percentages of proliferating cells after shRNA mediated TP53 silencing  in  all  12
cases (I, Fig. 2B & C). In addition, DNA damage responses detected by γ-H2AX foci
formation were seen in all cases but one (PIK3C2A) (I, Fig. S3). In the specific cases of
MYLK, MAP2K3, NEK1, EPHA3, and SMG1, elevated levels of CDKI p16INK4a mRNA
were also detected (I, Fig. 2D). Thus, the screen identified 12 putative tumour
suppressors, of which loss-induced senescence was associated with activation of well-
known cell cycle arrest pathways.
To further validate the tumour suppressive characteristics of the senescence hits, a
genomic copy number analysis using SNP array-CGH from 53 panels of human tumours
and cell lines was performed. The analysis identified significant loss in copy number in
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the loci of the senescence hits throughout the studied data sets, thus supporting their
tumour suppressive role (I, Fig. 3).
The senescence gene hits were grouped into three functional categories: (1)
regulators of accurate mitotic cell cycle progression and cytokinesis, DNA damage
signalling and the spindle assembly checkpoint: AURKA, CDK1, CSNK1A1, LATS1,
NEK1, SMG1, (2) regulators of adhesion and migration: EPHA3, MYLK, PIK3C2A, and
(3) regulators of growth factor-induced mitogenic signalling via p38 stress-activated
protein kinases (SAPK) and jun amino-terminal kinases (JNK) pathways: KSR2,
MAP2K3, MAP4K1.
An interesting hit in the senescence screen was EPHA3, a member of the large EPH
RTK family generally known to control cell sorting and tissue patterning via cell
attraction and repulsion (Pasquale, 2008). Several cancer sequencing studies have
reported point mutations in EPHA3, with mutations particularly pronounced in lung and
colorectal primary tumours (5,8% and 3% respectively, Catalogue of Somatic Mutations
In Cancer). Thus, we decided to concentrate our studies on the functional validation of
the tumour suppressive role of EPHA3.
5.1.1 Loss of EPHA3 receptor signalling confers p16INK4A- and
p53-dependent senescence
The human EPH receptor family includes nine EPHA receptor members (EPHA1–8
and EPHA10) (Gucciardo et al., 2014). We first sought to determine if senescence
induced by the loss of EPHA3 was unique among the EPHA receptors expressed in
hTERT-RPE1 cells, i.e EPHA1, EPHA2, EPHA4, and EPHA5 in addition to EPHA3.
One of the characteristics of senescent cells in 2D cell culture conditions is a flattened
cell morphology and enlarged nuclear size (Mitsui and Schneider, 1976). We used
hTERT-RPE1 cells stably expressing GFP-tagged histone H2B to monitor the number
and size of the nuclei in 12 hours intervals for a total time of 132 hours. Both the nuclear
size and the cell number after 132 hours of monitoring indicated cellular senescence in
cells exposed to EPHA3, but not to EPHA1, EPHA2, EPHA4, or EPHA5 silencing. This
was further confirmed with SA-β-gal staining (I, Fig. S5A &B).
As EPHA3 was among the putative tumour suppressor hits, the silencing of which
led to regulation of p53 protein and p16INK4a mRNA levels (I, Fig. 2A & D & S5C), we
next asked if the senescence phenotype induced by EPHA3-loss was dependent on these
senescence-regulating tumour suppressors. We used the same readout as for the EPHA
receptor-associated senescence detection, namely nuclear count and size of hTERT-
RPE1 cells stably expressing GFP histone H2B. The silencing of either TP53 or p16INK4a
together with EPHA3 resulted in partial rescue of the senescence phenotype indicating
that EPHA3-loss induced senescence is dependent on both p53- and p16INK4a -mediated
signalling (I, Fig. 4A & B). This observation suggests that the putative tumour
promoting effects of EPHA3-loss possibly require additional alterations in genes
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functioning in these key senescence-inducing tumour suppressor pathways. Our initial
search using the CONAN CGP copy number analysis tool (Sanger Institute) for co-
occurrence of p16INK4a mutations with EPHA3 copy number loss, did not detect
enrichment between these two genetic alterations. However, recent molecular profiling
of lung ACs has delivered large amounts of new data, enabling deeper in silico analyses
of genetic alterations and their co-occurrence {Cancer Genome Atlas Research, 2014
#165. Indeed, mutations in TP53 showed statistically significant (p-value: 0,005,
depicted from cBioportal) co-occurrence with genetic alterations (point mutations or
copy number variation) in EPHA3 (Cancer Genome Atlas Research, 2014; Cerami et al.,
2012). Taken together, these results established EPHA3 as a regulator of cellular
senescence in nontransformed epithelial cells and highlighted its role as a putative
tumour suppressor. Moreover, the results clearly linked known senescence activators,
p53 and p16INK4a,  to  loss  of EPHA3-induced senescence, suggesting possible interplay
between these pathways during tumourigenesis (Figure 9A). However, the exact
mechanism remains still to be elucidated.
5.1.2 EPHA3 cancer mutations cause loss of kinase function,
supporting its tumour suppressive role
Our finding that EPHA3-loss confers p53- and p16INK4a-dependent senescence led us
to further investigate its tumour suppressive role. At this time in our study, several
cancer sequencing studies had reported point mutations in EPHA3, with one of the
highest incidence seen in lung ACs (up to 16%) (Cerami et al., 2012; Imielinski et al.,
2012). In support of its tumour suppressive role, EPHA3 mutations are spread along the
protein rather than clustered in hot spots as seen in known oncogenes such as KRAS.
Thus, we decided to study the effect of selected EPHA3 cancer point mutations. We
hypothesised that reduced autophosphorylation activity of the receptor caused by the
mutations would support a putative tumour suppressor function of EPHA3.
We selected nine EPHA3 cancer point mutations and created hTERT-RPE1 and
293T Flp-In cell lines stably expressing these variants tagged with a localisation and
affinity purification (LAP)-tag. The selected mutations were located in different protein
domains  of  EPHA3  (I, Fig. 5A). The mutations located in the extracellular part of
EPHA3 included T166N situated in the LBD, M269I in the cysteine rich domain (CRD),
and N379K and D446Y in the fibronectin-type-III repeats (FN-III 1 and FN-III 2). These
mutations were detected in primary lung ACs (Ding et al., 2008). Four mutations,
R728L, K761N, G766E, D806N were located in the tyrosine kinase domain of EPHA3.
Two of these, R728L and K761N, were reported in primary lung ACs (Ding et al.,
2008), G766E in a lung cancer cell line (Davies et al., 2005) and D806N in colorectal
cancer (Bardelli et al., 2003). One mutation, T933M, located in the sterile α motif
(SAM) of the intracellular part of EPHA3, and had been reported in lung cancer (Wood
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et al., 2006) (see illustration of the selected mutations and their locations in EPHA3
protein in Figure 9B).
To study the cellular activation capacity of the selected EPHA3 mutation variants,
we treated 293T cells expressing the tagged EPHA3 variants with pre-clustered
recombinant ephrin-A5 protein. The autophosphorylation of EPH receptors is a
prerequisite for their forward downstream signalling (Binns et al., 2000). Thus, by
monitoring the autophosphorylation status, we aimed to study the effect of the selected
EPHA3 cancer variants on EPHA3 activity. As reported previously (Nievergall et al.,
2010), the activation status of EPHA3 detected by phosphotyrosine rose rapidly and was
detected already 2 min after ephrin-A5 treatment. The activation level of wild-type (wt)
EPHA3 peaked at 20 min after ephrin-A5 addition and decreased back to normal levels
at  60  min.  Two  kinase  domain  mutation  variants,  G766E  and  D806N,  showed  a  clear
reduction in the ephrin-A5 induced activation status of EPHA3 (I, Fig. 5B).
To further confirm the effect of EPHA3 cancer mutations, we performed in vitro
kinase assays in which tagged EPHA3 variants were incubated with excess of ATP to
induce autophosphorylation. Again, kinase domain mutation variants G766E and D806N
showed decreased activation (I, Fig. 5C). Additionally, one kinase domain mutation,
R728L, showed a reduction in overall receptor levels (I,  Fig.  5B  &  C,  S6A,  B  &  C).
These results were in line with two other studies addressing the functional effect of
EPHA3 cancer mutations (Lisabeth et al., 2012; Zhuang et al., 2012). The only
exception was the EPHA3 kinase domain K761N mutation, as our results did not detect
a decrease in its phosphorylation level, opposing results by Pasquale and colleagues
(Lisabeth et al., 2012). This difference may be a result of the methodologies used; we
expressed variants from a single genome-integrated copy (Flp-In system) to more closely
mimic endogenous receptor function.
The crystal structure of the juxtamembrane and kinase domain (JMKIN) of wild-
type EPHA3 has been characterised (Davis et al., 2008). This enabled us to analyse
structural changes caused by the EPHA3 point mutations and find possible explanations
for the decreased EPHA3 activity and expression levels. We found that mutation of
arginine 728 to leucine shifts the surface charge of EPHA3 from positive to non-charged,
possibly leading to altered protein-protein interactions and decreased expression level.
Moreover, mutation of residue 806 from aspartic acid to asparagine suggested altered
interaction with residues aspartic acid recidue 746 and histidine 744. These residues face
the ATP binding pocket, thus possibly affecting EPHA3 receptor tyrosine kinase activity
(I, Fig. 5D & E). The crystal structure surrounding G766 was disordered, impeding
analyses of the effect of G766E mutation. Interestingly, structural alignment of the
kinase  domain  of  EPHA3  with  the  tumour  suppressor  LKB1  identified  a  common
mutation site in these two kinases (D806 and D237, respectively). LKB1 D237Y
mutation had been reported in primary AC (Ding et al., 2008). We therefore analysed the
kinase activity of the EPHA3 D806Y variant to mimic LKB1 D237Y, and showed that
this lost its kinase activity (I, Fig. 5F & G). Taken together, our structural analysis
suggested that the EPHA3 cancer mutations possibly alter protein-protein interactions
and direct connections with kinase domain structural determinants.
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The regulation of EPHA3 phosphorylation and endocytosis has been shown to be
controlled by protein tyrosine phosphatase 1B (PTP1B). This was shown to be
dependent on the EPHA3 kinase domain, as no interaction between EPHA3 and PTP1B
was detected in cells expressing a kinase domain deletion mutant of EPHA3 (Nievergall
et al., 2010). However, we did not detect any defects in cellular internalisation upon
ephrin-A5 activation of the studied EPHA3 cancer mutations (I, Fig. S7), indicating that
the internalisation is independent on the autocatalytic capacity of EPHA3, and
suggesting that PTP1B binds the full kinase domain. Indeed, only the EPHA3 mutants
lacking the cytoplasmic domain or kinase domain showed absence of interaction with
PTP1B, whereas EPHA3 mutated at the essential juxtamembrane and activation loop
tyrosines showed marginal interaction with PTP1B (Nievergall et al., 2010).
EPHA3 cancer mutation variants that failed to show a decrease in
autophosphorylation or total receptor levels may still confer alternative EPHA3
inactivating effects, for example via altering ephrin binding or cellular trafficking. In
support of these alternative mechanisms, a study by Pasquale and colleagues showed that
two of the extracellular domain mutations situated in the LBD (T166N), and in CRD
(M269I) decreased the ephrin-A5 binding capacity of EPHA3 (Lisabeth et al., 2012).
This  was  shown  with  ephrin-A5  Fc  immobilised  on  sepharose  beads.  Moreover,  the
EPHA3 FN-III 2 lung cancer mutation G518L has been shown to enhance cis interaction
of EPHA3 with co-expressed ephrin-A3, possibly inhibiting EPHA3 activation via
decreasing its interaction with ephrins in trans (Falivelli et al., 2013).
Together, these results indicate that EPHA3 cancer mutations confer loss of EPHA3
activity via multiple mechanisms, one of them being loss of the autocatalytic capacity
(Figure 9B). Moreover, EPHA3 agonist or ligand-induced EPHA3 activation in
glioblastoma, neural precursors or in lung cancer cell lines leads to reduced cell
proliferation, increased cell differentiation, or apoptosis, respectively (Aoki et al., 2004;
Day et al., 2013; Zhuang et al., 2012). This further supports the tumour suppressive role
of EPHA3. EPHA3 has also been shown to have kinase activity independent tumour
promoting functions linked to maintenance of tumour cells in an undifferentiated and
cancer stem cell-like state, as evidenced in glioblastoma (Day et al., 2013). However, the
dual functions of EPHA3 in tumour suppression and promotion do not prohibit targeting
of EPHA3 as monoclonal antibody treatment shown to activate EPHA3 leads to
apoptosis and prevents tumour cell proliferation in in vitro cultured glioblastoma cells or
grafted tumours (Day et al., 2013), suggesting that targeted EPHA3 treatment could be
effective in cancer cases showing elevated EPHA3 levels, but absence of EPHA3
inactivating and dominant negative mutations.
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Figure 9. EPHA3 demonstrates characters of a tumour suppressor (A) Proposed model
for loss of EPHA3 induced OIS. (B) Selected cancer point mutations of EPHA3 cause
receptor inactivity possibly altering the tumour suppressive functions of the wild-type
EPHA3. The EPHA3 protein contains an N-terminal ligand-binding domain (LBD), two
fibronectin type-III repeats (FN3), a single-pass transmembrane domain (TM), an
intracellular region containing a juxtamembrane region, a tyrosine kinase domain
(Kinase), a sterile α motif (SAM), and a postsynaptic density protein PSD95, Drosophila
disc large tumor suppressor DlgA, and zonula occludens-1 protein ZO-1 (PDZ)-binding
motif.
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5.2 EPHA3 fails to demonstrate a tumour
suppressive role in the murine lung (II)
Our results from the cellular senescence screen and subsequent functional EPHA3
cancer mutation analysis indicated that EPHA3 may  act  as  a  tumour  suppressor.  We
therefore decided to investigate the in vivo tumour suppressive role of EPHA3 using a
previously reported EphA3 constitutive knock out model, with which a crucial role of
EphA3 in embryonic heart development has been established. 75% of the EphA3-null
mice were reported to die at birth due to cardiac abnormalities including defects in the
development of their atrial septa and atrioventricular endocardial cushions (Stephen et
al., 2007; Vaidya et al., 2003). As EPHA3 mutations are frequently found in lung
cancers we decided to study the putative functional role of EPHA3 during murine lung
tumourigenesis.
5.2.1 Constitutive loss of EphA3 does not accelerate mutant
Kras-driven lung tumourigenesis
To test the hypothesis that EPHA3 functions as a tumour suppressor in murine lung
tumourigenesis, we used a constitutive knock out mouse model of EphA3 generated by
Brown and colleagues (Stephen et al., 2007; Vaidya et al., 2003). Monitoring of EphA3-
heterozygous and -null mice for an approximate one year period showed no reduced
survival due to lung tumour formation (data not shown), indicating that EPHA3-loss on
its own does not initiate lung tumourigenesis. Similar results have been shown for the
known lung tumour suppressors LKB1 and PTEN, as their loss is not sufficient to initiate
lung tumourigenesis in mice. However, conditional Pten- and Lkb-1-loss together with
activation of oncogenic Kras in murine lungs accelerates Kras-driven lung
tumourigenesis (Iwanaga et  al., 2008; Ji et  al., 2007a). We thus next asked if loss of
EPHA3 might modulate oncogene-induced lung tumourigenesis. Lung cancer mutations
in EPHA3 show an occasional, albeit not statistically significant co-occurrence with
KRAS mutations (II, Fig. S1A) (Cancer Genome Atlas Research, 2014; Cerami et al.,
2012). We therefore crossed the EphA3-null mice with mice carrying a conditional
G12D Kras mutation allele (KrasLSL-G12D/+) (Jackson et  al., 2001). The activation of
oncogenic Kras in epithelial cells was induced by intranasal delivery of adenovirus
expressing Cre-recombinase (Ad5-CMV-Cre). The efficacy of each infection was
monitored with a dual fluorescence Rosa26mT/mG Cre-reporter strain (II, Fig. S1B)
(Muzumdar et al., 2007). KrasLSL-G12D/+;EphA3+/+ (n=9), KrasLSL-G12D/+;EphA3+/- (n=16),
and KrasLSL-G12D/+; EphA3-/- (n=8)  mouse  cohorts  were  monitored  for  19  weeks,  a  time
period which was selected based on initial condition monitoring of the mice. Tumour
burden analysis was performed with H&E-stained lung paraffin sections representing
two separate regions of the mouse lungs. This showed no difference between the KrasLSL-
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G12D/+;EphA3+/+, KrasLSL-G12D/+;EphA3+/-, and KrasLSL-G12D/+;EphA3-/- cohorts (average
tumour/lung ratio 19,7%, 16,1%, and 18,5%, respectively) (II,  Fig.  1A  &  B,  S1C).
Furthermore, no shift in the tumour histopathology was detected, and all tumours were
positive for the AC marker NKX2-1 and negative for the SCC marker p63 (II, Fig. 1C).
5.2.2 Constitutive loss of EphA3 does not accelerate Trp53-
loss-driven lung tumourigenesis
Our in vitro results showing loss of EPHA3-induced, and p53 and p16INK4a
dependent senescence (I, Fig. 4B), suggested possible cooperation between alterations in
these genes during tumourigenesis. Mutations in TP53 show statistically significant co-
occurrence with genetic alterations (point mutations or copy number variation) in
EPHA3 in human lung ACs {Cerami, 2012 #168}(Cancer Genome Atlas Research,
2014). We therefore decided to test if loss of EphA3 would  alter  loss  of Trp53-driven
lung tumourigenesis. As Trp53-loss on its own leads to lung tumourigenesis with a long
latency (350–530 days) (Meuwissen et al., 2003), we decided to monitor the
Trp53fl/fl;EphA3+/+ (n=7), Trp53fl/fl;EphA3+/- (n=11) and Trp53fl/fl;EphA3-/- (n=13)
cohorts for 15 months (450 days) following intranasal delivery of Ad5-CMV-Cre. At 15
months, three mice had died due to AC formation. These included two
Trp53fl/fl;EphA3+/+ mice and one Trp53fl/fl;EphA3-/- mouse. Analysis of the remaining
mice  without  any  signs  of  reduced  condition  in  all  three  cohorts  at  15  months  post
infection, showed absence of lung tumourigenesis. These results suggest that loss of
EphA3 does  not  cooperate  with  loss  of Trp53 in murine lung tumourigenesis (II, Fig.
1D).
Taken together, our results from the murine lung tumourigenesis studies showed that
constitutive loss of EphA3 does not alter oncogenic Kras- or Trp53-loss driven lung
tumourigenesis. This might be due to compensating effects by the other lung expressed
Eph receptors, thus distinguishing the used method of constitutive loss of EphA3 from
the sporadically occurring human lung cancer mutations. Alternatively, it is possible that
other EPH receptors instead of EphA3 are functionally important in murine lung
tumourigenesis. Indeed, a recent study exploring genetic alterations in mouse SCLC
driven by loss of Trp53 and Rb1 revealed recurrent somatically acquired EphA5 and
EphA7 mutations (McFadden et al., 2014). Furthermore, a recent in vivo shRNA screen
identified EphA2 as a tumour suppressor cooperating with oncogenic Kras in promoting
murine lung AC (Yeddula et al., 2015), suggesting that these Eph receptors, rather than
EphA3, may modulate murine lung tumourigenesis (Figure 10).
The senescence induced by EPHA3-loss was dependent on both p53 and p16INK4a.
However, our study did not address the possible effect of EphA3-loss together with
combined loss of Trp53 and p16INK4a shown to lead to low tumour multiplicity and high
frequency of fatal pulmonary haemorrhage (Ji et al., 2007a). Therefore, it remains
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possible that loss of EphA3 may accelerate Trp53- and p16INK4a-loss induced lung
tumourigenesis.
Figure 10. EphA3 fails to demonstrate tumour suppressive role in murine lung
tumourigenesis driven by oncogenic Kras and Trp53-loss. This suggests possible murine
lung tumourigenesis specific functional importance of other Eph receptors such as
EphA5 and EphA7, which were recently found to be somatically mutated in murine
SCLC (McFadden et al., 2014) or EphA2 which was recently found to cooperate with
oncogenic Kras in murine lung AC progression (Yeddula et al., 2015).
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5.3 The role of EPHA3 in lung morphogenesis (II)
EPH receptors play important roles in embryonic development, controlling tissue
boundaries and patterning (Nievergall et al., 2012). EphA3 also plays a critical role in
embryogenesis, with 75% of EphA3-null mice showing increased perinatal mortality due
to defects in cardiogenesis. Perinatally mortal EphA3-null mice have enlarged, blood-
filled atria and almost absent atrial septum. This is caused by hypoplastic endocardial
cushions, a specific mesenchymal cell layer derived from endocardium via EndMT
(Stephen et al., 2007).
Despite the well-established role of EPHs and ephrins in embryonic development,
still relatively little was known about their role in lung development. Ephrin-B2 is linked
to alveolar epithelial and endothelial cell viability and vascular growth in hyperoxic rats
(Vadivel et al., 2012). shRNA-mediated in vivo silencing of Efnb2 (coding ephrin-B2)
during the postnatal stage of alveolar development in rats resulted in defects in alveolar
and vascular growth. Efnb2LacZ/6YFDV mice, which expresses a truncated ephrin-B2
incapable of reverse signalling, showed reduced elastic properties of lungs indicating a
link between ephrin-B2 and pulmonary compliance in mice (Bennett et  al., 2013).
Important regulators of lung morphogenesis such as Fgf9 and Nkx2-1 have been
functionally implicated in lung tumourigenesis. Thus, we decided to investigate the
possible role of EphA3 in murine lung development, aiming to elucidate functional
mechanisms, which could be translated to lung tumourigenesis.
5.3.1 EphA3 is expressed in the distal mesenchyme of the
developing lung
To investigate the localisation of EphA3 expression in embryonic lungs, we analysed
the expression profile of EphA3 mRNA  and  protein  expression  during  the
pseudoglandular stage of lung development. We first performed an in situ hybridisation
analysis using radiolabeled probe against the EphA3 nucleotide sequence ranging from
658 to 1474, on sagittal sections of wt and EphA3-null embryos at E14.5. This revealed a
distal mesenchymal expression pattern of EphA3 mRNA in wt embryos confirmed by the
absence of the signal in EphA3-null embryos (II, Fig. 2A). We then analysed the EPHA3
protein expression using a commercial polyclonal rabbit anti-EPHA3 antibody, at three
different time points of the pseudoglandular stage, E11.5, E13.5, and E15.5. In all time
points, EPHA3 was detected in the distal mesenchyme of the embryonic lungs (II, Fig.
2B & S1D). This was further confirmed by a Q-PCR-based expression analysis of
dissected embryonic lung epithelium and mesenchyme, interestingly showing highest
expression at E13.5 (II,  Fig.  2C  &  3A).  The  expression  of EphA3 correlated with the
known mesenchymal expression pattern of Fgf10 and Cd31 (official gene symbol
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Pecam1), and opposed the epithelial expression of Cdh1 and Nkx2-1 in the epithelium-
and mesenchyme-specific Q-PCR expression analysis (II, Fig. 3B & S2A).
We next asked if the expression of EphA3 in the developing lung mesenchyme was
unique among other Eph receptors. We analysed the expression patterns of selected
EphA receptors, namely EphA1-EphA5 and EphA7, as well as selected ephrins at E11.5,
E13.5, and E15.5. Our Q-PCR expression analysis at E13.5 and E15.5 confirmed the
reported epithelial expression of Efnb2 encoded ephrin-B2 (data not shown) (Bennett et
al., 2013). EphA1 and EphA5 were absent in both epithelium and mesenchyme at all
three time points whereas EphA2, EphA4, and EphA7 showed a low to medium level of
expression in the epithelium. EphA4 showed  a  low  and EphA7 a medium level of
expression in the mesenchyme, but EphA3 was the only Eph receptor with restrictive
expression in the embryonic lung mesenchyme. Of note, no change in the expression of
EphA7 was detected in EphA3-heterozygous or -null lungs (II,  Fig.  S2B).  When  we
compared the expression levels of adult mouse lung to embryonic lung mesenchyme at
E13.5, only expression of EphA2 and EphA4 was detected in the adult lung. This may
suggest a negligible role for EphA3 in postnatal lung homeostasis, and may thus explain
the absence of the discernible effect of EphA3 on murine lung tumorigenesis (II, Fig.
S3A & B). Efna1 (encoding ephrin-A1) and Efna5 (endoding ephrin-A5) showed
medium and very low expression in the development lung epithelium, respectively,
suggesting that ephrin-A1 is the primary ligand for EPHA3 in the developing lung (II,
Fig. 3B). Epithelial expression of Efna1 was confirmed by in situ hybridisation assay
using a probe against the Efna1 nucleotide sequence ranging from 20 to 421 (II, Fig.
S2C).
Together, these results showed, for the first time, the expression of EphA3 in the
developing lung and its expression restricted to the lung mesenchyme was a unique
expression patter among the studied EphA receptors. Since the expression was found
specifically during the pseudoglandular stage, during which the epithelial branching
takes place, we hypothesised that EPHA3 may play role in this process. Alternatively,
given that the pulmonary vasculature develops in parallel to the branching epithelia and
one of the well-established roles of EPHs is control of vascular development (Gerety and
Anderson, 2002; Nievergall et al., 2012) we hypothesised that EPHA3 may control
development of the pulmonary vasculature.
5.3.2 EphA3 loss is associated with altered expression of
branching morphogenesis and vasculogenesis genes
To first investigate if expression of epithelial or mesenchymal genes are altered due
to the loss of EphA3, we measured the mRNA expression levels of known regulators of
lung morphogenesis in these two tissue compartments. This was done with epithelial and
mesenchymal cells dissected from the lungs of wt, EphA3-heterozygous and -null
embryos, at E11.5, E13.5, and E15.5 (II, Fig. 3A). Q-PCR-based expression analyses
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showed a small but statistically significant increase in the expression of Nkx2-1 in the
epithelium of the EphA3-heterozygous embryonic lungs at E13.5 when compared with
wild-type tissue. This was accompanied with a similar increase in endothelial Cd31 and
mesenchymal Fgf10 measured from the mesenchymal cell fraction of E13.5 EphA3-
heterozygous embryonic lungs (II,  Fig. 3C). Both Nkx2-1 and Fgf10 are key regulators
of lung morphogenesis. Nkx2-1 deletion in mice leads to unbranched lungs, causing
prenatal mortality of the embryos (Kimura et al., 1996) and Fgf10-null embryos display
complete absence of lungs (Min et  al., 1998; Sekine et al., 1999). Furthermore, the
ectopic expression of Fgf10 in lung development has been linked to prevention of
proximal cell differentiation and promotion of basal cell fate (Volckaert et al., 2013).
Opposing expression patterns of epithelial Nkx2-1 and mesenchymal Fgf10 are detected
early in lung development and interestingly, ectopic Fgf10 expression is shown to induce
ectopic expression of Nkx2-1 in chicken embryonic lungs resulting (Sakiyama et  al.,
2003). Thus, our observation that a small but significant change was detected in the
expression of these two key regulators of lung morphogenesis suggested a possible role
for EphA3 in lung development. Additionally, the altered Cd31 expression levels in
endothelial cells of the developing mesenchyme suggested a possible effect on the
development of pulmonary vasculature. Of note, we did not detect similar expression
changes  in  the  lungs  of EphA3-heterozygous and -null embryos with age E15.5,
indicating a dynamic role for EphA3 in the possible regulation of these genes (II, Fig.
S3C).
5.3.3 Constitutive loss of EphA3 does not overtly affect
murine lung morphogenesis
Our finding that EphA3-reduction has a small but significant effect on the expression
levels of epithelial Nkx2-1 and endothelial and mesenchymal Cd31 and Fgf10,
respectively, suggested a possible role for EphA3 in lung morphogenesis and/or
development of the pulmonary vasculature. To investigate if constitutive loss of EphA3
affects lung branching morphogenesis, we analysed the branch end-points of the
embryonic lungs at E13.5 by E-cadherin whole-mount immunohistochemistry staining
and optical projection tomography (OPT). 3D image analysis-based branch end-point
counting showed no difference between the wt (average 108), EphA3-heterozygous
(average 113), and EphA3-null embryonic lungs (II,  Fig. 4A & B). We also performed
whole mount staining for E-Cadherin on lungs of embryos aged E11.5 and E15.5.
Qualitative analysis of these embryonic lungs further confirmed that constitutive loss of
EphA3 does not lead to defects in lung branching morphogenesis (II, Fig. S3C).
Proliferation and differentiation of the pulmonary mesenchyme is coordinated by
reciprocal signalling between the growing epithelia and the surrounding mesenchyme
(Morrisey and Hogan, 2010). Therefore, we hypothesised that EphA3-loss could impair
this interplay and possibly affect mesenchymal cell proliferation. We investigated the
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effect of EphA3-loss on embryonic lung cellular proliferation of the distal mesenchyme
at E13.5. We measured the percentage of distal mesenchymal cells in the S phase of the
cell cycle by BrdU incorporation. No statistically significant change was measured in the
amount of mesenchymal cells in S phase between wt (26%), EphA3-heterozygous (36%)
or EphA3-null lungs (26%) (II, Fig. 4C).
Previous studies have established a role for EPHB4-ephrin-B2 signalling in
vasculogenic development. Efnb2 (gene encoding ephrin-B2) is expressed in arterial but
not venous endothelial cells, whereas EphB4 expression is detected in veins but not
arteries. Efnb2-null embryos exhibit defects both in arteries and veins of the head and
yolk sac, as well as in myocardial trabeculation (Wang et al., 1998). Supporting the role
of EPHB4 as a specific receptor for ephrin-B2 in vascular endothelial cells, mice
carrying a mutation of EphB4 have a similar phenotype as Efnb2 null mice (Gerety et al.,
1999). Both EPHB4 and ephrin-B2 are also expressed in pulmonary arterial and venous
vessels during the pseudoglandular stage of lung development (Schwarz et al., 2009). As
EphA3 was expressed in the distal mesenchyme of the developing lung, we hypothesised
that its loss may affect pulmonary vasculogenesis, as evidenced with both ephrin-B2 and
EphB4 loss. To test this, we qualitatively analysed CD31 positive pulmonary endothelial
cells at E13,5. Again, no difference in the amount nor in the localisation of CD31
positive endothelia was detected when comparing wt, EphA3-heterozygous or EphA3-
null lungs (II, Fig. 4D).
Taken together, our study identified EphA3 expression to be restricted to the
mesenchyme, a unique pattern for the developing lung-expressed Eph receptors (Figure
11A). However, in contrary to our hypothesis based on the small but significant
expression changes in epithelial Nkx2-1, mesenchymal Fgf10 and endothelial Cd31 in
EphA3-heterozygous embryonic lungs, EphA3 failed to demonstrate a critical role in
lung epithelial branching, mesenchymal cell proliferation, or in the abundance and
localization of CD31 positive endothelia. This can be explained by at least two
phenomenon. First, partial penetrance of the EphA3-null genotype reported in the
original analysis of EphA3-null mice (Vaidya et al., 2003), which we confirmed by
monitoring the viability of EphA3-null pups and subsequent macroscopic inspection,
could explain why no overt difference was detected in the comparison between the wt
and EphA3-null embryos at the studied time points. Secondly, functional redundancy
between lung-expressed EphA receptors could explain the negative results observed in
the lung morphogenesis analysis of EphA3-heterozygous and –null embryonic lungs
(Figure 11B). Indeed, a recent study suggested possible functional compensation
between EphA3, EphA4, and EphA7, all co-expressed during embryonic palate
development in mice (Agrawal et al., 2014). Compound homozygous EphA3- and
EphA4-loss did not lead to defective midfacial development, suggesting a possible
functional compensation by EphA7. However, we did not detect any misexpression of
mesenchymal EphA7 at the studied time points (II, Fig. S2B), which indicates that
possible EphA3-loss induced compensation by EphA7 would not be mediated by
transcriptional upregulation. EphA3, EphA4, and EphA7 were still the EphA receptors
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we observed to be coexpressed in the embryonic lung mesenchyme, though EphA4 at
very low levels, and EPHA4 functions as a receptor for ephrin-A1 (Jellinghaus et al.,
2013). In the future, EphA3-Efna1 double knock out mouse model could elucidate the
role  of  the  EPHA3-ephrin-A1  axis  in  the  lung  morphogenesis.  However,  it  is  also
possible that mesenchymal Fgf10,  which  expression  was elevated in EphA3-
heterozygous lung mesenchyme at E13,5, would compensate the loss of EphA3.
Figure 11. EphA3 in murine lung development. (A) Ephs and ephrins found to be
expressed during the pseudoglandular phase of murine lung development. Size of the
text refers to the level of observed expression. (B) Constitutive loss of EphA3 does not
overtly affect murine lung morphogenesis. Despite the embryonic lung mesenchymal
expression of EphA3, no alterations are seen in lung branching morphogenesis or cell
proliferation of EphA3 heterozygous or homozygous embryos at E13.5. This suggests
possible redundancy between the lung-expressed Eph receptors including EphA4 and
EphA7. Scale bars 300 μm in E-cadherin whole-mount images and 100 μm in BrdU
images.
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5.4 Cell-of-origin links histopathology spectrum
and immune microenvironment in mutant Kras
and loss of Lkb1 driven NSCLC (III)
NSCLC comprises a heterogeneous group of lung cancers, with a variety of
prognostic and predictive characteristics including patient’s performance score, clinical
stage, and tumour histopathology. The three main tumour histopathology subclasses of
NSCLC, namely AC, SCC, and LCC, all have been detected in murine GEMMs
modelling human NSCLC. These studies have confirmed and revealed insights in human
lung tumourigenesis, and have functionally connected the underlying genetic driver
events to the development of specific histopathologies (Chen et al., 2014). Activation of
oncogenic Kras (G12D) in CC10+ airway cells, SPC+ alveolar cells or BASCs positive
for both CC10 and SPC and located at the BADJ, can induce lung ACs (Kim et al., 2005;
Sutherland et al., 2014). However, the role of BASCs as cell-of-origin for oncogenic
Kras driven ACs is somewhat controversial and would need further investigation (Kim
et al., 2005; Sutherland et al., 2014). Similarly, contradictory results have been gained in
studies initiating Kras-driven tumourigenesis from CC10+ cells. Adenovirus mediated
inflammation has been suggested to promote oncogenic Kras-driven tumourigenesis
from CC10+ cells (Mainardi et al., 2014). Also, whereas the CC10-CreER mediated
induction of oncogenic Kras combined with heterozygous loss of Trp53 in mouse lungs
fails to lead to tumourigenesis (Xu et al., 2012), adenovirus mediated induction of the
same genetic alterations in CC10+ cells results not only tumourigenesis but also ACs
with increased invasive and metastatic characters when compared to ACs derived from
SPC+ cells (Sutherland et al., 2014). Thus, these results suggest progenitor- or niche-
specific dependency on microenvironmental factors during lung tumourigenesis.
While the progenitor-specific aetiologies for lung ACs are relatively well described,
the influence of the cell-of-origin for SCC or more rare ASC histopathology is less clear.
Airway basal cells have been proposed to act as SCC progenitors following loss of Pten
with Tgfbr2 or Lkb1 (Malkoski et al., 2014; Xu et al., 2014a). Moreover, SPC+ alveolar
cells are shown to initiate ACs which transdifferentiate to SCCs via an ASC intermediate
(Han  et  al.,  2014).  However,  it  is  not  yet  known  if  the  CC10+ airway cells and SPC+
alveolar cells exhibit differential propensities to originate SCCs or ASCs.
Lung cancer in vivo studies have revealed a critical role for Lkb1-loss in promoting
oncogenic Kras-driven lung tumourigenesis towards more rapid tumour development
(shorter latency), and generation of a wider spectrum of tumour histopathologies
accompanied with frequent metastasis (Ji et al., 2007a). The transdifferentiation from
ACs to SCCs during KrasLSL-G12D/+;Lkb1fl/fl (KL) tumourigenesis, which has been
mechanistically linked to modulation of tumour ECM and regulation of cell growth and
apoptosis, as well as ROS and metabolic adaptation (Gao et al., 2014; Han et al., 2014;
Li et al., 2015), possibly partly explains the wide spectrum of tumour histopathologies.
The KL model is a particularly interesting model to study the role of cell-of-origin,
because it develops a large variety of NSCLC histopathologies and therefore permits one
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to  ask  if  the  role  of Lkb1-loss differentially modulates oncogenic Kras-driven
tumourigenesis depending on the progenitor. Thus, we decided to investigate if the cell-
of-origin could contribute to the development of divergent histopathologies initiated by
the expression of oncogenic Kras and Lkb1-loss.
5.4.1 Cell-of-origin defines survival and histopathology
spectrum in NSCLC driven by mutant Kras and Lkb1-loss
To test how the cell-of-origin influences tumourigenesis driven by mutant Kras and
Lkb1-loss, we analysed cohorts of KL mice (n=9) intranasally infected with
adenoviruses expressing Cre-recombinase in a progenitor-restrictive manner, either
under a CC10 or SPC promoter (Ad5-CC10-Cre and Ad5-SPC-Cre respectively).
Crossing the KL mice to the Rosa26mT/mG strain (Muzumdar et al., 2007) enabled us to
monitor the Cre expression activation in the lung epithelial cells. Analysis of the mGFP
signal at 2-4 weeks post infection showed accurate bronchiolar and alveolar mGFP
signal, respectively, correlating with previous findings (Sutherland et al., 2011) (III, Fig.
S1A). The amount of Ad5-CC10-Cre (1x107 pfu) and Ad5-SPC-Cre (2.5x109 pfu) was
adjusted based on their ability to achieve comparable infection rates. We followed both
Ad5-CC10-Cre and Ad5-SPC-Cre infected KL mice until they showed signs of illness
(breathing abnormalities and weight loss), at which time they were sacrificed.
Interestingly, we observed a clear difference in the survival of mice in these two cohorts.
Ad5-CC10-Cre infected KL mice showed a statistically significant (Kaplan-Meier
survival analysis, p=0,0125, Gehan-Breslow-Wilcoxon test) shorter latency when
compared to Ad5-SPC-Cre infected KL mice (median survival 79 and 120 days
respectively) (III, Fig. 1A). This suggested that lung tumours which originate from
CC10+ lung epithelial cells grow and/or progress faster.
To address if the cell-of-origin defines the generation of tumour histopathology
spectra in KL mice, we analysed Ad5-CC10-Cre and Ad5-SPC-Cre infected KL mice
(n=5 in both cohorts) and quantitatively assessed the amount of each lesion type from
full lung lobe sets of individual mice. Immunohistological staining for NKX2-1 and p63
was used to guide the histopathology classification (III, Fig. 1B). Of note, the KL ASCs
in our mouse cohorts showed clear positivity for CK5 in the SCC component, whereas
contrary to previously reported results on KL SCCs (Han et al., 2014), no SOX2
positivity was detected in the SCC component of ASCs (III, Fig. S1D). When the lung
lesions were normalised against the total lesion count in each lung, clear differences in
the predominant lesion type were observed. The Ad5-CC10-Cre infected KL mice had
ASC tumours as the predominant lesion type (average 51%), whereas the invasive AC
(characterised with a lepidic growth pattern at the lesion border) and papillary ACs
(PACs) comprised the major part of Ad5-SPC-Cre induced lesions (average 66% and
17%, respectively). Moreover, the Ad5-CC10-Cre induced tumours included invasive
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ACs classified as acinar (average 3%) and mucinous ACs (average 9%), two invasive
AC growth patterns which were not detected among the Ad5-SPC-Cre induced lesions in
this cohort. ASCs were rarely detected in Ad5-SPC-Cre mice (3%). These results
suggested that the Ad5-CC10-Cre-specific histopathology spectrum could explain the
difference seen in the survival of Ad5-CC10-Cre and Ad5-SPC-Cre mice (III, Fig. 1B &
C). Luminal papillary hyperplasias or AIS were detected at 6 weeks following Ad5-
CC10-Cre or Ad5-SPC-Cre infection of KL mice, respectively, indicating that these
could represent precursors for the detected late-stage tumours (III,  Fig. S1G). Of note,
only one pure SCC lesion was detected at 9 weeks post infection (III, Fig. S1G).
To strengthen our hypothesis that the Ad5-CC10-Cre specific histopathology
spectrum could explain the reduced survival of Ad5-CC10-Cre infected KL mice, we
assessed the proliferation status and size of both Ad5-CC10-Cre and Ad5-SPC-Cre
induced lesions. We found that Ad5-CC10-Cre infected mice had more proliferating
cells, detected with Ki67 proliferation marker, in common invasive ACs, namely
invasive  ACs  and  papillary  ACs  as  well  as  AIS  (III,  Fig.  1D  &  S2A).  Of  these,  the
difference between AISs and papillary ACs was statistically significant. We did not
observe any size difference between the lesions in Ad5-CC10-Cre and Ad5-SPC-Cre KL
mice. However, the size of the ASCs was substantially bigger than the size of the other
lesions, often occupying the whole lung lobe, suggesting that they grew faster (III, Fig.
1E). Mucin production was assessed with periodic acid Schiff’s (PAS) staining, and it
was  detected  in  mucinous  invasive  ACs  and  ASCs  (III, Fig. 1F). To assess the
differentiation status of the lesions, we performed a quantitative analysis of NKX2-1
positive cells for the Ad5-CC10-Cre-induced lesions, which represented a broader lesion
spectrum than the Ad5-SPC-Cre-induced lesions. The amount of NKX2-1 positive cells
was lower in acinar and mucinous invasive ACs, as well as in ASCs when compared to
PACs (III, Fig. 1G). Moreover, unlike the other lesions, the ASCs were homogenously
expressing the high mobility group AT-hook 2 (HMGA2) transcription factor.
Expression of HMGA2 is commonly detected in more poorly differentiated and invasive
tumours such as oncogenic Kras and Trp53- or Nkx2-1-loss driven lung tumours (Snyder
et  al.,  2013;  Sutherland  et  al.,  2014;  Winslow  et  al.,  2011)  (III, Fig. S2B). Taken
together, our results indicate that the lung lesions derived from the CC10+ cells grow
faster, and show decreased differentiation.
Our  results  thus  show  an  increased  incidence  of  ASCs  as  well  as  other  less
differentiated acinar and mucinous invasive ACs in Ad5–CC10–Cre cohorts, and suggest
that CC10 progenitors may have an increased propensity to initiate faster growing lung
tumours. This corroborates previous results in KrasLSL-G12D/+ and KrasLSL-G12D/+;Trp53fl/fl
(KP) models which also showed ACs with increased invasive and metastatic characters,
possibly indicating faster tumour progression, upon Ad5-CC10-Cre-mediated tumour
initiation (Sutherland et al., 2014). Interestingly, studies in human lung tissue have
indicated LKB1 expression to be restricted to airway cells (Ghaffar et al., 2003). This
suggests a possible lung airway epithelium- restricted role for LKB1 in the normal lung,
potentially explaining the different effects of Lkb1 deletion in CC10+ and SPC+ epithelial
progenitors.
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Our results further suggest that oncogenic Kras activation combined with Lkb1-loss
in SPC+ alveolar cells predominantly initiates lung ACs (specifically, invasive AC and
PACs), recapitulating lung tumour phenotype initiated by oncogenic Kras only (Johnson
et al., 2001b). This is in line with previous studies showing oncogenic Kras-driven AC
formation originating from alveolar regions (Mainardi et al., 2014; Sutherland et al.,
2014; Xu et al., 2012). We however also observed a small percentage of ASCs in Ad5–
SPC–Cre infected KL mice, supporting the previously reported AC-ASC
transdifferentiation of lesions derived from SPC+ alveolar cells (Han et al.,  2014; Li et
al., 2015).
5.4.2 NSCLC driven by mutant Kras and Lkb- loss shows
histotype-specific gene expression signatures
To gain insights in the biological differences between the predominant Ad5-CC10-
Cre- and Ad5-SPC-Cre-induced lung tumour histopathologies, we performed
transcriptional profiling of Ad5-CC10-Cre-induced ASCs and Ad5-SPC-Cre-induced
PACs collected at the end-stage of the tumour bearing mice. PACs were the second most
frequently detected lesion type in Ad5-SPC-Cre infected mice (17%, III, Fig. 1C), and
because it represents a progressive invasive AC subtype with a substantially larger size
than invasive ACs, they were selected for transcriptional profiling. Two tumours per
mouse from three Ad5-CC10-Cre- or three Ad5-SPC-Cre-infected mice were harvested
and processed for RNA extraction, protein lysates and histological examination (III, Fig.
S3A). The ASC histopathology was confirmed by western blot analysis using anti-p63
antibody (III, Fig. S3B). Unsupervised hierarchical clustering of 340 genes that were
differentially expressed between ASCs and PACs (cut-off adjusted p-value<0,01
LogFC>1) revealed distinct clustering of ASC and papillary AC tumours (III, Fig. 2A).
To characterise the data, we performed a comparative gene expression analysis using a
Venn diagram generation tool and ENSEMBL GENE IDs as gene identifiers. The Venn
diagram generation tool identifies commonalities in the studied data sets. The datasets
we used for  the  comparison were  a  comparison of  human SCC and AC (Kuner  et  al.,
2009), and a comparison of murine SCC and AC (Lkb1- and Pten-loss driven SCC,
called LP, and KrasLSL-G12D/+ driven ACs) (Xu et al., 2014a) expression profiles.
Altogether 40 (29 upregulated and 11 downregulated) commonly differentially altered
genes were found between these data sets (III, Fig. 2B). This set of 40 genes was
enriched for increased expression of squamous markers, such as Trp63, Krt5 and
multiple other cytokeratins. Downregulated genes included the recently described AC
marker napsin A (Napsa) (Turner et al., 2012) (III, Fig. 2C).
Together, these results underlined previously reported results of an ASC-specific
squamous expression profile (Ji et al., 2007a), and further identified Napsa expression in
the KL PACs. Our expression profiling therefore underscores a predominant squamous
component in ASC tumours driven by oncogenic Kras and Lkb1-loss.
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We further compared the set of genes that were differentially expressed between KL
ASCs and PACs to genes expressed differentially in wt murine basal cells (Griffonia
simplicifolia isolectin A3B, GSI-A3B+ and KRT5+) versus non-basal cells (GSI-A3B-
and KRT5-) (Rock et al., 2009). This revealed 108 commonly up- or downregulated
genes in these two data sets (III, Fig. S3C). This included up regulation of known basal
and squamous epithelial marker genes Trp63,  snail  family  zinc  finger  2  (Snai2),
basonuclin (Bnc1), stratifin (Sfn), and cytokeratins. We also found common enrichment
of the pro-inflammatory cytokine interleukin 1β (Il1b) and its type II interleukin 1
receptor (Il1r2). As expected, the AC biomarker SPC was downregulated in both airway
basal  cells  and  ASC  (III, Table S1). As the analysed ASCs originated from CC10+
airway  cells,  the  enrichment  for  genes  typically  expressed  in  basal  cells  suggests  a
transcriptional switch of transformed CC10+ cells to more basal-like expression during
ASC development. Our last comparison was with the published KL data, in which
transcriptional profiles of Ad5-CMV-Cre induced ACs and ASCs were compared (Ji et
al., 2007a). We found 23 commonly enriched genes, including SCC signature genes
Trp63 and cytokeratins (III, Fig. S3C & Table S1).
5.4.3 ASCs and PACs driven by mutant Kras and Lkb1-loss
show histotype-specific expression of immune-related genes
To gain more in depth understanding of the possible mechanisms contributing to the
two predominant lung tumour histopathologies, we analysed the 340 differentially
expressed genes between KL ASCs and PACs using the Ingenuity Pathway Analysis
(IPA) tool. Analysis identified enrichment in immune related canonical pathways
including granulocyte adhesion and diapedesis (upregulated in ASCs: Ngfr, Il1b, Hspb1,
Il1r2, Cldn23, Ppbp; downregulated in ASCs: Cldn18, Cxcl15, Itga2, Ccl6, Ccl17) and
antigen presentation (downregulated in ASCs: Cd74, Ciita, H2-D1, H2-DMa, H2-
DMb1), indicating possible differences in immune-related properties between ASCs and
PACs (III, Fig. 3A).
We then asked if the observed histopathology-dependent immune-related gene
expression patterns would exist independently of driver genotypes. Indeed, expression
pattern analysis of selected immune related genes in KL ASCs and PACs together with
KP Ad5-CC10-Cre- and Ad5-SPC-Cre-derived ACs, revealed histopathology-dependent
expression differences (III, Fig. 3B). These included ASC-specific elevated expression
of the pro-inflammatory cytokine Il1b and  arginase  1  enzyme  gene  (Arg1), a key
mediator of T-cell immunosuppression (Munder et al., 2006). Moreover, as partly
identified with the IPA analysis, expression of class II major histocompatibility complex
(MHC) genes (H2-DMa, H2-Ab1, H2-DMb1), and class II MHC associated gene Cd74
as well as the chemokine Cxcl15 and the lymphocyte and monocyte chemoattractant
chemokines Ccl17 and Ccl6,  were  significantly  lower  in  ASCs  than  in  ACs  (III, Fig.
3B). Expression of class I MHC genes (H2-M2, H2-D1) was lower in KL ASCs when
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compared to KL PACs, but showed variable expression in KP ACs. Cxcl5, a downstream
chemokine target of Il1b,  showed  elevated  levels  in  both  KL  ASCs  and  KP  ACs,
suggesting a possible association with tumour grade rather than histopathology (III, Fig.
3B). Interestingly, some of these immune-related genes were found to be commonly
enriched between KL ASC-AC and the published mouse SCC-AC (LP vs KrasLSL-G12D/+)
comparison (Xu et al., 2014a). These included Ciita, H2-DMa, Ngfr, Cldn23, Ppbp,
Cldn18, Cxcl15, Cxcl5, and H2-Ab1 (III, Table S1). In addition, Arg1 was commonly
upregulated in both KL ASC and LP SCC, but was excluded from the comparison
analysis because of the used cut-off values (cut-off 0,01, Arg1 Adj.p-value: 0,012). Q-
PCR-based validation of selected genes confirmed the KL ASC-specific upregulation of
immune-related gene expression differences including Il1b and Arg1 and the decreased
expression of class I MHC genes (III, Fig. 3C).
In summary, these results indicated immune-related expression differences between
the KL ASCs and PACs, possibly contributing to their differential tumourigenic growth.
Moreover, the observation that both KL and KP ACs express very similar immune genes
together  with  the  overlap  between  the  KL  ASC-AC  and  LP  SCC-KrasLSL-G12D/+ AC
expression profiles, suggested that tumour progression may coincide with immune
modulation of the tumour microenvironment in a histopathology-specific manner and
simultaneously excluded the effect of potential adenovirus-associated inflammatory
response.
5.4.4 ASCs show recruitment of Gr-1+CD11b+myeloid cells
with possible immune suppressive characteristics
Elevated Il1b expression has been linked to mobilisation and recruitment of
neutrophils representing subpopulation of MDSCs in murine models of stomach and
breast cancer (Coffelt et al., 2015; Tu et al., 2008). In the stomach, recruitment of
MDSCs sensitises to gastric inflammation and carcinoma (Tu et al., 2008), whereas in
breast cancer the tumour-infiltrated MDSCs suppress CD8+ T-cell activation and
facilitate lung metastasis (Coffelt et al., 2015). Additionally, Arg1 expression  by  the
MDSCs is linked to regulation of T-cell function. Thus, we reasoned that the observed
immune-related gene expression profile of KL ASCs, particularly the elevated Il1b and
Arg1 and decreased MHC expression, may indicate a histotype-specific immune cell
contexture.
To know if KL ASCs were enriched with myeloid cells expressing murine MDSC
markers, namely Gr-1 and CD11b, we performed a quantitative IHC-based analysis of
lesions from Ad5-CC10-Cre- and Ad5-SPC-Cre-infected KL lungs (n=5 in both
cohorts). The amount of both Gr-1+ and CD11b+ immune cells was normalised against
the total amount of cells in each lesion, enabling inspection of these cells relative to the
size of the lesion. The analysis between the KL ASCs and KL PACs revealed a clear
difference  in  the  amount  of  Gr-1+ (average 4,4% and 0,3% respectively) and CD11b+
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neutrophils (average 9,4% and 2% respectively) (III,  Fig.  4A,  4B  &  S3E).  Next  we
asked  if  the  increased  amount  of  Gr-1+ and CD11b+ neutrophils correlated with the
number of infiltrating T-cells in these lesion types. Indeed, we found decreased numbers
of CD3+ T-cells in ASCs when compared to PACs (average 0,8% and 1,4%
respectively), suggesting a negative correlation between the recruitment of MDSCs and
the amount of T-cells (III, Fig. 4A & 4B). Double positivity of Gr-1+ and CD11b+ was
confirmed by flow cytometry analysis, which further confirmed the increased number of
neutrophils  in  ASCs  when  compared  to  PACs  (average  15%  and  0,3%  of  live  cells,
respectively) (III,  Fig.  4C  &  4D).  Since Il1b and Arg1 expression was significantly
lower  also  in  KP  ACs  when  compared  to  ASCs (III, Fig. 3B), we analysed Gr-1+,
CD11b+ and CD3+ immune cells in KP tumours. Spleen-derived Ly6ChiCD11b+
monocytic and Ly6GhiCD11b+ granulocytic immune cells have been shown to promote
tumourigenesis of KP ACs (Cortez-Retamozo et al., 2012). Our IHC-based quantitation
of Gr-1+, CD11b+ and CD3+ immune cells in KP ACs (n=2 in both Ad5-CC10-Cre and
Ad5-SPC-Cre cohorts) indeed showed positive but also highly variable numbers of Gr-
1+ and CD11b+ cells in both Ad5-CC10-Cre- and Ad5-SPC-Cre-induced KP tumours.
Furthermore, the results suggested increased numbers of Gr-1+ and CD11b+ cells in the
Ad5-CC10-Cre cohort (III, Fig. S3F & G), suggesting that neutrophil infiltration in the
KP model may correlate with the tumour differentiation status.
Taken together, our results show a differential contribution of specific lung
epithelial progenitors to oncogenic Kras and loss of Lkb1 driven lung tumourigensis,
detected as separate histopathology spectrums in Ad5-CC10-Cre- and Ad5-SPC-Cre-
infected KL mice. Our results tentatively suggest that KL tumours derived from CC10+
cells progress faster than those derived from SPC+ cells (Figure 12). However, this was
not absolute, since tumours with a higher differentiation status, namely AIS, invasive
ACs and PACs, were also detected in Ad5-CC10-Cre cohorts, and more poorly
differentiated ASCs were also detected in the Ad5-SPC-Cre cohorts. Thus, significant
histotype heterogeneity is seen within each of the CC10+- and SPC+-derived lesions.
Indeed, a specific naphthalene-resistant subpopulation of CC10+ Clara cells in the NEB
microenvironment argues that CC10+ cellular subpopulations show varied stem cell-like
regenerative properties (Hong et al., 2001). Similarly, some but not all AT2 cells express
low levels of CC10, indicating heterogeneity among the alveolar SPC expressing AT2
cells as well (Rawlins et al., 2009b).
Expression profiling of the two predominant tumour histopathology classes in Ad5-
CC10-Cre and Ad5-SPC-Cre KL cohorts, ASCs and PACs respectively, underlined the
squamous characteristics of ASCs. Furthermore, immune-related gene expression
patterns separated these two predominant histopathology classes suggesting role for the
tumour immune modulation in the progression of these lesion types. In support of this,
we identified an ASC-specific enrichment of Gr-1+ and CD11b+ neutrophil infiltration
and decrease in CD3+ T-lymphocytes. Thus, our results suggest a tumour histotype-
specific immune modulation of the tumour microenvironment leading to more rapid
tumourigenesis.
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Figure 12. The niche specific effect of oncogenic Kras and Lkb1-loss on murine lung
tumourigenesis. (A) Ad5-CC10-Cre infected KL mice show shorter latency when
compared to Ad5-SPC-Cre infected KL mice (median survival 79 and 120 days
respectively). (B) CC10+ airway cells possess higher propensity to initiate faster growing
and progressing lung tumours, namely ASCs, mucinous and acinar ACs. (C) ASCs are
characterised by immunosuppressive microenvironment.
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7 Concluding remarks and future
prospects
As the molecular profiles of lung tumours are becoming more clear, validation of
their functional importance is needed to translate this information into the clinic. The
studies presented here extend from functional in vitro validation of a putative tumour
suppressor gene EPHA3 (I) to its in vivo validation in murine lung cancer (II), and
further continue to the characterisation of progenitor cell-specific murine lung
tumourigenesis driven by expression of oncogenic Kras and  loss  of  the  tumour
suppressor Lkb1 (III).
Our results, together with data published during the course of this work (Lisabeth et
al., 2012; Zhuang et al., 2012), support the notion that EPHA3 has tumour suppressor-
like functions, which are specifically dependent on its kinase activity (I). An EPHA3
monoclonal agonistic antibody, mAb IIIA4, known to trigger kinase activity-dependent
apoptosis in vitro and to prevent xenograft tumour formation in vivo (Day et al., 2013),
now has a humanised therapeutic counterpart, named KB004.  KB004 show promising
tolerance and has shown evidence of clinical activity in phase I clinical trials of
advanced hematologic malignancies (Swords et al., 2013). Our results show that
inactivation of the EPHA3 kinase domain caused by the EPHA3 cancer mutations may
imply that mutational testing prior to KB004 treatment of EPHA3-expressing solid
cancers, such as NSCLC, may predict efficacy of the treatment. However, the suitability
and efficacy of the KB004 for the treatment of solid cancers requires more testing and
clinical trials.
Our attempt to model loss of EPHA3 function in murine lung AC using a
constitutive knock out model of EphA3 was challenged by biological complexity.
Constitutive EphA3-loss in combination with two key genetic alterations of human lung
cancer, namely oncogenic Kras or Trp53-loss, did not result in discernible changes in
lung tumourigenesis. It  is possible that other EPH receptors such as EphA5 or EphA7,
recently found to be somatically mutated in murine SCLC (McFadden et al., 2014) or
EphA2 which loss cooperates with oncogenic Kras promoting murine lung AC (Yeddula
et al., 2015), may compensate for loss of EphA3 function in murine lung tumourigenesis.
Nevertheless, more sophisticated methods, such as genome editing by CRISPR-Cas9 to
enable rapid in vivo generation of (combinatorial) genetic alterations (Sanchez-Rivera et
al., 2014), are required to validate the putative NSCLC-specific in vivo relevance of
EPHA- loss of function.
Tumourigenesis often overthrows developmental regulatory mechanisms,
underlining the importance of understanding the normal physiological function of genes.
Interestingly, in our search for EphA3 lung developmental functions, we found that
EphA3 expression was uniquely restricted to the developing lung mesenchyme.
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However, we did not find any defects in lung morphogenesis due to EphA3-loss, though
small changes in the expression of key lung morphogenesis regulators were detected.
Our results highlight the complexity of multicellular signalling networks that inherently
exhibit redundant mechanisms to overcome alterations in single molecules. Indeed,
redundancy between Ephs and ephrins has been suggested. EphA3, EphA4, and EphA7
have been suggested to redundantly function in cleft palate formation (Agrawal et al.,
2014), and ephrin-B1 and ephrin-B2 are shown to function redundantly in thymocyte
development, peripheral T cell differentiation, and antiviral immune responses (Luo et
al., 2011).
The latter section of this thesis work concentrated on known lung cancer genes
KRAS and LKB1, and their site-specific functional importance in murine lung
tumourigenesis. Two questions were addressed: (1) Do cells in the proximal airways and
distal alveolar space show differential propensities to transform and progress to specific
lung tumour histopathologies driven by oncogenic Kras and Lkb1-loss,  and (2)  Do the
growth, progression and histopathology of mutant Kras- and Lkb1-loss-driven lung
tumours correlate with a specific, possibly immunosuppressive immune contexture.
In support of differential tumourigenic propensities between the cells in airways and
alveoli, we found that CC10+ lung epithelial cells, the majority of which are located in
the airways (Rawlins et al., 2009b), have an increased propensity to give rise to faster
growing and progressing lung tumours, classified as acinar and mucinous ACs, and
ASCs. Of these, the predominant histopathology class was ASC. SPC+ alveolar cells
predominantly gave rise to invasive ACs, with or without a papillary growth pattern,
representing moderately or well differentiated lung histopathologies.
Lung ASCs represent a rare but aggressive type of NSCLC, representing 0,4-4% of
diagnosed lung cancer cases (Travis et al., 2015). Its mutational spectrum resembles that
of lung ACs, and harbour EGFR (13-31%), KRAS (13%) or LKB1 (up to 22%) mutations
(Koivunen et al., 2008; Tochigi et al., 2011; Vassella et al., 2015), all shown to be trunk
mutations. In support of clonal evolution contributing to the different histopathological
AC and SCC components, the SCC component is indicated to acquire branch mutations
in genes functioning in the PI3K pathway (Vassella et al., 2015). Interestingly, both
AKT activation and SCC transdifferentiation have been suggested as an acquired
resistance mechanism following combination treatment with docetaxel and the MEK
inhibitor selumetinib, or docetaxel in combination with  the metabolic drug phenformin,
respectively (Chen et al., 2012; Li et al., 2015). This suggests that the clonality of ASC
provides resistance mechanism to this aggressive type of NSCLC. Our closer
investigation of the transcriptional differences between KL ASCs and PACs led to
identification of immune-related transcriptional profiles in these two murine lung tumour
histopathologies. The elevated expression of cytokine Il1b and arginase 1 enzyme gene
Arg1 by the ASCs led us to study the immune contexture within the KL lung lesions.
Correlating with the results from human lung cancer patients (Liu et al., 2010) we found
increased infiltration of myeloid cells, representing a likely subpopulation of MDSCs, in
the faster growing and more poorly differentiated KL ASCs when compared to slower
growing and more differentiated KL PACs. We also detected a decreased number of
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tumour-infiltrating T-cells in KL ASCs, further supporting the immunosuppressive
microenvironment  of  ASCs.  It  remains  to  be  seen  if  these  findings  correlate  with  the
corresponding human lung tumour histopathologies exhibiting a similar differentiation
status. If so, then the KL ASC model represents a relevant preclinical model for the
study of MDSC-specific immune therapy in ASCs, a lung cancer type for which
treatment is challenged by its clonal heterogeneity.
Taken together the results presented in this thesis work underline the importance of
the niche specific investigation of molecular factors of lung cancer. Furthermore, the
ASC specific immunosuppressive microenvironment highlights the necessity of pre-
clinical models in future investigation of systemic lung cancer treatments such as
modulation of the immune cell contexture.
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Introduction
Cancer genomic profiling studies have revealed that the majority 
of drivers for malignant tumor progression are mutations in tumor 
suppressors,1,2 illustrating the need to accurately catalog cancer-
specific tumor suppressors and their impact on treatment efficacy. 
Reverse genomics approaches using RNA interference (RNAi) 
libraries allow for rapid identification of novel gene functions and 
ideally, monitor cellular parameters tightly linked to the function 
in question. Common to many potent oncogenic signals is the 
activation of built-in checkpoint mechanisms that halt aberrant 
proliferation, instead triggering irreversible cellular fates, includ-
ing apoptosis and senescence.3 It is well-established that senes-
cence can result not only from prolonged oncogene activation 
(e.g., oncogenic Ras, cyclin E), but also loss of tumor suppression 
(e.g., loss of PTEN, VHL or NF1 genes).4 A physiological role 
for senescence in suppressing malignant progression is supported 
by its in vivo detection during early stages cancer development.5,6
The program of cellular senescence comprises permanent 
cell cycle arrest associated with cell morphological changes, 
Activation of a cellular senescence program is a common response to prolonged oncogene activation or tumor suppressor 
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activation should identify candidate tumor suppressors. Using a high-content siRNA screening assay for cell morphology 
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to mine for novel candidate tumor suppressors and provides compelling evidence that EPHA3 mutations may promote 
tumorigenesis only when key senescence-inducing pathways have been inactivated.
A high-content cellular senescence screen 
identifies candidate tumor suppressors,  
including EPHA3
Jenni Lahtela,1 Laura B. Corson,2 Annabrita Hemmes,1 Matthew J. Brauer,2 Sonja Koopal,1 James Lee,2 Thomas L. Hunsaker,2 
Peter K. Jackson2,† and Emmy W. Verschuren1,†,*
1Institute for Molecular Medicine Finland (FIMM); University of Helsinki; Helsinki, Finland; 2Genentech Inc.; South San Francisco, CA USA
†These authors share co-senior authorship.
Keywords: senescence, DDR, p53, p16INK4a, tumor suppressor, EPHA3, RTK
Abbreviations: DDR, DNA damage response; SA-β-Gal, senescence associated-β-galactosidase; CGH, comparative genomic 
hybridization; EPHA3, EPH receptor A3; RTK, receptor tyrosine kinase
notably cell and nuclear flattening and an increase in senescence-
associated β-galactosidase (SA-β-Gal) activity.7 Senescence in 
vitro and in vivo coincides with the occurrence of ATM/ATR 
and p53/p21Cip1 DNA damage response (DDR) pathways, and 
previous research, including our own, suggests this to be a con-
sequence of unbalanced DNA replication vs. mitotic cell cycle 
stages.8-10 Senescence is also commonly triggered by activation 
of the Ets/p16INK4a/Rb tumor suppressor pathway. Although the 
role of DDR and p16INK4a pathways in mediating senescence is 
well established, their relative contributions remain ill-defined 
and multiple pathways may act cooperatively.4
Since senescence is commonly detected in cells containing 
intact cellular DDR and p16INK4a pathways, we reasoned that a 
siRNA screen in untransformed cells would potentially identify 
putative tumor suppressor genes. Our screen contrasts with pre-
vious studies, which focused on senescence bypass events, and 
biased for discovery of genes intrinsically linked to or required 
for the specific arrest pathway.11-13 Furthermore, the proposed 
pro-tumorigenic effect of a senescence-associated inflammatory 
response14 warrants a closer study to assess whether senescence can 
626 Cell Cycle Volume 12 Issue 4
(Fig. S1A). Normalized senescence scores were calculated by 
quantitation of the staining intensities per single oligonucleotide 
or pool (Fig. S1B and Table S2). To correlate the phenotype 
with knockdown efficiency, we performed TaqMan RNA expres-
sion analysis (Fig. S2). Genuine hits were assigned if both the 
siRNA pool, plus at least two oligonuceotides conferring > 50% 
knockdown efficiency, scored positive (Table S3). This approach 
validated 12 of 16 senescence-like kinome siRNAs as genuine 
senescence hits (Fig. 1C).
Delineation of senescence signatures. Activation of a 
p53-dependent DNA damage response (DDR) and increased 
p16INK4a CKI expression have been causally linked to senescence. 
hTERT-RPE1 cells contain an intact p53 checkpoint, and p53 
stabilization and nuclear accumulation are seen upon sustained 
damage signaling.8,26 A two- to 4-fold increase in cells express-
ing threshold p53 and p21CIP1 protein levels was measured in the 
HCS analysis (Fig. 2A). In all cases, total cell numbers and per-
centages of proliferating cells were significantly increased in p53 
knockdown cells compared with p53+ cells (Fig. 2B; Fig. S3A), 
suggesting a p53-dependent growth arrest. Furthermore, we 
measured increased DNA damage by γ-H2AX foci formation 
upon senescence induction in all but one case (PIK3C2A), 
with strongest hits showing foci in 40–50% of cells (Fig. S3B). 
Finally, a decreased senescence score was measured after transfec-
tion of six of 12 senescence hit siRNAs in p53 knockdown cells 
(Fig. 2C), implying that senescence typically required activation 
of a p53-dependent DDR.
Next, we assessed activation of the p16INK4a tumor suppressor 
pathway following senescence suppressor siRNA transfection. In 
hTERT-RPE1 cells, classic senescence induction following onco-
genic RAS expression did not result in a significant increase in 
p16INK4a mRNA (data not shown). Contrary to p53 pathway acti-
vation, significant increases in p16INK4a mRNA expression were 
less frequently detected upon senescence hit siRNA transfection, 
and most clearly upon knockdown of MYLK, MAP2K3, NEK1, 
EPHA3 and SMG1 (Fig. 2D). We conclude that in a majority of 
cases senescence induction is associated with activation of well-
known cell cycle arrest pathways, schematically summarized in 
Figure 2E. As expected, this corresponds to a delayed cell cycle 
progression, as measured by DNA replication analysis in syn-
chronized cells (Fig. S4).
Genome copy number and mutational analysis to appoint 
putative tumor suppressors. To establish whether senescence hits 
encompass tumor suppressors, we combined a cancer genomic 
analysis approach with cancer mutation and literature surveys. 
Validating our hypothesis, three hits identified have previously 
been shown to display bona fide tumor suppressor functions 
in murine models (Fig. 1C). Specifically, AurkA heterozygous 
mice present haploinsufficient tumor suppression with increased 
incidence of lymphoma, lung and liver tumors;27 conditional 
Csnk1a1 ablation triggers colorectal carcinogenesis and LOH;28 
and Lats1-deficient mice develop soft tissue sarcoma and ovar-
ian tumors.29 Interestingly, all three models exhibit signs of chro-
mosomal instability or DDR activation, and a p53-dependent 
DDR-senescence response is proposed to halt carcinogenesis in 
the Csnk1a1-null or heterozygous animals.28 This verifies that 
be induced upon loss of relevant gene function. Here we identify 
12 kinases as newly identified regulators of cellular senescence 
using quantitative senescence β-galactosidase staining, and show 
that senescence frequently correlates with DNA damage induction 
and is mostly p53- and sometimes p16INK4A-dependent. In sup-
port of our hypothesis to reveal candidate tumor suppressor genes, 
analysis of SNP aCGH data showed that a significant number of 
candidate genes displayed gene copy loss in sets of tumor samples.
Interestingly, one novel senescence regulator, the EPHA3 
receptor tyrosine kinase (RTK) gene, is among the most fre-
quently mutated genes in human lung adenocarcinomas and 
colorectal cancers.15-18 EPHA receptors have traditionally been 
assigned oncogenic roles due to their overexpression in a vari-
ety of cancers including carcinomas, melanoma and gliomas.19,20 
However, in support of additional tumor suppressor functions, 
certain ephrin-EPHs are suggested to show temporally bi-pha-
sic roles during tumor progression,21 and EPHA7 receptor was 
recently shown to act as a tumor suppressor in follicular lym-
phoma.22 We here show that senescence upon loss of EPHA3 
is regulated by p16INK4a and p53 and, in agreement with recent 
data from the Pasquale and Zhuang labs,23,24 show that selected 
EPHA3 tumor-associated mutations decrease receptor expres-
sion levels and overall kinase activity. Our results suggests that 
concomitant loss of EPHA3 and key senescence-inducing tumor 
suppressor functions may cooperatively stimulate tumorigenesis, 
and conclude that our senescence screen successfully identified 
strong candidates for tumor suppressor genes.
Results
Identification of senescence-inducing kinase siRNAs. We 
utilized a cell-based screen to identify regulators of premature 
senescence in untransformed cells, hypothesizing that a loss-of-
function screen may identify new tumor suppressor genes. We 
chose to screen the hTERT-immortalized retinal pigmented 
epithelial line hTERT-RPE1, because it models key aspects of 
untransformed cells, including quiescence with a high efficiency 
of G
0
 markers, notably the presence of primary cilia.25 Unlike 
quiescent cells, senescent cells exhibit an irreversible proliferative 
arrest, followed by formation of enlarged nuclei and a flattened 
cytoplasmic morphology, with rare exceptions.4 These features 
were used to analyze a multiparametric HCS siRNA screen of 
hTERT-RPE1 cells engineered to express a doxycycline-inducible 
p53 shRNA (from here on called hTERT-RPE1 p53shRNA), 
designed to identify proteins that impinge on the p53 pathway 
(Corson LB, et al., manuscript in preparation). Our analysis 
focused on loss of the proliferation marker Ki67 and decreased 
nuclei counts, combined with an average increase in nuclear size 
(Fig. 1A). This approach identified a group of 16 kinase siRNAs, 
which we labeled as “senescence-like” (Fig. 1B).
We next tested hits as bona fide senescence regulators in a sec-
ondary screen detecting the widely studied SA-β-Gal senescence 
biomarker, on parallel transfections using siRNA pools plus the 
four individual siRNAs per gene. Knockdown of Emi1, previ-
ously reported to elicit pronounced DNA damage-induced senes-
cence in hTERT-RPE1 cells, was included as a positive control8 
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database. Indeed, out of the 12 genes, seven genes were mutated in 
1–4% of tumors. Of outstanding interest, with a reported muta-
tion frequency of 4–6%, the EPHA3 RTK gene was shown to be 
among the most frequently mutated genes in human colorectal, 
lung and ovarian carcinomas.15-18,31 Furthermore, EPHA RTK fam-
ily kinases have pleiotropic functions and EPHA3 was originally 
assigned oncogenic properties in lymphomas.21,32 We thus decided 
to key in on a putative new role for EPHA3 as a tumor suppressor.
Loss of EPHA3 receptor signaling confers p16INK4A and 
p53-dependent senescence. Since the EPHA RTK family con-
sists of nine members, we first asked if EPHA3 uniquely induced 
cellular senescence using SA-β-Gal staining upon siRNA trans-
fection of additional EPHA receptors expressed in hTERT-RPE1 
(EPHA1, A2, A4, and A5 mRNAs, data not shown). Knockdown 
of Emi1 was included as a positive control.8 Our results showed 
that senescence was uniquely detected after knockdown of 
EPHA3 and not measurably apparent after knockdown of other 
EPHA RTKs expressed in hTERT-RPE1 cells (Fig. S5).
individual findings from our in vitro study have a capacity to 
broaden our knowledge of physiological disease progression.
Among the candidates, only LATS1 is suggested to act as 
a tumor suppressor in human disease, supported by its con-
served role in growth control from flies to man30 (Fig. 1C). We 
therefore next asked if we could observe an increased propen-
sity for genome copy number loss of our senescence genes in 
human tumor samples. Validating our strategy, loci encompass-
ing known tumor suppressors showed significant copy number 
loss across data sets, defining a “tumor suppressor copy num-
ber signature.”Importantly, clustering analysis of this signature 
identified a set of five screen candidates with a similar genomic 
profile, namely LATS1, CDK1, EPHA3, NEK1 and MAP2K3 
(Fig. 3). Locus inspection showed none to be in the vicinity of 
known tumor suppressors, supporting the deduction that these 
constitute candidate tumor suppressor genes.
As a final in silico approach, we surveyed the increasing col-
lection of cancer-specific mutations as reported in the COSMIC 
Figure 1. Identification of senescence-inducing kinase siRNAs. (A) Schematic overview of the high-content senescence screen. (B) Scatterplot analysis 
of data from the kinome HCS screen in p53+ cells. Cells were stained for Ki67, p53, p21CIP1 and Hoechst at day 3, and multiparametric analysis was 
performed to determine siRNAs displaying decreased proliferation (< 0.5 StDev Ki67%) and an increased nuclear size (> 2.0 StDev Hoechst mean area). 
High, medium and low cell number indicators are assigned as the third parameter. (C) Senescence scores per gene are the sum of the senescence 
scores of its siRNA pool and the four individual siRNAs, omitting siRNAs conferring less than 50% specific gene knockdown. Scoring details are de-
picted in Table S2. References to studies establishing bona fide tumor suppressor functions for human (Hs) or mouse (Mm) genes are indicated.
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nuclear size. We therefore conclude that EPHA3 knockdown-
induced senescence requires p16INK4a and p53.
Selected EPHA3 gene mutations confer loss of kinase 
function. Similar to other EPHA RTKs, activation of EPHA3 
occurs via autophosphorylation of conserved tyrosine residues33 
and ephrin ligand binding triggers receptor oligomerisation and 
consequent receptor activation.34 To find how tumor-associated 
EPHA3 point mutations affect receptor activity we assayed for 
kinase activity monitoring autophosphorylation. HEK 293T 
and hTERT-RPE1 cells expressing a select set of EPHA3-LAP 
Characterization of the senescence signature showed that 
siRNA-mediated knockdown of EPHA3 leads to increased 
p16INK4a and p53 expression (Fig. 2A and D). We next asked if 
the senescence phenotype was mediated by p16INK4a or p53 activa-
tion using in vivo imaging. Time-lapse imaging of siRNA-treated 
hTERT-RPE1 cells stably expressing GFP-tagged H2B protein 
showed a rescue of EPHA3 knockdown-induced senescence 
when p16INK4a (Fig. 4A; Fig. S5E) or p53 (Fig. 4B; Fig. S5F) 
were co-depleted. A rescue of senescence was both measured by 
an increase in total cell number, as well as a decrease in average 
Figure 2. Delineation of senescence signatures. (A) hTERT-RPE1 p53 shRNA cells were transfected with kinome siRNAs in the absence of doxycycline 
and immunostained for p53 and p21CIP1 following 72 h culture. Percentages of cells expressing p53, p21CIP1 above threshold levels were calculated, and 
averages from four 384 wells are shown. (B) hTERT-RPE1 p53 shRNA cells were transfected with kinome siRNAs in the absence or presence of doxycy-
cline and immunostained for Ki67. Percentages of cells expressing Ki67 protein above threshold levels were calculated, and averages from four 384 
wells are shown. * indicates p ≤ 0.05 and ** indicates p ≤ 0.01. (C) Senescence scores per gene are the sum of the senescence scores of the siRNA pool 
plus four individual siRNAs, omitting siRNAs conferring less than 50% knockdown. Detailed scoring information is depicted in Table S3. (D) Quantita-
tive p16INK4A mRNA expression analyses during senescence induction. hTERT-RPE1 p53 shRNA cells were transfected with pooled siRNAs in the absence 
of doxycycline. RNA expression was quantitated using TaqMan analyses after 3 days of transfection. (E) Schematic model summarizing kinome screen 
data, using data depicted in (A) and (D). In an incipient tumor, modeled by hTERT-RPE1 cells, loss of selected tumor suppressors activates p53- and/or 
p16INK4A-dependent senescence, and overt DNA damage. In a premalignant tumor, senescence may serve as a cell-intrinsic tumor suppressor mecha-
nism to subvert oncogenic transformation. Loss of p16INK4A and/or p53 promotes malignancy.
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residue is disordered. Arginine 728 to Leucine alteration causes a 
shift in the surface charge from positive to non-charged (Fig. 5D), 
which may affect the steady-state expression level of the receptor 
via altered protein-protein interactions and/or increased receptor 
degradation, explaining its reduced expression level (Fig. 5B; Fig. 
S6A and B). Mutation of residue 806 from aspartic acid to aspara-
gine may alter the interaction between residues aspartic acid 746 
and histidine 744, which face the ATP binding pocket and may 
therefore directly affect the EPHA3 catalytic activity (Fig. 5E).
Interestingly, structural alignment of EPHA3 JMKIN with 
the tumor suppressor LKB1 kinase domain showed that LKB1 
lung cancer-associated point mutation D237Y is homologous to 
mutated residue D806 in EPHA3.15 We therefore tested EPHA3 
D806Y mutation for kinase activity, and show that this mutant is 
kinase-defective (Fig. 5F and G). We conclude that selected can-
cer-associated point mutations appear to affect EPHA3 kinase 
activity either through altering protein-protein interactions, or 
through direct effects on kinase domain structural determinants, 
decreasing EPHA3 receptor tyrosine kinase activity. This sup-
ports our hypothesis that EPHA3 acts as a tumor suppressor gene.
Discussion
Cancer genomics initiatives have identified numerous often low-
frequency mutations that can prove predictive for clinical response 
to targeted therapy, creating new opportunities for personalized 
cancer care and biomarker discovery. Not surprisingly, clinical 
response and therapy resistance can be critically modified by the 
tumor-associated mutation variants were generated to assess rel-
ative cellular receptor activities (Fig. 5A; Fig. S6A and B). As 
expected, ephrin-A5 ligand activation leads to receptor inter-
nalisation and trafficking via the early endosomal compartment 
labeled with EEA135 (Fig. S7). Of note, a decreased steady-state 
expression of the R728L variant was detected in both cell lines, 
and the T933M variant in hTERT-RPE1 cells (Fig. S6A and B).
Wild type EPHA3 shows a transient activation curve fol-
lowing ephrin-A5 ligand-induced activation, peaking at 20 min 
(Fig. 5B), consistent with published data.35 Decreased normalized 
cellular kinase activities were detected for two receptor variants 
mutated in the cytoplasmic region (G766E and D806N) and one 
variant mutated in the cytoplasmic region showed a decrease in 
overall receptor level (R728L) (Fig. 5B). We next asked how point 
mutations affected absolute kinase activity using in vitro immuno-
precipitation kinase assays. In this assay, EPHA3 variants G766E 
and D806N showed a clear loss of kinase activity (Fig. 5C; Fig. 
S6C). We conclude that selected intracellular EPHA3 tumor-
associated point mutations lead to a decrease in receptor expres-
sion level and/or normalized tyrosine kinase activity.
Structural analysis of EPHA3 kinase domain cancer point 
mutations. Next, we examined the crystal structure of the juxta-
membrane and kinase domain (JMKIN) of wild type EPHA334 
to explain possible functional deficiencies of the tumor-associated 
mutations. The mutated residues K761, G766 and D806 are situ-
ated within the kinase domain, while R728 is situated on the sur-
face area between two α-helices (Fig. S6D). We were unable to 
assess the G766 variant as the crystal structure surrounding this 
Figure 3. Senescence gene loss evidenced by genomic copy number analysis. Heatmap clustering analysis of SNP array-CGH data from 2654 samples 
from 53 panels of human tumors and cell lines, to identify sets with a genome copy number lower than 1.5. A sliding scale density gradient was ap-
plied. Loci encompassing tumor suppressors CDKN2A, RB1, TP53 and VHL were included as positive controls and oncogenes CCND1, ERBB2, MDM2 and 
MYC as negative controls. Stars indicate genes closely resembling the tumor suppressor signature.
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progression and cytokinesis, DNA damage signaling and the spin-
dle assembly checkpoint (SAC): AURKA, CDK1, CSNK1A1, 
LATS1, NEK1, SMG1; (2) regulators of adhesion and migration: 
EPHA3, MYLK, PIK3C2A; and (3) regulators of growth factor-
induced mitogenic signaling via p38 SAPK and JNK: KSR2, 
MAP2K3, MAP4K1. Hence, a compendium of genes that inter-
sect on accurate spindle assembly checkpoint control and fine-
tuning of cell adhesion as well as cytokinesis machineries describe 
a likely set of candidate tumor suppressors. This is further sup-
ported by recent sequencing efforts that reveal frequent muta-
tions in mitotic kinases including Aurora, Polo and LATS kinases 
as well as Nek family kinases.17,37 Although conceptually perhaps 
unsurprising, functional data mining also reveals unexpected 
dual functions for previously established oncogenic proteins, as 
exemplified by the AURKA oncogene, which indeed was shown 
to be haploinsufficient for tumor suppression in mice.27
Senescence can be viewed as a cell-intrinsic fail-safe response 
to overt oncogenic proliferative signals,3 a key effector of cancer 
landscape of tumor suppressor mutations,36 which constitute in 
fact the majority of cancer drivers.1 Yet, the detailed consequences 
of tumor suppressor mutations are often unknown. We devel-
oped a “bottom-up” senescence-based strategy to functionally 
identify tumor suppressor candidates. Validating our approach, 
we identified three genes with known tumor suppressor func-
tion in human or mouse (AURKA, CSNK1A1 and LATS1), and 
SNP aCGH data showed that half of the candidates displayed 
increased genome copy loss in tumor sample sets (Fig. 3). Clearly, 
our study is not exhaustive and would be enhanced by parallel 
assessment of DNA methylation and gene expression changes. 
Nonetheless, it illustrates the power of combining functional 
genomics with delineation of somatic mutations. We propose 
that detection of senescence in cells harbouring intact damage 
checkpoint pathways, such as hTERT-RPE1, can be employed as 
a shortcut to identify cancer-promoting events.
Our senescence gene hits can readily be grouped in three 
functional categories: (1) regulators of accurate mitotic cell cycle 
Figure 4. Loss of EPHA3 confers p16INK4A- and p53-dependent senescence. Live cell analysis of (A) EPHA3 plus p16INK4a siRNA-treated and (B) EPHA3 
plus p53 siRNA-treated hTERT-RPE1 cells. The average nuclear area off all cells per image is shown. Representative 20× images from each condition are 
shown in the lower panels.
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previous studies describing p53 activation and/or senescence upon 
loss or inhibition of AURKA,42 CDK1,43 CSNK1A1,28 LATS1,44 
MAP2K345 and SMG1.46 This further illustrates the importance 
of perturbations in both surveillance systems and checkpoint 
response pathways as a frequent driver of tumor progression.
Contrary to p53 activation, significant increases in p16INK4a 
mRNA expression were less frequently detected upon senescence 
hit siRNA transfection, and most clearly upon loss of MYLK, 
MAP2K3, SMG1, NEK1 and EPHA3 (Fig. 2D). None of these 
genes were previously known to activate the p16INK4A-dependent 
senescence program. Of the candidate tumor suppressors, the 
EPHA3 RTK gene was shown to be frequently mutated in human 
chemotherapy response,38,39 or a barrier to tumor initiation in 
incipient human tumors.4,5 Contrary to such anti-proliferative 
responses, senescence in the stromal microenvironment may 
also promote paracrine epithelial tumor growth via secretion 
of inflammatory molecules, akin to a tissue repair response.40 
Furthermore, an elegant recent study suggested that inflam-
matory signals themselves can subvert a senescence barrier.41 
Its precise physiological role thus is likely complex and possibly 
context-dependent, yet common to a multi-step carcinogenesis 
paradigm wherein loss of p53 and/or p16INK4a affords prolifera-
tion of damaged cells. We confirm that senescence correlates with 
activation of a pronounced p53-dependent DDR, consistent with 
Figure 5. Selected EPHA3 cancer gene mutations confer decreased kinase function. (A) Schematic representation of EPHA3 protein domains and se-
lected cancer point mutations pertinent to this study. (B) Cellular kinase activities of selected EPHA3 tumor variants. 293T cells expressing EPHA3-LAP 
variants were treated with preclustered ephrin-A5 and immunoprecipitates were immunoblotted. Anti-GFP was used to detect EPHA3-LAP. Relative 
cellular kinase activities were determined by normalization of the PY (phosphotyrosine) against the EPHA3 signal, and normalized values relative to 
WT are shown in arbitrary units. (C) In vitro kinase assays of selected EPHA3 tumor variants. Immunoprecipitates from kinase assays or input lysate 
samples from 293T EPHA3-LAP lines were immunoblotted with indicated antibodies, and normalized values were calculated as in (B). (D–F) Struc-
tural analyses of EPHA3 tumor variants R728L and D806N and structural alignment of the EPHA3 and LKB1 kinase domains. PDB structure files were 
analyzed using the PyMOL molecular visualization package. Notable alterations are encircled. (G) In vitro kinase assay of EPHA3 D806Y variant. 293T 
cells expressing EPHA3-LAP proteins or control lysate were treated with preclustered ephrin-A5. GFP immunoprecipitates from kinase assays were 
immunoblotted with the indicated antibodies.
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following manufacturer recommendations. 293T cells were 
maintained in DMEM (Lonza) containing 10% FBS and 2 mM 
L-Glutamine, following manufacturer recommendations. 
Inducible p53 shRNA hTERT-RPE1 cells were constructed 
using the pHUSH tetracycline-inducible retrovirus gene transfer 
vector55 with a previously described p53 shRNA,56 and labeled 
hTERT-RPE1 p53 shRNA. Knockdown in the selected subclone 
was validated by absence of p53 and p21 induction upon etopo-
side treatment, and p53 protein was absent after 72h treatment 
with 1 μg/ml doxycycline. A stable H2B-GFP hTERT-RPE1 
clonal cell line was generated by transfection with GFP-tagged 
human H2B plasmid (pEGFP-H2B-N1) followed by clonal 
selection using G418 (Roche).
High-content kinase siRNA screen. hTERT-RPE1 p53 
shRNA cells were treated +/− 1 μg/ml doxycycline for three 
days prior to transfection, also called “p53+” or “p53−” cells. A 
Dharmacon siGENOME library, composed of 862 siRNA pools 
targeting kinases and proteins predicted to influence kinase sig-
naling was used (Table S1; Corson et al. manuscript in prepara-
tion). Following three days of culture, cells were fixed with 4% 
paraformaldehyde, permeabilized with 0.2% Triton X-100 and 
blocked in 5% fish gelatin (Sigma). Cells were immunostained 
with primary antibodies in 5% fish gelatin during overnight 
incubation at 4°C and incubated with secondary antibodies for 
1 h at ambient temperature. Primary antibodies were rabbit anti-
p53 (Cell Signaling 928; 1:1,500), goat anti-p21 (R&D Systems 
AF1047; 1:20,000) and mouse-anti-Ki67 (BD PharMingen 
55600; 1:1,500). Secondary antibodies were Cy5 anti-mouse 
(Jackson 715-495-150), Cy3 anti-rabbit (Jackson 711-165-152), 
and AF488 anti-goat (Invitrogen A11055). Hoechst 33342 was 
used at 1:50,000. For primary screen data analysis depicted in 
Figure 1B, the data set in which p53 was functional (p53+) was 
used.
HCS imaging, quantitation and statistics. 384 Multiwell 
plates were imaged with a 10× objective and 2× binning on the 
ImageXpress Micro high content imaging system (Molecular 
Devices). Four sites were acquired per well with duplicate wells 
for every condition. Analysis using MetaXpress Cell Scoring 
and Multiwavelength Modules included: (1) total number of 
nuclei; (2) percentage cells positive for p53, p21 and Ki67; and 
(3) average nuclear size. An image analysis example is shown in 
Figure S1C. Data was collected in an Oracle database managed 
through Molecular Devices MDCStore. Images, measurements, 
annotations, normalizations, and statistical analysis were man-
aged through AcuityXpress software.
Senescence-associated β-galactosidase (SA-β-gal) stain-
ing and quantitation. Cellular senescence was detected in cells 
transfected in 96-well cellBIND plates (Corning), by staining 
for acidic β-galactosidase as described,7 followed by DNA coun-
terstaining with Hoechst 33342. Cells were imaged on a Nikon 
Eclipse Ti microscope equipped with a monochrome camera, 
applying a DAPI scan and sequential brightfield RGB images. 
Composite color images were generated using a NIS Elements 
AR (Nikon) colorcombine journal. Image analysis was performed 
using a MetaMorph journal (Molecular Devices) following a scor-
ing system detailed in the Supplemental Materials and Methods.
lung adenocarcinomas and colorectal cancers.15-18 Consistent with 
its candidacy as a tumor suppressor, array CGH data showed fre-
quent loss of the chromosome 3 arm encoding EPHA3 in the lung 
cancer data set in particular. This is confirmed by recent data 
reporting a striking loss of the EPHA3 gene in 42% of primary 
lung adenocarcinomas.24 We found that senescence upon EPHA3 
loss is partially rescued by concomitant p16INK4a or p53 depletion, 
and that this is a function unique to EPHA3. Our data therefore 
suggests that loss of EPHA3 activity may promote tumorigen-
esis only when key senescence-inducing tumor suppressor path-
ways are absent. We however did not detect an enrichment for 
p16INK4a mutations in lung cancer samples that display EPHA3 
copy number loss, using the CONAN CGP copy number analy-
sis tool available via the Sanger Institute. The in vivo functional 
cooperation of EPHA3 and p16INK4a loss of function is, however, 
unlikely straightforward and uniform, warranting closer inspec-
tion of their co-dependencies during tumorigenesis.
Previous EPH receptor studies have revealed dual opposing 
roles during tumor initiation vs progression,47,48 and EPHA3 has 
been ascribed both oncogenic49,50 and tumor-suppressive func-
tions.51 In support of its role as a tumor suppressor, EPHA3 gene 
mutations are distributed along the gene rather than clustered 
in hot spots. Importantly, we show that cancer-associated point 
mutations G766E and D806N are kinase-defective, as well as 
a mutation analogous to D237Y in the well-established LKB1 
tumor suppressor. Furthermore, we show that the R728L vari-
ant decreases overall receptor levels and cellular receptor activity. 
Our results agree with recent reports by Lisabeth and Zhuang 
and colleagues that describe a disruption of RTK functions for 
selected EPHA3 tumor variants,23,24 likely acting to decrease 
apoptotic susceptibility in a dominant-negative fashion.24 In con-
clusion, our results strengthen evidence for a role for EPHA3 as a 
candidate tumor suppressor gene.
It is well-established that the interplay between different EPH 
receptors influences their signaling outcome.22 Furthermore, 
EPH receptors cross signal to other tyrosine kinase families, with 
evidence for negative regulation of c-MET by EPHA signaling.52 
Interestingly, a secreted form of EPHA7 was recently shown to 
act as a tumor suppressor in follicular lymphoma via inhibition 
of EPHA2 in a dominant-negative fashion.22 Since also EPHA3 
is expressed as an alternative isoform, it will be interesting to 
study how it may influence the EPH-RTK signaling network. 
Furthermore, while no increased tumor growth is detected in a 
constitutive EPHA3 murine-null model,53,54 our study warrants 
further comprehensive in vivo loss-of-function analyses. Taken 
together, we developed a successful cell-based strategy to func-
tionally mine for novel candidate tumor suppressors, and pro-
vide compelling evidence that loss-of-function EPHA3 variants 
may promote tumorigenesis when common senescence-inducing 
pathways are inactive.
Materials and Methods
Cell lines, culture and treatment. hTERT-RPE1 cells (Clontech) 
were maintained in DMEM:F-12 (Invitrogen) containing 10% 
FBS, 2mM L-Glutamine and 0.348% sodium bicarbonate, 
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Live cell imaging. hTERT-RPE1 cells expressing H2B-GFP 
protein were treated with 50 nM pooled siRNA using for-
ward transfection with Oligofectamine reagent (Invitrogen) on 
24-well plates. Transfections were in replicates of four and imag-
ing was performed using the IncuCyte™ FLR instrument (Essen 
BioScience) for five days. A duplicate plate was harvested at day 
three to confirm siRNA knockdown. IncuCyte object analysis 
was performed with default parameters.
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SNP array-CGH tumor sample analysis. SNP/CHIP array-
CGH data available at Genentech (CARFOG, June 2009) for 
2654 samples from 53 human tumor and cell line panels was 
mined using the “genoset” package from Bioconductor57 and 
plotted as a heatmap to show the fraction of samples per data set 
containing a genome locus copy number lower than 1.5 copies. 
For visualization, the scale was trimmed at a value of 0.3: data 
sets with this value or greater were shown with the maximum 
density of the scale.
Immunoprecipitation and western blotting. Cells express-
ing stable LAP-tagged EPHA3 proteins were serum starved 
for 1 h, and then incubation with 1.5 μg/ml recombinant 
human ephrin-A5-Fc or IgG1-Fc proteins (R&D Systems) pre-
clustered for 20 min with anti-human Fc antibody (Jackson 
ImmunoResearch) at 10:1 molar ratio. Ligand-activated 293T 
cells expressing LAP-tagged EPHA3 proteins were lysed in 
RIPA buffer containing Protein Inhibitor Cocktail (Roche) and 
Phosphatase Inhibitor Cocktail (Roche). 500 μg of protein was 
rotated for 16h with 1 μg of anti-GFP antibody (Invitrogen). 
Antigen was captured using Protein G/A Sepharose beads 
(Sigma). Alternatively, specific antigen was captured using 
S-protein agarose beads (Novagen). Samples were immu-
noblotted using anti-phosphotyrosine (PY 4G10; Upstate 
Biotechnology Inc.) or in-house affinity-purified anti-GFP 
antibodies.
In vitro kinase assay. 293T and hTERT-RPE1 cells express-
ing LAP-tagged EPHA3 proteins were lysed in RIPA buffer con-
taining protease inhibitors. 500 μg of total protein was incubated 
for 1h with 1 μg of antibodies to GFP (Invitrogen). Specific anti-
gen was captured using Protein A/G Sepharose beads (Thermo 
Scientific), or, alternatively, with S-protein agarose beads 
(Novagen), and washed using RIPA and kinase buffer (50 mM 
NaCl, 20 mM Hepes pH 7.2, 10 mM MgCl
2
, 2 mM EDTA, 
0.02% Triton X-100). Beads were next incubated in kinase buffer 
supplemented with 20 μM Adenosine 5'-triphosphate disodium 
salt hydrate (Sigma). Samples were immunoblotting using anti-
phosphotyrosine or anti-GFP antibodies.
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Supplementary Materials and Methods
Generation of EPHA3-LAP variant cell lines 
The 293T Flp-In T-REx cell line was purchased from Invitrogen. The hTERT-RPE1 cell line 
was converted to a Flp-In cell line by the insertion of a FRT site. Stable cell lines were 
created as previously described 1. Briefly, human EPHA3 cDNA and tumor variants were 
synthesised by DNA 2.0 into Gateway compatible pDONR221 entry vectors and cloned into 
appropriate pG-LAP5 or pG-LAP5/puro Gateway destination vectors using LR 
recombination technology (Invitrogen). pG-LAP constructs encoding proteins of interest 
were co-transfected with pOG44 plasmid encoding the Flp recombinase (Invitrogen) into Flp-
In cell lines using Fugene 6 (Roche), followed by selection for stable integrants using 
Hygromycin B (pG-LAP5) or Puromycin (pG-LAP5/puro) selection. Pooled lines were used 
for 293T cell, clonal cell lines were used for hTERT-RPE1 cells. 
Cell transfections
For gene knockdown, cells were treated with 50 nM pooled siRNA duplexes or 12.5 nM 
single siRNAs using reverse transfection with Dharmafect #2 reagent (Dharmacon) in 384 
well CellBIND Surface polystyrene plates (Corning), or with Oligofectamine reagent 
(Invitrogen) in 96 well plates for forward transfections. Dharmacon pools comprising the 
siGENOME kinase pool library are listed in the Supplementary Table 1, and Dharmacon 
siGENOME SMARTpool siRNAs used in follow up studies were: CDK1 M-003224-03; 
CSNK1A M-003957-03; EPHA3 M-003117-03; KSR2 M-005322-03; LATS1 M-004632-03; 
MAP2K3 M-003509-03; MAP4K1 M-003586-03; MYLK M-005351-03; NEK1 M-004864-
03; PAK7 M-003973-03; PASK M-005018-03; PIK3C2A M-006771-03; PIP5K1A M-
004780-03; RPS6KA1 M-004663-03; SMG1 M-005033-03; AURKA M-003545-03; 
p16INK4 M-011007-03; siCONTROL non-targeting siRNA #3 (siCtrl) D-001210-03. 
Dharmacon ON-TARGETPlus SMARTpool siRNAs were: EMI1 (FBXO5) L-012434-00; 
siCONTROL non-targeting siRNA pool #1 (siCtrl) D-001206-13 or non-targeting pool 
(siCTRL) D-001810-10.
RNA expression analysis
For quantitative real-time RT-PCR analysis, total RNA was prepared using the RNeasy Mini 
kit (QIAGEN). RNA (100 ng) was used for qRT-PCR reactions using TaqMan One-step RT-
PCR Master Mix kit and primers (450 nM) plus MGB probe (125 nM) supplied in TaqMan® 
Gene Expression Assays (Applied Biosystems), using probes listed below. Triplicate 
reactions were run and analysed on an ABI 7500 thermocycler, using relative quantitation 
against housekeeping RPL19 mRNA. Alternatively, total RNA was prepared using
NucleoSpin RNA II (Macherey-Nagel). cDNA synthesis was performed from 750 ng of total 
RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) which was 
used for quantitative PCR analysis with iQ Supermix (BIO-RAD) reagent. The following 
TaqMan® probes were used: CDK1 Hs00364293_m1; CSNK1A; Hs00740463_m1; EPHA3 
Hs00739096_m1; KSR2 Hs00543274_m1; LATS1 Hs00177987_m1; MAP2K3 
Hs00177127_m1; MAP4K1 Hs00179345_m1; MYLK Hs00364926_m1; NEK1
Hs00404339_m1; PAK7 Hs00379321_m1; PASK Hs00209470_m1; PIK3C2A
Hs00153223_m1; PIP5K1A Hs00801004_s1; RPS6KA1 Hs00179731_m1; SMG1 
Hs00247891_m1; AURKA Hs00269212_m1; RPL19 Hs02338565_gH; INK4a 
Hs00923894_m1; EPHA1 Hs00178313_m1; EPHA2 Hs00171656_m1; EPHA3 
Hs00739096_m1; EPHA4 Hs00177874_m1; EPHA5 Hs00300724_m1;RPL19 
Hs02338565_gH. Triplicate reactions were run and analysed on a Biorad CFX384 
thermocycler, using relative quantitation against housekeeping RPL19 mRNA expression. 
For RNA expression analysis using SYBR Green (BioRad) reagent, the following TaqMan®
probes were used: INK4a Hs00923894_m1; EPHA3 Hs00739096_m1; RPL19 
Hs02338565_gH with the following primers: EPHA3 fwd 
5’GCAGACAAAGACCCTCCAT3’ rev 5’GTAACATCTTTCCGGCCTC3’; p16INK4a fwd 
5’CCCAACGCACCGAATAGTTAC3’ rev 5’CCAGCGTGTCCAGGAAG3’; p53 fwd
5'GTCCCTTCCCAGAAAACCTA3’ rev 5’CTCGGATAAGATGCTGAGGA3’ RPL19 fwd 
5’ACCCCAATGAGACCAATGAA3’ rev 5’CGCAAAATCCTCATTCTCCT3’.
Senescence-associated -galactosidase quantitation
A color threshold was assigned to RGB images of SA- Gal staining to remove background
signal, followed by binarisation and smoothening to remove pixels <5 or >5000. The number 
of nuclei per image was calculated, followed by image binarisation, dilation of nuclear 
objects by 15 pixels, and drawing of a region limit. DNA regions were overlaid onto the 
binarised RGB images, followed by quantitation of the percentage of SA- -Gal positive 
pixels per region. A macro was run to bin cells according to their average staining intensity 
(intensity/cell/image in bins of 0, 0-10%, 11-20% etc.). The senescence score per siRNA 
(pools or singles) was calculated as the sum of the staining intensities normalised against the
].
DNA damage measurements 
hTERT-RPE1 p53 shRNA cells growing on coverslips were transfected with siRNAs, and at 
96h fixed in 4% paraformaldehyde, permeabilised with 0.2% Triton X-100, followed by 
immunostaining using 0.4-2 g/mL primary phospho-Histone H2A.X Ser139 (Upstate) 
antibody and Alexa Fluor 488 secondary antibody (Molecular Probes). DNA was 
counterstained with Hoechst 33342 dye and image analysis was performed using a Zeiss 
AX10 microscope and Slidebook4.1 software. 
Protein variant structural domain analysis 
A PDB file with EPHA3 kinase and juxtamembrane domain structure information 2 was 
downloaded from the RCSB protein data bank (http://www.pdb.org/pdb/home/home.do). A 
PDB file with EPHA3 kinase and juxtamembrane domain structure information (2QOC) 2
and the structural information of LKB1 tumor suppressor (2WTK) 3 was downloaded from 
the RCSB protein data bank (http://www.pdb.org/pdb/home/home.do). Mutation analysis, 
distance measurements and alignment analysis were performed using the PyMOL molecular 
visualisation system.  
BrdU DNA replication analysis
For measurements of DNA replication, cells were transfected for 15h with pools of siRNAs 
and synchronised by treatment with 100 nM Nocodazole for 8h, followed by wash-out and 
release for 9 or 12h. During the last 30 minutes of release from Nocodazole, cells were pulsed 
with 50 M 5-bromodeoxyuridine (BrdU, Sigma). Cells were trypsinised, washed twice in 
1% BSA/PBS, fixed with cold 70% ethanol for at least 16h at -20 C. BrdU incorporation was 
determined with an anti-BrdU-FITC conjugate (Becton Dickinson) according to the 
manufacturer’s protocol, followed by flow cytometric analysis on a FACScan (Becton 
Dickinson) using CellQuest software to quantitate the S phase fraction. 
Immunostaining and fluorescence microscopy
hTERT-RPE1 Flp-In cells expressing stable LAP-tagged EPHA3 proteins with or without 
ephrin-A5 treatment were fixed on coverslips and immunostained for GFP (EPHA3-LAP) 
and early endosomes (EEA1, BD Biosciences). Fluorescence microscopy imaging was 
performed with the Nikon 90i microscope using 60X objective. Image handling was done 
with Adobe Photoshop CS5 software. 
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Fig. S1. Confirmation of senescence by quantitative SA- -Gal staining. 
(A) hTERT-RPE1 p53 shRNA cells were reverse transfected with pooled siGENOME siRNAs 
in the absence of doxycycline (p53+). Five days after siRNA transfection cells were fixed 
and stained for SA- -Gal, and representative images are shown. 
(B) Representative examples of senescence image processing and scoring for siCtrl and 
AURKA oligonucleotide #1 siRNAs. Five days after siRNA transfection cells were fixed 
and stained for SA- Gal, and DNA was counterstained with Hoechst. Images were 
binarised (right panels), and nuclear object regions were dilated by 15 pixels and overlaid 
with RGB images (bottom panels). The percentage of SA- -Gal positive pixels per cell 
region was calculated, and cells were binned according to the average staining intensity per 
image (intensity/cell/image in bins of 0, 0-10%, 11-20% etc.). The senescence score was 
]. 
(C) Representative example of the HCS siRNA screen quantitative image analysis and scoring 
for siCtrl and AURKA pooled oligonucleotides. 
Fig. S2. Correlation of senescence with gene knockdown efficiency
Quantitative RNA expression analysis to measure gene knockdown efficiencies. hTERT-
RPE1 p53 shRNA cells were reverse transfected with siRNAs in the absence of 
doxycycline (p53+). Total RNA was prepared three days later, and relative RNA 
expression was quantitated using TaqMan analyses. PAK7 RNA was not expressed in 
hTERT-RPE1 cells, correlating with its negative senescence score (Table S1), thus 
confirming it as a false negative; knockdown of RPS6KA2 was efficient but failed to 
induce senescence (Table S1). Three of four PIP5K1A siRNA oligonucleotides strongly
induced senescence without efficient knockdown, implying an off-target effect. The 
expression levels of KSR2 were too low to be detected by the TaqMan probe, and its low 
expression level was confirmed in expression microarray analysis of hTERT-RPE1 cells.
However, since the pool and three of four KSR2 oligonucleotides scored positive, we 
assigned KSR2 siRNA as a genuine hit. Overall, no strict correlation between senescence 
scores and knockdown efficiency was detected; all senescence-inducing oligonucleotides 
showed 80-98% knockdown efficiency. 
Fig. S3. Characterisation of senescence signatures. 
(A) hTERT-RPE1 p53 shRNA cells (treated or not with doxycycline) were reverse transfected 
with indicated SMARTpool kinome siRNAs, and stained with Hoechst following 72h of 
culture. Total numbers of cells were calculated via MetaXpress image normalisation and 
analysis. HCS data shown are averaged percentages and standard deviations of cells from 
four 384 wells each.   
(B) hTERT-RPE1 p53 shRNA cells (not treated with Doxycycline) were reverse transfected with 
indicated pooled siRNAs and immunostained for -H2AX and stained with Hoechst to mark 
the DNA following 96h of culture. A total of 300-500 cells were analysed, and percentages 
of cells containing discrete nuclear foci or staining are shown. 
Fig. S4. DNA replication analysis after Nocodazole release.
hTERT-RPE1 p53 shRNA cells (not treated with Doxycycline) were transfected with 
control or senescence hit siRNAs for 15h, arrested in mitosis by Nocodazole treatment, and 
released by Nocodazole wash-out. Cells were harvested and fixed at the indicated 
timepoints, processed for BrdU and PI staining, and analysed by flow cytometry. 
Percentages of BrdU-positive cells are indicated.
Fig. S5. EPHA receptor knockdown-associated cellular senescence.
(A) SA- -Gal staining of EPHA receptor siRNA-treated hTERT-RPE1 cells assessed at five 
days after siRNA transfection. 
(B) Live cell imaging analysis of EPHA receptor siRNA treated hTERT-RPE1 cells. The cells 
were imaged during 6h intervals for five days after siRNA transfection.
(C) Quantitative p16INK4a RNA expression analysis of EPHA receptor siRNA treated hTERT-
RPE1 cells. Total RNA was prepared from duplicate plate three days after siRNA 
transfection
(D) Knockdown verification of EPHA receptor depletion. Relative RNA expression three days 
after siRNA transfection was quantitated using quantitative real-time RT-PCR for 
indicated EPHA receptor mRNAs.
(E) Quantitative p16INK4a, p53 and EPHA3 RNA expression analysis of siRNA treated hTERT-
RPE1 cells. Total RNA was prepared from duplicate plate three days after siRNA 
transfection.
Fig. S6. Characterisation of EPHA3-LAP variant cell lines.
Verification of EPHA-LAP variant expression in 293T (A) and hTERT-RPE1 Flp-In 
cells (B). The samples were immunoblotted with the indicated antibodies.
(F) In vitro kinase assay of selected EPHA3 receptor cancer mutation variants. GFP 
immunoprecipitates from kinase assays or input lysate samples from hTERT-RPE1 stable 
EPHA3-LAP cell lines were immunoblotted with the indicated antibodies. GFP antibody 
was used for detection of EPHA3-LAP variants. Relative kinase activities were determined 
by normalisation of the PY (phosphotyrosine) against the EPHA3 signal where the 
normalised values are presented relative to WT.  
(G) EPHA3 kinase and juxtamembrane domain (JMKIN) structure highlighting kinase 
domain residues in the kinase domain pertinent to this study (red arrows). 
Fig. S7. EPHA3-LAP localises to early endosomes
EPHA3-LAP cancer variants localise to early endosomes after ephrin-A5 activation. 
hTERT-RPE1 stable EPHA3-LAP cell lines were stained with EEA1 and GFP (EPHA3) 
antibodies and imaged using fluorescence microscopy.
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Table S2. Normalised cellular senescence scores.
Gene Pool #1 #2 #3 #4 Sumb
1. AURKA 23.4 32.4 0.0 1.9 17.7 75.3
2. CDK1 12.5 9.5 7.3 2.4 4.8 36.5
3. CSNK1A1 1.5 4.4 1.8 8.4 2.2a 16.0
4. EPHA3 2.4 1.9 1.0 3.7 2.8 11.8
5. KSR2 7.4 5 3.1 1.1 3.1 19.7
6. LATS1 1.7 2.9 0.9 6.2 0.1 11.8
7. MAP2K3 2.1 1.5 1.3 3.7 6.8 15.4
8. MAP4K1 10.1 2.8 9.3 4.6a 10.3 32.5
9. MYLK 3.8 1.7 5.6 5.6 2.0 18.7
10. NEK1 1.7 5.4 0.6 4.1 1.5 13.2
11. PAK7 c 1.5 0.9 0.0 0.7 2.1 5.2
12. PASK 0.5 3.8 6.0 3.6 4.3 18.2
13. PIK3C2A 1.9 6.2 6.6 2.3 19.5 36.5
14. PIP5K1A 0.2 7.6 2.4a 2.9a 11.6a 7.8
15. RPS6KA2 0.1 2.7 3.0 0.3 2.1 8.2
16. SMG1 11.3 3.8a 1.3 9.2 13.6 35.3
Pos. FBXO5 5.9 2.0 2.7 1.0 5.9 17.5
Neg. siCTRL 0.7 0.7 0.7 0.7 0.7 3.5
Cellular senescence scores per siRNA or siRNA pool were calculated as the sum of the staining 
[(normalised #cells * maximum bin intensity)]. Values lower than 1.4 (2-fold negative control value) 
and siRNAs conferring less than 50% knockdown efficiency were scored as negative (grey font). 
Genuine hits were assigned if both the pool AND two single siRNAs gave a positive score (black 
font). asiRNAs resulting in less than 50% knockdown of specific gene expression measured by RNA 
expression analysis (Fig S1B). bSum of senescence scores excluding siRNAs conferring less than 
50% knockdown. cNo expression of Pak7 RNA is detected in hTERT-RPE1 cells. 
Table S3. Normalised cellular senescence scores in p53 knockdown cells (doxycycline
treatment).
Gene Pool #1 #2 #3 #4 Sumb
1. AURKA 14.2 2.5 0.1 0.4 5.5 22.6
2. CDK1 31.2 13.3 4.8 2.6 4.1 56.1
3. CSNK1A1 2.2 0.1 0.9 0.1 0.1a 3.3
4. EPHA3 5.7 3.3 1.6 7.9 2.0 20.5
5. KSR2 5.4 2.6 0.9 0.6 0.1 9.5
6. LATS1 1.3 1.0 2.2 4.8 0.7 9.9
7. MAP2K3 0.9 6.7 1.8 0.7 1.4 11.4
8. MAP4K1 8.6 1.3 8.7 5.9a 9.6 28.2
9. MYLK 1.1 2.4 3.8 11.9 0.2 19.3
10. NEK1 5.0 8.9 1.1 0.4 0.5 15.9
11. PIK3C2A 1.2 9.5 2.7 5.1 10.9 29.4
12. SMG1 1.6 6.1a 3.1 4.9 9.3 19.0
Pos. FBXO5 8.9 0.0 2.9 1.3 1.3 14.4
Neg. siCTRL 0.3 0.3 0.3 0.3 0.3 1.3
Cellular senescence scores per siRNA or siRNA pool were calculated as the sum of the staining 
[(normalised #cells * maximum bin intensity)]. Values lower than 0.6 (2-fold negative control value) 
and siRNAs conferring less than 50% knockdown efficiency were scored as negative (grey font). 
asiRNAs resulting in less than 50% knockdown of specific gene expression measured by RNA 
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ABSTRACT
Treatment of non-small cell lung cancer (NSCLC) is based on
histological analysis and molecular profiling of targetable driver
oncogenes. Therapeutic responses are further defined by the
landscape of passenger mutations, or loss of tumor suppressor
genes. We report here a thorough study to address the physiological
role of the putative lung cancer tumor suppressor EPH receptor A3
(EPHA3), a gene that is frequently mutated in human lung
adenocarcinomas. Our data shows that homozygous or
heterozygous loss of EphA3 does not alter the progression of murine
adenocarcinomas that result from Kras mutation or loss of Trp53, and
we detected negligible postnatal expression of EphA3 in adult wild-
type lungs. Yet, EphA3 was expressed in the distal mesenchyme of
developing mouse lungs, neighboring the epithelial expression of its
Efna1 ligand; this is consistent with the known roles of EPH receptors
in embryonic development. However, the partial loss of EphA3 leads
only to subtle changes in epithelial Nkx2-1, endothelial Cd31 and
mesenchymal Fgf10 RNA expression levels, and no macroscopic
phenotypic effects on lung epithelial branching, mesenchymal cell
proliferation, or abundance and localization of CD31-positive
endothelia. The lack of a discernible lung phenotype in EphA3-null
mice might indicate lack of an overt role for EPHA3 in the murine
lung, or imply functional redundancy between EPHA receptors. Our
study shows how biological complexity can challenge in vivo
functional validation of mutations identified in sequencing efforts, and
provides an incentive for the design of knock-in or conditional models
to assign the role of EPHA3 mutation during lung tumorigenesis.
KEY WORDS: EPHA3, EPH receptor A3, GEMM, Adenocarcinoma,
Lung morphogenesis
INTRODUCTION
Lung cancer is a leading cause of cancer-related deaths worldwide.
More than 85% of all lung cancers are classified as non-small cell
lung cancer (NSCLC), which is further sub-classified as
adenocarcinoma (ADC; ~50%) and squamous cell carcinoma (SCC;
~40%) (Chen et al., 2014). In recent years, excellent progress in
molecular profiling of NSCLC has identified stratified patient groups
RESEARCH ARTICLE
1Institute for Molecular Medicine Finland (FIMM), University of  Helsinki, Helsinki
FI-00014, Finland. 2Department of  Pathology, HUSLAB and Haartman Institute,
Helsinki University Central Hospital and University of  Helsinki FI-00014, Finland.
3Spinal Cord Injury Team, Robarts Research Institute, University of  Western
Ontario, London, ON N6A 5K8, Canada.
*Author for correspondence (emmy.verschuren@helsinki.fi)
This is an Open Access article distributed under the terms of  the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted
use, distribution and reproduction in any medium provided that the original work is properly
attributed.
Received 19 November 2014; Accepted 12 February 2015
that benefit from targeted therapies (Oxnard et al., 2013). Specifically,
erlotinib or gefitinib are prescribed to patients that carry mutations in
epidermal growth factor receptor (EGFR), and crizotinib to carriers of
anaplastic lymphoma kinase (ALK) gene rearrangements. However,
despite an increase in progression-free survival, the overall survival
benefit of such tyrosine kinase inhibitors remains marginal, and
profound intra- and inter-tumor genetic heterogeneity confounds
effective long-term responses (de Bruin et al., 2014).
Next-generation sequencing of lung cancer patient tumors has
identified numerous putative new cancer drivers, including EPH (also
defined as erythropoietin-producing hepatocellular) receptor A3
(EPHA3), which is mutated in 6–16% of lung ADC samples (Cancer
Genome Atlas Research Network, 2014; Ding et al., 2008; Imielinski
et al., 2012). The EPH receptors make up the largest family of receptor
tyrosine kinases (RTKs) and, together with their ephrin ligands, they
control a variety of biological processes. They are classified into two
subclasses based on sequence homologies, namely EPHA and EPHB
receptors and their ephrin-A and ephrin-B ligands. Interaction between
the EPH receptors and their ligands at cell-cell contacts triggers
signaling into both the receptor- and ligand-expressing cell. Such
bidirectional signaling induces changes in the actin cytoskeleton, cell-
substrate adhesion, intercellular junctions and cell shape, impinging
on cell movement and tissue patterning (Pasquale, 2010). Context-
dependent cellular responses are finely tuned by the abundance and
type of receptor-ligand pairs expressed in neighboring cells, leading to
specialized cell functions known to control synaptic plasticity, insulin
secretion, epithelial homeostasis and inflammatory immune responses
(Gucciardo et al., 2014; Pasquale, 2010).
The expression pattern of EphA3 in mammalian tissues suggests
that there is a role for EPHA3 in neuronal development and
formation of mesoderm-derived tissues (Kilpatrick et al., 1996;
Kudo et al., 2005; Yue et al., 1999). However, in contrast to
predictions made based on its expression in the developing medial
motor column, constitutive loss of murine EphA3 does not lead to
abnormal motor axon topography (Vaidya et al., 2003). Instead, 75%
of the null mice die at birth owing to cardiac abnormalities caused
by defective endothelial-to-mesenchymal transition, a specific form
of mesenchymal conversion that generates progenitors of the
atrioventricular valves (Stephen et al., 2007).
With respect to its putative role in tumorigenesis, previous studies
have indicated that EPHA3 can signal both in a kinase-dependent
and kinase-independent manner, inducing both tumor-promoting and
tumor-suppressing effects (Boyd et al., 2014). For example, in
glioblastoma multiforme, EPHA3 is highly expressed in
undifferentiated mesenchymal cells where it has been shown to
confer a kinase-independent oncogenic role through regulating
mitogen-activated protein kinase (MAPK) signaling (Day et al.,
2013). A tumor-suppressive role of EPHA3, in particular for lung
cancer, is supported by the reduction in receptor activity conferred
by the point mutations found in cancers, and ligand- and EPHA3-
The putative tumor suppressor gene EphA3 fails to demonstrate
a crucial role in murine lung tumorigenesis or morphogenesis
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dependent apoptosis of tumor and stroma cells upon receptor agonist
treatment, suggesting that wild-type EPHA3 has anti-tumorigenic
properties (Lahtela et al., 2013; Lisabeth et al., 2012; Vail et al.,
2014; Zhuang et al., 2012). Furthermore, the finding that senescence
elicited by acute EPHA3 loss is rescued by loss of p16INK4A
(encoded by Cdkn2a) or p53 (encoded by Trp53) suggests that
EPHA3 mutation might promote tumorigenesis only in the absence
of senescence-inducing pathways (Lahtela et al., 2013). Given the
opposing outcomes of aberrant EPH-ephrin signaling, careful
dissection of the tissue and cell-context-specific EPH receptor
functions requires studies that utilize valid in vivo model systems.
Genetically engineered mouse models (GEMMs) are the most
widely applied and functionally validated in vivo models of human
lung cancer, in particular to validate gene cooperation concomitant
with conditional expression of the oncogenic Kras gene (Jackson et
al., 2001; Jackson et al., 2005; Ji et al., 2007; Schramek et al., 2011;
Snyder et al., 2013). Importantly, murine clinical studies have shown
that oncogenic signaling in Kras-driven GEMMs is crucially defined
by the cooperating tumor suppressor, with loss of liver kinase B1
(Lkb1) conferring different therapeutic responses compared with loss
of Trp53 (Chen et al., 2012). Despite convincing data suggesting a
tumor suppressor role for EPHA3 during lung tumor progression, thus
far no studies have addressed its in vivo functional role. We therefore
decided to utilize the EphA3-null mice to test the effect of constitutive
loss of EphA3 on lung ADC progression driven by mutant Kras (LSL-
KrasG12D/+) (Jackson et al., 2001) and loss of Trp53 (p53fl/fl) (Marino
et al., 2000), hereafter referred to as Kras and p53. Our data shows that
the constitutive loss of EphA3 does not alter the progression of murine
ADC in either of these models. Moreover, despite clear evidence for
EphA3 expression in the developing lung, similar to key regulators of
morphogenesis known to regulate lung tumorigenesis (Clark et al.,
2001; Snyder et al., 2013; Yin et al., 2013), an analysis of selected
EphA family receptors shows that EphA3 has a non-unique or minimal
function during lung morphogenesis. Our study thus provides an
incentive for rational design of novel GEMMs to unequivocally assign
the role of EPHA3 during lung tumorigenesis in vivo.
RESULTS
Constitutive loss of EphA3 does not accelerate mutant
Kras- or p53-loss-driven lung tumorigenesis
To test the hypothesis that EPHA3 acts as a lung tumor suppressor,
we used a previously described constitutive EphA3-null mouse
model (Stephen et al., 2007; Vaidya et al., 2003). EphA3-null mice
did not show any marks of reduced survival during a 1-year follow-
up period, indicating that mere EphA3 loss does not drive
tumorigenesis. We therefore assessed whether EphA3 loss could
accelerate tumorigenesis induced by conditional alleles known to
initiate lung ADC, following a classic multi-allele paradigm. These
‘first hit’ conditional models comprised mutant Kras (Jackson et al.,
2001) and loss of p53 (Marino et al., 2000), which are also 
common drivers of human disease found in at 17% and 35% of
ADCs, respectively (COSMIC, 2014; http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/). In lung ADC, EPHA3 mutations
show a statistically significant tendency towards co-occurrence with
mutations in TP53 (P<0.01) and occasional, but not statistically
significant, co-occurrence with KRAS mutations (supplementary
material Fig. S1A). We established cohorts of 8-16 mice for each
genetic combination (homozygous p53 or heterozygous Kras with
wild-type EphA3, or homozygous or heterozygous null EphA3).
Lung-specific deletion of conditional alleles was achieved through
intranasal inhalation of adenoviral Cre recombinase (CMV-AdCre),
affording transduction of bronchiolar and alveolar progenitor cells,
to initiate carcinoma progression. The infection efficacy was
confirmed with a dual fluorescence mT/mG Cre-reporter strain that
monitors in vivo integration efficiency through activating a Cre-
dependent switch from membrane-tagged Tomato to GFP
(supplementary material Fig. S1B) (Muzumdar et al., 2007). Tumor
burden analysis at 19 weeks after CMV-AdCre infection showed
that constitutive loss of EphA3 did not alter mutant Kras-driven lung
ADC progression (Fig. 1A,B; supplementary material Fig. S1C).
Similar to previous findings in murine Kras lung cancer studies
(Jackson et al., 2001), all EphA3 genotype cohorts displayed distinct
types of progressive lesions, including epithelial hyperplasia,
adenomas and ADCs. In addition, we detected previously described
profound inflammatory responses as infiltrations of macrophages
and neutrophils (supplementary material Fig. S1C) (Ji et al., 2006).
Furthermore, analysis of histopathology and NKX2-1 and tumor
protein 63 (p63) biomarker expression to respectively depict ADC
and SCC tissue, showed that constitutive absence of EphA3 did not
alter the tumor histology (Fig. 1C). We further found that the loss of
EphA3 did not alter the latency of p53-loss-driven ADCs (Fig. 1D).
Thus, the constitutive absence of EPHA3 expression does not
accelerate mutant Kras- or p53-loss-driven lung tumorigenesis.
Mesenchymal expression of EphA3 suggests that it has a
functional role during lung development
As previous studies have indicated a role for EphA3 in embryonic
development, we undertook a detailed expression analysis of EphA3
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TRANSLATIONAL IMPACT
Clinical issue
Lung cancer is the leading cause of cancer-related deaths worldwide.
Molecular profiling to identify targetable driver mutations is increasingly
being applied in the clinic, and can stratify patient groups. However,
pronounced patient- and tumor-specific lung tumor heterogeneity
confounds long-term or predictable clinical responses. Hence, validation
of de novo driver mutations using appropriate in vivo model systems is
important. The EPH receptor A3 (EPHA3) tyrosine kinase is among the
most frequently mutated cancer genes in human lung adenocarcinomas.
However, we still lack mouse genetic studies to unequivocally validate
its previously assigned putative tumor suppressor function in human lung
adenocarcinomas.
Results
Here, the authors test the applicability of EphA3-null mice to address the
functional importance of EPHA3 in mutant Kras- or p53-loss-driven
mouse lung adenocarcinomas. The study shows that constitutive loss of
EphA3 does not alter mutant Kras-driven lung adenocarcinoma
progression, nor the histopathology or latency of p53-loss-driven
adenocarcinomas. Moreover, the study identifies EPHA3 as a receptor
that is expressed in embryonic lung mesenchyme and describes subtle
lung morphogenesis gene expression changes in EphA3 heterozygous
embryonic lungs. No gross phenotypic changes in morphogenesis-
related functions are detected in EphA3 heterozygous or null embryonic
lungs.
Implications and future directions
This study highlights the importance of creating appropriate model
systems to study the in vivo functional relevance of putative cancer
drivers, such as EPHA3. Our studies utilizing Epha3-null mice fail to
validate a putative tumor suppressor function for EPHA3 in human lung
cancer. Furthermore, the overlapping expression pattern of EPH
receptors detected in the developing mouse embryonic lung might imply
functional redundancy. Therefore this study provides an incentive to the
design of sophisticated, possibly tissue-specific, knock-in or conditional
mouse models using genome-editing tools such as the prokaryotic type
II CRISPR/Cas-system to elucidate the role of EPHA3 mutations during
















in the developing mouse lung. Both RNA in situ hybridization
(Fig. 2A) and immunohistochemical staining (Fig. 2B) demonstrated
expression of EphA3 in the distal mesenchyme of the embryonic
lung. The specificity of the EPHA3 antibody was confirmed by
absence of detectable immunohistochemical staining in EphA3-null
embryos (Fig. 2A,B), as well as a decreased signal in hTERT-RPE1
cells treated with EPHA3 small interfering RNA (siRNA)
(supplementary material Fig. S1D). Expression of EPHA3 in the
developing lung was detected during embryonic ages E11.5 to E15.5
(Fig. 2B,C), which falls into the pseudoglandular (E9.5-E16.5) stage
of murine lung development. During this stage, the newly generated
primary lung buds develop into a complex branched tree-like
structure ending in thousands of epithelial terminal tubules,
accompanied by continued mesenchymal growth around the
growing epithelia (Morrisey and Hogan, 2010). Based on this
mesenchymal expression in the developing mouse lungs we
hypothesized that EPHA3 might function during the
pseudoglandular stage of lung development.
Expression of multiple EPH receptors in the developing
mouse lung suggests involvement in lung morphogenesis
We next asked how mRNA expression of EphA3 during murine lung
morphogenesis might correlate with or impact on mRNA expression
of other EphA receptors in epithelial and mesenchymal cells at
E11.5, E13.5 and E15.5 of lung development (Fig. 3A). At E11.5
we performed quantitative PCR (q-PCR) expression analysis on
both proximal and distal epithelium and mesenchyme. At E13.5 and
E15.5, the analysis was restricted to the distal regions,
approximating the terminal epithelial buds and their surrounding
mesenchyme. We found that among the studied EphA receptors,
only expression of EphA3 was restricted to the developing lung
mesenchyme, and closely overlapped with expression of known
mesenchymal Fgf10 and endothelial Cd31 (also known as Pecam1)
genes (Fig. 3B; supplementary material Fig. S2A). EphA7
expression was detected both in the mesenchyme and epithelia, and
was the only other EphA receptor co-expressed with EphA3 in the
mesenchyme (Fig. 3B). Importantly, we did not detect any
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Fig. 1. Constitutive loss of EphA3 does not alter mutant Kras-driven or p53 loss-induced lung ADCs. (A) Representative sections (stained with H&E)
depicting the tumor burden in Kras;EphA3+/+, Kras;EphA3+/ and Kras;EphA3 / lungs 19 weeks post CMV-AdCre infection (3.3×107 PFUs) show no difference
between the genotypes. Black arrows indicate the site of magnified images. (B) Average tumor-to-lung area at 19 weeks after CMV-AdCre infection of the
Kras;EphA3+/+, Kras;EphA3+/ and Kras;EphA3 / lungs. Two separate lung regions were used for tumor burden analysis. n=9 for Kras;EphA3+/+, n=16 for
Kras;EphA3+/ and n=8 for Kras;EphA3 / . Results are mean±s.d. (C) Immunohistochemical analysis of the ADC marker NKX2-1 and squamous cell carcinoma
marker p63 in Kras;EphA3+/+, Kras;EphA3+/ and Kras;EphA3 / tumors, indicating positive nuclear staining for NKX2-1 and negative for p63. (D) Survival
curves of n=7 for p53;EphA3+/+, n=11 for p53;EphA3+/ and n=13 for p53;EphA3 / mice treated with CMV-AdCre (3.3×108 pfu). Mice were monitored for 15
months, during which one out of seven p53;EphA3+/+ and two out of 13 p53;EphA3 / mice died due to CMV-AdCre-induced ADC formation. NS, P>0.05

















compensatory changes in EphA7 expression levels in the
heterozygous or homozygous EphA3-null embryonic lungs
(supplementary material Fig. S2B). EphA2 and EphA4 were found
to be expressed mainly in epithelial cells, whereas expression of
EphA1 and EphA5 was absent in both tissue compartments
(Fig. 3B). These results correlate with in situ hybridization data
described by the Allen Institute for Brain Science, with the
exception of EphA1, for which moderate expression was detected in
murine lung epithelia (Allen Institute for Brain Science, 2013). We
further confirmed the epithelial expression of the known ligand of
EPHA3, ephrin-A1 (encoded by Efna1), at E11.5, E13.3 and E15.5
(Fig. 3B; supplementary material Fig. S2C). Finally, postnatal
murine lung expression analysis revealed very low EphA3 and
EphA7 expression levels when compared to that of the embryonic
mesenchyme (E13.5), whereas EphA2 and EphA4 expression were
higher in the adult tissue (supplementary material Fig. S3A). Taken
together, our data identifies EphA3 as a mesenchymal EPH receptor
and suggests that its ligand ephrin-A1 is expressed in the adjacent
branching epithelia. Furthermore, the low expression of EphA3 in
adult tissue suggests that EPHA3 is absent or has a minimal role in
postnatal lung homeostasis.
EphA3 heterozygosity is associated with altered expression
of branching morphogenesis and vasculogenesis genes
Next, we investigated whether constitutive loss of EphA3 affected
the mRNA expression of known lung morphogenesis genes. A
targeted q-PCR analysis of known regulators of lung morphogenesis
identified a small but significant increase in the expression of Nkx2-
1 in heterozygous EphA3 embryonic epithelium at E13.5 when
compared with wild-type tissue (Fig. 3C). Furthermore, similar
expression increases were detected in endothelial Cd31 and
mesenchymal Fgf10 (Fig. 3C). In contrast, analysis at E15.5 failed
to show statistically significant expression differences for these three
genes (supplementary material Fig. S3B) suggesting that any role
for EphA3 during pseudoglandular lung development is transitory.
Taken together, the partial loss of EphA3 appears to induce subtle
and transitory alterations in epithelial Nkx2-1, endothelial Cd31 and
mesenchymal Fgf10 mRNA expression, suggesting that EPHA3
function might modulate lung morphogenesis.
Constitutive loss of EphA3 does not overtly affect murine
lung morphogenesis
We next asked whether the constitutive loss of EphA3 was directly
associated with altered lung branching morphogenesis. We first
performed a quantitative analysis of lung branch end-points at E13.5
by E-cadherin whole-mount immunohistochemistry staining and
optical projection tomography (OPT) to visualize branching
epithelia. The number of terminal branches was found to be identical
in EphA3 heterozygous (average 113) and null embryonic lungs
(average 110) when compared to age-matched littermate controls
(average 108) (Fig. 4A,B). Additional qualitative analysis using E-
cadherin-stained E11.5 and E15.5 whole-mount lungs further
confirmed that EPHA3 does not overtly affect lung branching
morphogenesis (supplementary material Fig. S3C). Next, we
assessed whether loss of EphA3 was associated with an alteration in
distal mesenchymal cell proliferation. Analysis of in vivo BrdU
incorporation showed that there was no statistically significant
increase in the percentage of mesenchymal S phase cells in EphA3
heterozygous (36%) or EphA3-null (26%) lungs at E13.5 when
compared to littermate controls (26%) (Fig. 4C). Finally, we studied
whether the pulmonary vasculature formation was altered by loss of
EphA3 by analyzing CD31 expression at E13.5. In both EphA3-null
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Fig. 2. Mesenchymal expression of EphA3 during lung development. (A) In situ hybridization analysis of EphA3 expression in embryonic mouse lungs at
E14.5, showing its distal mesenchymal expression. (B) Immunohistochemical analysis of EPHA3 protein in embryonic mouse lungs at E11.5, E13.5 and E15.5
confirms the distal mesenchymal expression. (C) Quantitative PCR analysis of epithelial and mesenchymal mRNA expression of EphA3 at E11.5, E13.5 and
















and heterozygous lungs, the number of CD31-positive endothelial
cells at E13.5 was identical to that of the controls (Fig. 4D). Taken
together, the data presented here show that constitutive loss of
EphA3 does not overtly alter murine lung morphogenesis.
DISCUSSION
The functional validation of de novo mutations identified in lung
cancer sequencing efforts is a prerequisite for the development of
novel targeted therapies. EPHA3 is among the most frequently
mutated RTKs in human lung ADCs, and has been assigned a
candidate tumor suppressor role based on its mutation spectrum and
findings from in vitro and in vivo studies (Lahtela et al., 2013;
Lisabeth et al., 2012; Vail et al., 2014; Zhuang et al., 2012).
However, the actual role of EPHA3 during lung tumor progression
has not been investigated nor validated using GEMMs. Our previous
findings linked loss of EPHA3 to p53 activation (Lahtela et al.,
2013), and EPHA3 and TP53 point mutations display statistically
significant co-occurrence in lung ADC (supplementary material
Fig. S1A). We hence asked whether the absence of EphA3 enhanced
the incidence of p53-loss-driven lung cancer progression.
Additionally, we asked whether loss of EphA3 accelerated lung
ADC progression caused by the commonly mutated Kras oncogene.
We here show that the constitutive absence of EPHA3 does not
affect tumor progression and histopathology of both p53-loss- and
mutant Kras-driven lung ADCs. Thus, EphA3-null mice fail to
validate a putative tumor suppressor function for EPHA3 in human
lung cancer, perhaps owing to functional redundancy between
murine EphA receptors expressed in adult lungs. Interestingly,
sequencing of murine small cell lung cancer (SCLC) tumors
initiated by loss of p53 and retinoblastoma 1 (Rb1) revealed that
there were recurrent somatically acquired EphA5 and EphA7
mutations (McFadden et al., 2014). This means that there is a strong
case for further lung tumorigenesis studies to study the role of EphA
receptor biology in GEMMs, and in particular the physiological role
of EphA5 and EphA7.
Re-activation of EPH-receptor–ephrin pathways, generally known
to contribute to cell sorting and tissue patterning in embryonic
development, has been causally linked with tumorigenesis
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Fig. 3. Embryonic lung gene expression analysis of selected EphA family and morphogenesis genes. (A) Schematic workflow describing the mRNA
expression analysis of E11.5, E13.5 and E15.5 embryonic lung epithelium and mesenchyme. (B) Average mRNA expression levels of selected EphA family
receptors and Efna1 ligand. Expression of epithelial Nkx2-1 and Cdh1, mesenchymal Fgf10 and endothelial Cd31, correlates with their known expression
patterns. E11.5, n=2, E13.5 and E15.5, n=4. The inset shows the distribution of the samples within the observed expression values. (C) Comparative mRNA
expression analysis of EphA3+/+, EphA3+/ and EphA3 / dissected embryos at E13.5 shows a minor but statistically significant difference between EphA3+/+and

















(Nievergall et al., 2012). Moreover, expression of key regulators of
embryonic lung morphogenesis, Fgf9 and Fgf10 (Colvin et al.,
2001; Min et al., 1998; White et al., 2006), has been shown to
trigger ADC and adenoma progression, respectively (Clark et al.,
2001; Yin et al., 2013). Thus far, of all EphA receptors and ligands,
only a role of the ephrin-B2 ligand has been described during lung
development. Specifically, ephrin-B2 has been shown to regulate
alveolar epithelial and endothelial viability and vascular growth in
hyperoxic rats (Vadivel et al., 2012), as well as pulmonary
compliance in mice (Bennett et al., 2013). Our current data shows
that EphA3 is expressed specifically in the mesenchymal distal lung
tips during the pseudoglandular stage of branching morphogenesis,
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Fig. 4. Constitutive loss of EphA3 does not alter morphogenesis of murine lungs. (A) Representative E-cadherin whole-mount images of EphA3+/+,
EphA3+/ and EphA3 / embryonic lungs at E13.5 and corresponding images from branch end-point analyses, indicating end points in green. (B) Mean±s.d. of
the branch end-point number from EphA3+/+, EphA3+/ and EphA3 / lungs at E13.5 shows no difference between EphA3+/ and EphA3 / embryonic lungs
when compared to EphA3+/+ lungs; n=6 in all three genotypes. (C) Representative images from BrdU and nuclear Hoechst immunohistochemical staining in
EphA3+/+, EphA3+/ and EphA3 / embryonic lungs at E13.5. Segmentation of representative images was performed to calculate distal-mesenchyme-specific
BrdU proliferation analysis. Mean±s.d. values of the amount of BrdU-positive cells relative to the total number of Hoechst-stained nuclei shows no difference
between EphA3+/+, EphA3+/ and EphA3 / embryonic lungs at E13.5. n=3 for EphA3+/+ and EphA3 / ; n=1 for EphA3+/ . Analysis was done on two separate
regions of the embryonic lungs. NS, P<0.05 (Student’s t-test). (D) Representative images of CD31-positive endothelial cells of EphA3+/+, EphA3+/ and

















albeit at low levels. However, whereas for example the removal of
Fgf10 results in dramatic defects in lung organogenesis (Min et al.,
1998), partial loss of EphA3 appears to induce only subtle increases
in epithelial Nkx2-1, endothelial Cd31 and mesenchymal Fgf10
mRNA expression levels. Furthermore, no macroscopic phenotypic
effect on lung epithelial branching, mesenchymal cell proliferation,
or abundance and localization of CD31-positive endothelia was
measured. This lack of a discernible phenotype might indicate: (1)
lack of an overt, or a different, role for EPHA3 in the murine lung;
(2) functional redundancy between lung-expressed EphA receptors;
or (3) a partial penetrance of the EphA3-null genotype. 
Of the selected EphA receptors, we found that only EphA7 was
co-expressed with EphA3 in the lung mesenchyme. Interestingly, a
recent study has suggested that there is functional compensation of
EphA3 loss by EphA7 co-expression during palate development, as
compound homozygous mutation of EphA3 and EphA4 failed to
cause defective midfacial development (Agrawal et al., 2014).
Furthermore, a truncated form of EPHA7 has been reported to act
as a tumor suppressor in follicular lymphoma (Oricchio et al., 2011),
and it would thus be interesting to study its potential role in lung
tumor suppression in conjunction with EphA3 loss of function.
Taken together, we report that loss of EphA3 does not lead to
measurable effects on lung ADC progression, nor lung
morphogenesis, in the applied constitutive null GEMM. Importantly,
we cannot exclude the possibility that other EphA receptors co-
expressed in the (developing) lung, most notably EphA7, can
compensate for the decreased expression of EphA3. Our findings
therefore provide an incentive to perform a rational design of tissue-
specific knock-in or conditional mouse models to unequivocally
assign the role of EPHA3 mutation or loss of expression, possibly in
the context of compound EPHA-ephrin network mutations, on lung
tumorigenesis in vivo. In this respect, the ability to apply prokaryotic
type II CRISPR/Cas genome editing tools to introduce somatic
germline mutations in mice (Sanchez-Rivera et al., 2014; Yang et al.,
2013) provides promise for future tumor modeling approaches.
MATERIALS AND METHODS
Mouse cohorts and tissue preparation
Animal studies were carried out in accordance with guidelines from the
Finnish National Board of Animal Experimentation, and were approved by
the Experimental Animal Committee of the University of Helsinki and the
State Provincial Office of Southern Finland (License number ESAVI-2010-
04855/Ym-23). EphA3-null mice lacking a genetic region encompassing the
first exon of EphA3 were previously described (Stephen et al., 2007; Vaidya
et al., 2003). Mice carrying a conditional mutant allele of Kras (LSL-
KrasG12D/+) (Jackson et al., 2001) or a loss-of-function allele of Trp53
(p53fl/fl) (Marino et al., 2000) were purchased from The Jackson Laboratory.
EphA3-null mice were bred with Kras and p53 mice to generate the study
cohorts, and were maintained on a mixed genetic background using
littermates as controls. Multiple litters of the same age were used to provide
sufficient numbers of each genotype. Lung tumorigenesis was initiated by
infecting mice at 6-10 weeks of age with 3.3×107 (Kras) or with 3.3×108
(p53) plaque-forming units (PFUs) of recombinant adenovirus expressing
the Cre recombinase (University of Turku, Finland), using intranasal
instillation as described elsewhere (Jackson et al., 2001). Viruses were
administered in a Biosafety Level 2+ room according to the guidelines of
the Finnish Board for Gene Technology. Lungs from mice were fixed in 4%
formaldehyde, and all lobes were embedded in paraffin.
Tumor burden analysis and survival curves
Lungs from Kras;EphA3 / , Kras;EphA3+/ and Kras;EphA3+/+ mice at 19
weeks post infection were processed as described above and paraffin sections
(4 m) were cut from two distinct zones (middle and bottom) of each paraffin
block, thus generating two sections each representing the whole lung surface
area, which were stained with H&E. Whole slide scans of the H&E-stained
lung sections were acquired with a Pannoramic 250 3DHISTECH
(3DHISTECH Kft., Budapest, Hungary) digital slide scanner with a 20×
objective. Whole slide images were assessed for tumor burden using the
Tissue studio image analysis solution of the Definiens Developer XD 64 2.1
software (Definiens, Munich, Germany). The histopathology of the lesions
and inflammatory infiltrations were diagnosed by an expert pathologist. Long-
term follow up of infected p53;EphA3 / , p53;EphA3+/ and p53;EphA3+/+
mice was performed until 15 months, and mice were killed when showing
labored breathing. Sections (4 m) were cut from two distinct zones (middle
and bottom) of each paraffin block, stained with H&E and qualitatively
analyzed for tumor appearance. Kaplan-Meier survival curves were generated
using Prism (GraphPad Software, Inc., San Diego, CA).
Histology and immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded sections (4 m).
Sections were dehydrated and antigenic epitopes were exposed by heating in
10-mM citrate buffer (pH 6.0) or by incubation in 0.05% trypsin at +37°C.
Sections were incubated with the following antibodies: anti-NKX2-1 (Abcam,
Cambridge, UK); anti-p63 (Abcam, Cambridge, UK); anti-EPHA3
(Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA); anti-CD31 (Becton,
Dickinson and Company, Franklin Lakes, NJ); anti-GFP (polyclonal rabbit
serum 8 mg/ml, generated in house). Primary antibody staining was detected
using Bright vision poly-horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (ImmunoLogic, Duiven, The Netherlands), HRP-conjugated goat
anti-rat IgG (Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA) and
3,3 -diaminobenzidine (DAB) (Immunologic, Duiven, The Netherlands) or
Alexa-Fluor-488-conjugated anti-rabbit IgG (Life Technologies/Thermo
Fisher Scientific Inc., Waltham, MA). Sections were counterstained with
Mayers hemalum solution (Millipore, Billerica, MA) or Hoechst 33342 dye
(Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA). Image acquisition
was performed either using a Nikon 90i Eclipse microscope (Nikon
Instruments Europe BV, The Netherlands) and DS-Fi2 5 MP camera, or a
Pannoramic 250 3DHISTECH (3DHISTECH Kft., Budapest, Hungary)
digital slide scanner with a 20× objective.
In situ hybridization
Radioactive in situ hybridization was performed on paraffin sections
according to the standard protocols using probes labeled with 35[S]-UTP.
Dark-field images were inverted, linearly thresholded and combined with
brightfield images in Adobe Photoshop CS6 (Adobe Systems Software,
Dublin, Ireland). The mouse EphA3 probe was an 817-bp fragment
(nucleotides 658-1474) inserted into pGEM-3Zf- vector. The mouse Efna1
probe was a 402-bp fragment (nucleotides 20-421) inserted into pGEM-3Zf-
vector. The Fgf10 probe was a 584-bp fragment (nucleotides 11-579)
inserted into Bluescript KSII+ vector.
BrdU proliferation assay
A timed pregnant mouse was injected with 5-bromo-2 -deoxyuridine (BrdU)
(Sigma, St Louis, MO) and killed 4 hours later to harvest embryos at
embryonic age of 13.5. Embryos were fixed in 4% formaldehyde and
embedded in paraffin. Sections (4 m) were cut from two distinct zones of
the embryonic lungs. BrdU-positive cells were detected using anti-BrdU
antibody (Cell Signaling Technology, Danvers, MA) and counterstained with
Hoechst 33342 using standard immunohistochemical methods. Image
acquisition was performed with a Nikon 90i Eclipse microscope (Nikon
Instruments Europe BV, The Netherlands) and DS-Fi2 5 MP camera. Image
analysis was done using NIS-Elements AR 4.2 software (Nikon Instruments
Europe BV, The Netherlands).
Preparation of embryonic lung tissue
Embryonic lung dissection and epithelial and mesenchymal cell separation
was performed as previously described (del Moral and Warburton, 2010),
with small modifications. Briefly, pregnant mice were killed to harvest
embryos at E11.5, E13.5 and E15.5 by CO2 administration. Collected
embryos were dissected under a stereoscopic microscope in a glass Petri
dish immersed in PBS. Isolated lungs were then transferred to 24-well plates
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containing CO2-independent medium (Gibco by Life Technologies/Thermo
Fisher Scientific Inc., Waltham, MA). Epithelial and mesenchymal tissues
were separated by treating with 10 mg/ml collagenase (collagenase from
Clostridium histolyticum, Sigma) in CO2-independent medium at 37°C for
20 minutes. Enzymatic degradation was stopped by adding CO2-independent
medium supplemented with 5 U/ml RNase-free DNase (RQ1 RNase free
DNase, M6101, Promega, WI). Depending on the embryonic age,
mesenchymal and epithelial cells from one to five embryos were used to
reach high enough RNA yields.
Quantitative PCR analysis
Normal adult lung tissue was homogenized using a Precellys homogenization
kit (Bertin Technologies, Montigny-le-Bretonneux, France). Total RNA was
extracted using NucleoSpin RNA II kit (MACHEREY-NAGEL, Düren,
Germany) and quantified using NanoDrop 1000 (Thermo Fisher Scientific
Inc.). Complementary DNA (cDNA) was synthesized from the extracted RNA
using a High-capacity cDNA reverse transcription kit (Applied Biosystems by
Life Technologies/Thermo Fisher Scientific Inc.). The q-PCR amplification
was performed using iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, CA)
or iQ™ Supermix (Bio-Rad) and CFX384 Touch™ Real-Time PCR Detection
System C1000 Touch (Bio-Rad). The following TaqMan® probes were used
to measure the EPHA3 expression in hTERT-RPE1 cells: EPHA3
Hs00739096_m1 and RPL19 Hs02338565_gH (Applied Biosystems by Life
Technologies/Thermo Fisher Scientific Inc.). q-PCR primers were designed to
flank exon-exon boundaries and to give specific amplification. Following 3
minutes denaturation at 95°C, 40 cycles of 15 seconds at 95°C and 1 minute
in 60°C were run. A melting curve ranging from 57°C to 95°C was included
in every analysis to confirm the specific amplification. Primer details are listed
in supplementary material Table S1. An exponential expression ( Cq
Expression) was obtained with formula Cq Expression=2– Cq, where
Cq=Cq (target) – Cq (reference). The average of the Cq expression values
of the specific genotypes and time points were visualized with heatmaps
generated using an R statistical programing language heatmap function from
the Heatplus Bioconductor package. We used R version 2.15.3 freely available
at http://www.r-project.org/.
Whole-mount immunohistochemistry and optical tomography
scanning
Sample processing and whole-mount immunohistochemistry of dissected
embryonic lungs at E11.5-E15.5 were performed as described previously
(Alanentalo et al., 2007). Briefly, fixed lungs were dehydrated with methanol
followed by rehydration and processing to immunohistochemical staining.
Localization of anti-E-cadherin (Cell Signaling Technology) was detected
either by fluorescently labeled secondary antibody conjugated to Alexa-
Fluor-594-conjugated anti-rabbit IgG (Life Technologies/Thermo Fisher
Scientific Inc.) or visualized by using the chromogenic DAB substrate
(Immunologic, Duiven, The Netherlands) following the incubation with
poly-HRP-conjugated anti-rabbit IgG antibody (Immunologic, Duiven, The
Netherlands). Fluorescently labeled lungs were processed for OPT scanning
as described previously (Alanentalo et al., 2007), using a Bioptonics OPT
3001M Scanner. Three-dimensional (3D) visualization and branch end-point
analysis was performed with Imaris 3D and 4D data software, using the
Filament analysis function (Bitplane AG, Switzerland). Chromogenically
stained samples were imaged using a Leica MZFLIII stereomicroscope
(Leica, Germany) and Colorview camera (Software imaging system,
Olympus, Japan).
Cell culture and transfections
hTERT-RPE1 cells (Clontech, CA) were maintained in DMEM with 
F-12 (Sigma) containing 10% FBS, 2 mM L-glutamine, 0.348% 
sodium bicarbonate and penicillin-streptomycin (all Gibco by Life
Technologies/Thermo Fisher Scientific Inc.), following the manufacturer’s
recommendations. For gene knockdown, hTERT-RPE1 cells were treated
with 50 nM pooled siRNAs against EPHA3 (GE Dharmacon, Denver, CO)
or siCONTROL non-targeting siRNA #3 (SiCtrl; GE Dharmacon, Denver,
CO) after transfection with Oligofectamine reagent (Invitrogen/Thermo
Fisher Scientific Inc.) on 15-cm culture dishes. One fifth of the transfected
cells was pelleted for RNA extraction and EPHA3 mRNA quantification.
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Supplementary Table 1. List of primers used in the quantitative PCR analysis of mouse epithelial
and mesenchymal cells. Primer sequences for EphA1 and EphA4 were from the indicated
references.
Gene Primer sequence Primer efficiency
EphA1 (Forward) CAAGATTGCAAGACTGTGGC
(Abdul-Aziz et al., 2009) E=98.3% R²=0.949 Slope= -3.363EphA1 (Reverse) CCTCCCACATTACAATCCCA (Abdul-
Aziz et al., 2009)
EphA2 (Forward) GTCTATAAAGGGACGCTGAAGG
E=96.3% R²=0.987 Slope= -3.414EphA2 (Reverse) CGCTCCATTCTCCATGTACTC




(Andersson et al., 2011) E= 98.7 R²= 0.996 Slope= -3.354
EphA4 (Reverse)
GCCAGCAGTCCAGCATTAAC
(Andersson et al., 2011)
EphA5 (Forward) AGTGACAGTGGGAGTCATCT
E=90.7% R²=0.943 Slope= -3.566EphA5 (Reverse) GCAGTTTAATGTGCCCGTTATG
EphA7 (Forward) CAGCAGACGGGATTAGAGGA
E=100.4% R²=0.988 Slope= -3.313EphA7 (Reverse) GATGACTCCATTGGGATGCT
Efna1 (Forward) CAGGAATCCCAGTGCTTGAA
E=94.2%  R²=0.998 Slope= -3.468Efna1 (Reverse) CAGCAGTGGTAGGAGCAATAC
Efna5 (Forward) GAGATGTTGACGCTGCTCTT
E=102.4% R²=0.996 Slope= -3.266Efna5 (Reverse) TTCTGGGACAGAGTCCTCATAG
Efnb2 (Forward) CCAGACAAGAGCCATGAAGAT E=74.6% R²=0.975 Slope= -4.130
Efnb2 (Reverse) TGCGATCCCTGCGAATAAG
Fgf10 (Forward) GCTGTTCTCCTTCACCAAGTA
E=95.1% R²=0.969 Slope= -3.445Fgf10 (Reverse) ACTCCGATTTCCACTGATGTT
Pecam1 (Forward) GTGGTCATCGCCACCTTAATA
E=96.7%  R²=0.997 Slope= -3.404
Pecam1 (Reverse) TTCTCGCTGTTGGAGTTCAG
Nkx2.1(Forward) CTACTGCAACGGCAACCTG
E=92.3%  R²=0.997 Slope= -3.522Nkx2.1 (Reverse) CCATGCCACTCATATTCATGC
Cdh1 (Forward) CAGGTCTCCTCATGGCTTTGC
E=89.6% R²=0.994 Slope=-3.599Cdh1 (Reverse) CTTCCGAAAAGAAGGCTGTCC
Rpl19 (Forward) CGGGAATCCAAGAAGATTGA
E=93.4% R²=0.997  Slope= -3.492Rpl19 (Reverse) TTCAGCTTGTGGATGTGCTC
Supplementary figure legends
Supplementary Figure 1. (A) EPHA3 mutations co-occur with mutations in common drivers of
human lung adenocarcinoma. Grey bars represent patients with mutations in any of the three genes.
Green mark indicates existence of point mutation in the assigned gene. Mutation information is
based on the data from Cancer Genome Atlas Research Network (Cancer Genome Atlas Research
Network, 2014) and was exported from cBioportal (Cerami et al., 2012;Gao et al., 2013). (B) Lungs
from dual fluorescence mT/mG Cre-reporter mice at two weeks post CMV-AdCre infection (3,3 ×
107 pfu) show Cre activity-induced GFP expression in bronchiolar [Br] and alveolar [Av] progenitor
cells. Image acquisition was performed at 20x magnification. (C) Representative image of H&E
stained lung section from Kras;EphA3 lungs and the corresponding pseudo-colored image
describing the tissue segmentation performed with Definiens software. The quantitation of cancer
area [C] including epithelial hyperplasia, adenomas, and adenocarcinomas in all samples was
measured in relation to the area of combined normal [N] and stromal regions [S] including
infiltration of immune cells. Scale bars: 100 m. (D) Validation of a polyclonal rabbit anti-EPHA3
antibody via siRNA-mediated downregulation of EPHA3 in human hTERT-RPE1 cells. Cells were
treated with EPHA3 siRNA or siRNA control for 72 hours and processed for
immunohistochemistry. Image acquisition was performed at 20x magnification. EPHA3 mRNA
quantitation confirms the knockdown upon siRNA treatment. Results are mean±s.d.
Supplementary Figure 2. (A) In situ hybridization analysis of Fgf10 expression in embryonic
mouse lungs at E14.5 shows mesenchymal expression. Scale bars: 100 μm. (B) Constitutive loss of
EphA3 does not trigger altered expression of EphA7 in embryonic lung mesenchyme. Comparative
expression analysis of EphA3+/+, EphA3+/- and EphA3-/- embryonic lungs at E11.5, E13.5 and E15.5
shows statistically significant differences between EphA3+/+and EphA3-/- only in epithelial EphA7
expression. Results are mean±s.d. E11.5: n=2-3; E13.5 n=1-4; E15.5 n=3-4, *P < 0,05 (Student’s t-
test). (C) In situ hybridization of Efna1 expression in embryonic mouse lungs at E14.5 shows
epithelial expression. Scale bars: 100 μm.
Supplementary Figure 3. (A) EphA3 is expressed at low levels in adult mouse lungs when
compared with selected EphA receptors. Heatmap presentation of the comparative expression
analysis shows average expression values in EphA3 -wild type and -null adult mouse lung and
embryonic mesenchyme at E13.5 without scaling. Histogram presentation of the comparative
expression analysis shows scaled average expression values in EphA3 -wild type and -null adult
mouse lung and embryonic mesenchyme at E13.5. Results are mean±s.d. N=3 for all four groups.
(B) Comparative expression analysis of EphA3+/+, EphA3+/- and EphA3-/- embryonic lungs at E15.5
shows a statistically significant difference between EphA3+/+ and EphA3-/- only in epithelial Nkx2-1
expression. Results are mean±s.d. N=3-4 *P < 0,05 (Student’s t-test). (C) Constitutive loss of
EphA3 does not have gross effect on embryonic lung branching morphogenesis. Representative E-
cadherin whole mount images of EphA3+/+, EphA3+/- and EphA3-/- embryonic lungs at E11.5 and
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Summary
Lung cancers exhibit pronounced histological and genomic heterogeneity, confounding precision
medicine. We studied how the cell-of-origin contributes to phenotypic and immune
microenvironment heterogeneity following conditional expression of KrasG12D and loss of Lkb1
(Kras;Lkb1). Using progenitor cell type-restricted adenoviral-Cre targeting cells expressing
Surfactant Protein C (SPC) or Clara cell antigen 10 (CC10), we show that Ad5-CC10-Cre infected
mice exhibit a shorter latency compared with Ad5-SPC-Cre cohorts. We further demonstrate that
CC10+ cells are the predominant progenitors of adenosquamous carcinoma (ASC) tumors, and give
rise to a wider spectrum of histotypes that uniquely include mucinous and acinar invasive
adenocarcinomas. Transcriptome analysis indicates ASC histotype-specific downregulation of Class
I MHC genes, and upregulation of pro-inflammatory and immunomodulatory genes. ASC-specific
immunosuppression is evidenced by recruitment of Gr-1+CD11b+ myeloid derived suppressor cells
and decreased CD3+ T cell infiltration. We conclude that progenitor cell-specific etiology
influences the Kras;Lkb1-driven tumor histopathology spectrum and histotype-specific immune
microenvironment.
Highlights
 Cell-of-origin crucially defines tumor proliferation and histopathology spectrum
 CC10+ cells are the predominant progenitors of adenosquamous carcinoma in Kras;Lkb1
mice
 CC10+ cells uniquely give rise to pure mucinous and acinar adenocarcinoma histotypes




Lung cancers are relatively intractable with respect to detection and treatment, and pronounced
histological and genomic heterogeneity compromises prognosis and treatment success (Chen et al.,
2014). Factors contributing to tumor progression and therapy resistance may include genetic
modifiers of signaling responses, or stromal and immune regulators residing in the tumor-specific
microenvironment. In addition, disease etiology can be influenced by niche-specific stem or
progenitor cell functions (Leeman et al., 2014). In the murine lung, multiple stem/progenitor cell
types have been identified based on their capacities to self-renew and/or differentiate following lung
injury, and include Krt5+/p63+ tracheal basal cells in the proximal airways, CC10+ Clara cells and
dual CC10+/SPC+ bronchioalveolar stem cells (BASCs) in the distal airways and SPC+ alveolar type
2  (AT2)  cells  in  the  air  spaces  (Asselin-Labat  and  Filby,  2012).  However,  the  relative  roles  of
progenitor cells in establishing potential histotype-specific tumor microenvironments remain poorly
understood.
Clinically, non-small cell lung cancer (NSCLC) accounts for around 85% of total lung cancers, with
adenocarcinoma (AC; 40%) and squamous cell carcinoma (SCC; 30%) representing the major sub-
histotypes (Travis et al., 2013). Lesions containing both AC and SCC features are classified as
adenosquamous carcinoma (ASC; 0.4-4%), a rare disease with poor prognosis (Nakagawa et al.,
2003). NSCLC subtypes can be enriched for certain genetic alterations: activating mutations in
EGFR, KRAS or loss of function mutations in serine/threonine kinase 11 (STK11,  also  known  as
LKB1) are common for AC and ASC, while loss of function mutations in TP53, PTEN, or SOX2
amplification are common for SCC (Gridelli et al., 2015). KRAS mutation concurrent with loss of
LKB1 is detected in around 30% of NSCLC, and represents a more aggressive metastasis-prone
NSCLC type recapitulated by the preclinical KrasG12D/+;Lkb1fl/fl (Kras;Lkb1) model (Calles et al.,
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2015; Ji et al., 2007). This highlights the need for deeper understanding of this genetic subtype of
lung cancers.
Various genetically engineered mouse models (GEMMs) of NSCLC, utilizing conditional genetic
or viral induction, have been used to address the relative contributions of genetic drivers and cells-
of-origin to the generation of histopathological diversity and proliferative phenotypes (Leeman et
al., 2014). Specifically, expression of oncogenic Kras with or without additional loss of the Trp53
(p53) tumor suppressor drives transformation of CC10+ cells in the terminal bronchioles,
bronchioalveolar duct junctions (BADJ) including dual CC10+/SPC+ BASCs (Kim et al., 2005; Xu
et al., 2012), as well as of SPC+ AT2 cells (Sutherland et al., 2014). Interestingly, CC10+ and SPC+
progenitors appear to distinctly contribute to AC tumorigenesis, evidenced by differential Kras- or
Kras;p53-induced histopathology spectra (Lin et al., 2012; Sutherland et al., 2014). In addition,
KrasG12V yields malignant AC mostly from SPC+ progenitors, whereas CC10+ cells develop more
benign lesions requiring an adenoviral inflammatory response (Mainardi et al., 2014). Thus, CC10+
Clara cells or BASCs appear to show partial resistance to malignant transformation by oncogenic
Kras, possibly due to differential Notch activity (Xu et al., 2014b).
While progenitor-specific etiologies of lung ACs are well described, this is less clear for ASC and
SCC histotypes. Airway basal cells have been proposed to act as SCC progenitors following loss of
Pten with Tgfbr2 or Lkb1 (Malkoski et al., 2014; Xu et al., 2014a). Recent studies have further
shown that AC derived from SPC+ cells can transdifferentiate into SCCs via an intermediate ASC
stage (Han et al., 2014; Li et al., 2015). Among NSCLC GEMMs, Kras;Lkb1 mice infected with
Ad5-CMV-Cre uniquely produce the full spectrum of histotypes, namely AC, SCC, ASC and large
cell carcinomas (Ji et al., 2007). This prompted us to employ CC10+ and SPC+ progenitor cell-
restricted adeno-Cre viruses previously used to identify cells-of-origin in lung GEMMs (Sutherland
et al., 2011), to dissect progenitor cell roles in establishing NSCLC phenotypic and
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microenvironmental heterogeneity in conditional Kras;Lkb1 mice. Our results show that CC10+ and
SPC+ progenitor cells differentially contribute to histotype diversity, and that CC10+-derived
tumors are more proliferative. Furthermore, we establish CC10+ cells as the predominant
progenitors of the ASC histotype, and establish that ASCs exhibit a unique histotype-specific
immunosuppressive microenvironment conducive for tumorigenesis.
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Results
Cell-of-origin defines survival of mice following oncogenic Kras expression and loss of Lkb1
To investigate the relative contribution of lung progenitors in determining disease progression and
histopathology in the Kras;Lkb1 GEMM, mice were intranasally infected with 1x107 plaque
forming units (pfu) or 2.5x109 pfu of Ad5-CC10-Cre virus or Ad5-SPC-Cre virus, respectively.
Titers were set based on their ability to achieve comparable infection rates using mT/mG Cre-
reporter mice (Muzumdar et al., 2007), as distal airway-located SPC+ AT2 cells are not targeted as
readily. Lungs of fluorescent Cre-reporter Kras;Lkb1;Rosa26mT/mG mice were examined at 2-4 wk
post infection, and accurate alveolar and bronchiolar mGFP labeling following Ad5-SPC-Cre or
Ad5-CC10-Cre infection was detected, respectively (Fig. S1A). Similar to previous data
(Sutherland et al., 2014), BADJ areas were readily targeted by Ad5-CC10-Cre, which was not
observed with Ad5-SPC-Cre; no alveolar cells were targeted by Ad5-CC10-Cre. We next followed
cohorts for late-stage tumor formation and euthanized mice when moribund. Tumors from Ad5-
CC10-Cre and Ad5-SPC-Cre infection showed loss of LKB1 expression, confirming dual gene
recombination (Fig. S1B). Kaplan-Meier survival analysis showed that mice infected with Ad5-
CC10-Cre had a shorter latency compared with Ad5-SPC-Cre (median survival 79 vs 120 days; Fig.
1A), suggesting that tumors initiated from CC10+ progenitor cells developed faster and/or more
aggressive lung disease.
Cell-of-origin defines the Kras;Lkb1-driven histopathology spectrum
Next, histopathological analyses of lesions formed in the full set of lung lobes from moribund
Kras;Lkb1 mice were performed. We hereto adhered to the IASLC/ATS/ERS NSCLC classification
system (Travis et al., 2011), guided by an expert lung pathologist (Fig. 1B). Two major histotypes
were detected, namely (1) ASCs which contain an inner AC core expressing the NKX2-1 AC
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biomarker surrounded by an outer squamous region co-expressing the p63 squamous biomarker and
NKX2-1, and (2) ACs with invasive characteristics conferring loss of the alveolar structure. ASCs
were predominantly detected in the Ad5-CC10-Cre cohort (5/5 mice, 20 tumors total) when
compared to the Ad5-SPC-Cre cohort (1/5 mice, 3 tumors total) (Fig. 1C & S1C). All ASCs
expressed the cytokeratin 5 (KRT5) squamous cell marker, but no staining for the nuclear SOX2
SCC marker was detected (Fig. S1D).
Both Ad5-CC10-Cre and Ad5-SPC-Cre induced invasive ACs, comprised of well or moderately
differentiated lesions, and invasive ACs were accompanied with pre-invasive adenocarcinoma in
situ (AIS). Deeper analysis of moderately differentiated invasive ACs based on growth pattern
revealed a spectrum of three AC subtypes, namely pure mucinous AC, papillary AC, and acinar
AC. Tumors with a lepidic growth pattern at the lesion border, but otherwise invasive, were
considered invasive AC (Fig. S1E). Of these five lesion types, pure mucinous and acinar ACs were
uniquely detected following Ad5-CC10-Cre infection (Fig. 1B & 1C). The number of cells positive
for the AC biomarker NKX2-1, a differentiation marker frequently lost during invasive progression,
was highest  in invasive ACs with or without papillary growth, whereas mucinous and acinar ACs
uniquely induced by Ad5-CC10-Cre showed less NKX2-1 positive cells (Fig. 1B). The majority of
invasive AC subtypes were negative for p63 (Fig. 1B), although few Ad5-CC10-Cre-induced
papillary and mucinous ACs showed sporadic p63 staining (Fig. S1F). The latter resembles clinical
ACs,  where  30%  of  lesions  show  some  p63  expression,  yet  are  classified  as  AC  based  on
morphological features (Au et al., 2004).
Inspection of Kras;Lkb1 lesions during early-stage tumorigenesis showed that both viruses induced
detectable lesions at six wk post infection (Fig. S1G). At this stage, Ad5-CC10-Cre induced NKX2-
1 positive luminal papillary hyperplasias of epithelial cells in the terminal bronchioles, with sparse
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staining for p63. Ad5-SPC-Cre-induced lesions at 6 wk were NKX2-1 positive pre-invasive AIS
located in the alveoli. At nine wk post infection, Ad5-CC10-Cre lesions consisted of AIS, invasive
AC, papillary AC, mucinous AC and ASC similar to the histopathology types detected in moribund
mice. At this time point we observed SCC in one of four mice (Fig. S1G), while no SCC was seen
at later stages. Lesions at nine wk following Ad5-SPC-Cre infections were invasive or papillary
ACs and lacked squamous features altogether. Taken together, expression of oncogenic Kras with
Lkb1 loss elicited a progenitor cell-specific difference in histopathology spectrum formation;
CC10+-driven lesions showed a wider spectrum of AC histotypes to include pure mucinous and
acinar AC, and were predominantly of the adenosquamous histotype, while SPC+-driven tumors
were primarily ACs.
CC10+-derived lesions are more proliferative and often less differentiated
To investigate histotype-specific proliferation rates, percentages of Ki67 positive nuclei across all
lesions were quantified at the end stage. This showed that Ad5-CC10-Cre-induced lesions exhibited
increased proliferation rates compared with Ad5-SPC-Cre infections, and that the squamous regions
of ASCs were more proliferative than the AC regions (Fig. 1D & S2A). We further analysed
expression of the high mobility group AT-hook 2 (HMGA2) transcription factor commonly
expressed in more poorly differentiated and invasive tumors (Snyder et al., 2013; Sutherland et al.,
2014; Winslow et al., 2011). Homogeneous expression of HMGA2 in ASCs was seen, whereas all
other histopathologies had negative to low expression (Fig. S2B). Furthermore, macroscopically all
ASCs were much bigger in size, ranging from 20-30 mm2 compared to smaller than 3 mm2 lesions
for all other histotypes (Fig. 1E). The shorter survival of Ad5-CC10-Cre infected mice thus
correlated with an increased propensity for progression of highly proliferative and larger ASC
tumors.
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Since the molecular basis and etiology of AC subtypes is thus far unknown, we decided to more
deeply study the mucinous ACs, a subtype of human lung cancer here uniquely detected upon Ad5-
CC10-Cre infection. First, mucin production was confirmed with periodic acid Schiff’s (PAS)
staining (Fig. S2C). Consistent with the finding that haploinsufficiency of NKX2-1 cooperates with
KrasG12D in mucinous AC progression (Maeda et al., 2012; Snyder et al., 2013), we further
observed reduced expression of NKX2-1 in PAS positive mucinous tumors compared to well-
differentiated papillary ACs (Fig. 1F, 1G, S2D & S2E). PAS positivity was also detected in the AC
regions of ASCs, bronchiolar luminal papillary hyperplasias, and in some of the invasive ACs (Fig.
S2C & S2F). This suggests that progression to mucinous AC may involve bronchiolar luminal
papillary hyperplasias or invasive AC as an intermediate state. Taken together, CC10+ progenitor
cells have the unique ability to give rise to advanced AC with mucinous differentiation.
Kras;Lkb1 tumors show histotype-specific gene expression signatures
To gain insights in histotype-specific molecular heterogeneities, we compared RNA expression
profiles of Ad5-CC10-Cre-derived ASCs and Ad5-SPC-Cre-derived papillary ACs, representing the
predominant progenitor-specific Kras;Lkb1 histotypes at the end stage of the disease progression
(Fig. S3A). Tumor histopathology was confirmed by expression of p63 protein specifically in ASCs
(Fig. S3B). Unsupervised hierarchical clustering using adjusted p value <0,01 LogFC>1 as a cut-off
revealed 340 differentially expressed genes showing distinct clustering of ASC and papillary AC
tumors (Fig. 2A). We next asked how these gene signatures related to previously published
histotype-specific gene signatures. Since no human ASC gene signatures are available, we instead
utilized SCC vs AC comparative gene expression data. These were comprised of a recently
described comparison of SCC elicited by conditional Lkb1 and Pten loss to KrasG12D/+-derived AC
tumors (Xu et al., 2014a), and a human SCC vs AC comparative gene expression study (Kuner et
al., 2009). Using a cut-off value of p<0,01 LogFC>1, we identified 29 and 11 commonly
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upregulated or downregulated genes, respectively (Fig 2B & Table S1). SCC-enriched genes
encompassed known human SCC biomarkers transformation related protein 63 (Trp63) and
multiple basal cytokeratins (Krt) (Fig. 2C). Interestingly, the recently described AC biomarker
napsin A (Napsa), a pepsin family aspartic proteinase (Turner et al., 2012), was found enriched in
our murine ACs.
We further compared our dataset to untransformed murine airway basal cell expression profiles, to
determine if basal or epithelial signatures contribute to ASC (Rock et al., 2009). This identified 108
genes commonly enriched in Ad5-CC10-Cre-derived ASC and airway basal cells (Fig S3C & Table
S1). In addition to known stratified squamous epithelial marker genes Trp63, basonuclin (Bnc1),
stratifin (Sfn) and cytokeratins, we found common enrichment of pro-inflammatory cytokine
interleukin 1  (Il1b) and its type II interleukin 1 receptor (Il1r2). As expected, the AC biomarker
SPC was commonly downregulated in airway basal cells and ASC. Finally, our dataset was
compared with published ASC gene expression signatures from the Kras;Lkb1 GEMMs  (Ji et al.,
2007), showing 23 commonly enriched genes (Fig. S3C & Table S1), including SCC signature
genes such as Trp63 and cytokeratins. Collectively, our results show that even though CC10+ lung
progenitor cell-derived ASCs display features of AC at the histological level, they exhibit SCC
histotype-specific gene signatures.
Histotype-specific expression of immune-related genes
Interestingly, analysis of Kras;Lkb1 histotype-specific gene signatures by Ingenuity Pathway
Analysis (IPA) revealed several immune-related canonical pathways, implying differences in
immune-related functions (Fig. 3A). We thus asked if this apparent histotype-specific difference in
immune-related signatures might exist independently of the genetic drivers. Indeed, by comparing
RNA  expression  profiles  of Kras;p53 Ad5-CC10-Cre- and Ad5-SPC-Cre-derived ACs to
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Kras;Lkb1 expression data, we found that selected cytokine, chemokine and antigen presentation
pathway genes showed histopathology-dependent expression differences (Fig. 3B). Pro-
inflammatory cytokine Il1b and the arginase 1 enzyme gene (Arg1), a key mediator of T cell
immunosuppression (Munder et al., 2006), were specifically enriched in ASCs. ASCs further
showed  downregulation  of  class  II  (H2-DMa, H2-Ab1, H2-DMb1) major histocompatibility
complex (MHC) genes, and  class  II  MHC  associated  gene Cd74 as well as the lymphocyte and
monocyte chemoattractant chemokines Ccl17, Ccl6, and the chemokine Cxcl15. Notable exceptions
were class I (H2-M2, H2-D1) MHC genes, which expression was lower in Kras;Lkb1 Ad5-CC10-
Cre-derived ASCs when compared to Kras;Lkb1 Ad5-SPC-Cre-derived papillary ACs but showed
variable expression in Kras;p53 ACs. Cxcl5, a downstream chemokine target of Il1b, showed
elevated levels in both Kras;Lkb1 ASCs and Kras;p53 ACs, suggesting a potential association with
tumor grade rather than histopathology. Quantitative real-time PCR (qPCR) analysis on a select set
of inflammatory genes confirmed increased Il1b and Arg1 expression in Kras;Lkb1 ASC histotype
tumors and variable expression of class I (H2-M2, H2-D1) MHC genes in ACs (Fig. 3C). Finally, to
assess whether the cell-of-origin has an effect on histotype-specific expression of immune-related
genes, we included in the validation panel also a rare Ad5-CC10-Cre-derived papillary AC and two
rare Ad5-SPC-Cre-derived Kras;Lkb1 ASCs. Validation by qPCR also in this set confirmed the
ASC histotype-specific expression of Il1b and Arg1, as well as decreased MHC gene expression
(Fig. S3D). In summary, our data indicates that immune-related genes are expressed in a histotype-
specific manner, independent of the driver genotype, cell-of-origin, or potential adenovirus-
associated inflammatory response.
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ASC histotype-specific recruitment of Gr-1+CD11b+ myeloid derived suppressor cells
(MDSCs)
Tumor tissue-expressed interleukin 1  (encoded by Il1b) has been shown to activate and mobilize
MDSCs, a heterogeneous population of activated immature myeloid cells that mediate
immunosuppression among others by expression of arginase 1, an enzyme responsible for depletion
of extracellular L-arginine required for T cell proliferation (Coffelt et al., 2015; Monu and Frey,
2012; Raber et al., 2012; Tu et al., 2008). Since we identified ASC-specific expression of both Il1b
and Arg1, we next studied Kras;Lkb1 tumor histotype-specific immune cell infiltration by
immunostaining. This confirmed the enrichment of Gr-1+ and CD11b+ cells, concomitant with a
reduced number of CD3+ T cells specifically in ASCs compared to papillary ACs (Fig. 4A, 4B &
S3E). Flow cytometric analysis identified MDSC cell populations by virtue of double Gr-1 and
CD11b staining, and further verified the enrichment of Gr-1+CD11b+ MDSCs in multiple ASC
tumors (Fig. 4C & 4D). Interestingly, although spleen-derived Ly-6ChiCD11b+ monocytic and Ly-
6GhiCD11b+ granulocytic cells have been shown to promote tumorigenesis of Kras;p53 ACs
(Cortez-Retamozo et al., 2012), our Kras;p53 tumor analysis showed low yet highly variable
amounts of Gr-1+CD11b+ cells  (Fig.  S3F  &  G).  This  suggests  that  MDSC  infiltration  in  the
Kras;p53 model could be dependent on tumor differentiation status. Taken together, we provide
evidence that Ad5-CC10-Cre-derived Kras;Lkb1 ASC tumors exhibit an immunosuppressive
microenvironment and, importantly, this appears to be a histotype-specific phenomenon.
13
Discussion
Until now the relative roles of progenitor cells in establishing potential histotype-specific tumor
microenvironments remain poorly understood. We show here that CC10+ and SPC+ progenitor cells
differentially contribute to histotype diversity, with CC10+ cells being the predominant progenitor
of the ASC histotype. Furthermore, we show that CC10+-derived tumors are more proliferative and
that ASCs create an immune suppressive microenvironment conducive for tumorigenesis (Fig. 4E).
Interestingly, similar to our observations, human ASCs often contain PAS positive AC regions
(Kanazawa et al., 2000) indicating recapitulation of human ASC features in our Kras;Lkb1 model.
Clinically, AC is the most common lung cancer subtype, further sub-classified as pre-invasive,
minimally invasive, and invasive AC (Travis et al., 2011). We here find that Kras;Lkb1 progenitors
have a capacity to generate three subtypes of invasive AC, namely papillary, acinar and mucinous
AC, thus closely resembling the mixed histotype spectrum typical of human disease. Importantly,
mucinous and acinar ACs are exclusively initiated from the CC10+ progenitors, implying unique
niche/stem cell-dependent contributions to histotype diversity. Phenotypic diversity could hence be
causally linked to targeting of functionally distinct, albeit CC10 expressing, progenitors lining the
lung epithelium. One such progenitors could be airway goblet cells co-expressing mucin and CC10,
located near the terminal bronchioles (Boers et al., 1999), as we observe many PAS positive cells in
early bronchiolar luminal papillary hyperplasias. Mucinous AC may thus arise from a secretory cell
conferring dual goblet and Clara cell features. In line with our observations in Kras;Lkb1 ASCs, a
recent study detected mucin-encoding Muc5b also in CC10-Cre induced Pten;Smad4 ASCs (Liu et
al., 2015). Importantly, this is the first study addressing progenitor-specific histotype diversity in
the Kras;Lkb1 GEMM, revealing a previously underappreciated capacity to model human ACs,
where LKB1 mutation is enriched across the spectrum of AC (13%) and adenosquamous NSCLC
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(22%) (Koivunen et al., 2008). Our data hence warrants deeper dissection of progenitor cell
subtypes contributing to histotype diversity, possibly by using bimodal promoters.
We show novel evidence for a clear propensity of bronchiolar CC10+ progenitors to form
adenosquamous lesions, with all Ad5-CC10-Cre treated animals developing ASC, while SPC+
progenitors gave rise to ASCs at a low incidence of one in five mice. These rare ASCs may
transdifferentiate from papillary ACs, as reported earlier (Li et al., 2015). Alternatively, this may
reflect Ad5-SPC-Cre infection of rare SPC+ cells around the BADJ area. Interestingly we observed
rare SCC among the invasive AC and ASC at nine wk following Ad5-CC10-Cre infection, whereas
at later stages no pure SCC lesions were detected. This stands in stark contrast to previous studies
describing transdifferentiation of AC lesions to SCC via an intermediate ASC stage in the identical
Kras;Lkb1 GEMM (Han et al., 2014). The same group recently showed Ad5-SPC-Cre-induced SCC
and ASC at respective incidences of 40% and 60% (Li et al., 2015). One factor contributing to these
differences could be the appreciated influence of mouse genetic background on tumor incidence and
histotype spectrum formation. Future lineage-tracing studies could confirm whether ASCs
transdifferentiate from a specific precursor histotype lesion, and further if SPC+ BADJ cells and/or
BASCs act as a cell-of-origin for ASC.
Comparative gene expression analysis displayed that Kras;Lkb1 ASCs show characters of murine
and human SCCs. Furthermore, the analysis of Kras;Lkb1 and Kras;p53 tumor histotype specific
expression profiles revealed differential immune-related gene signatures, which in Kras;Lkb1 ASCs
were associated with recruitment of MDSCs and concomitant low T cell numbers, while ACs
expressed chemoattractants and showed higher yet variable T cell infiltration. Furthermore, ASCs
may escape tumor antigen presentation and hence T cell-mediated toxicity due to decreased Class
Ia/b MHC gene expression. We thus provide evidence that lung histotype-specific pathogenesis and
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disease progression are closely intertwined with immune modulation. Some ASC-specific immune
modulatory features may be shared with SCC tumors, which showed a partial immune signature
overlap (Table S1). Indeed, MDSC recruitment has been reported in SCCs of the Lkb1;Pten GEMM
(Xu et al., 2014a). Furthermore, data from a recent human lung cancer immune cell profiling
suggests higher infiltration of neutrophils, possibly representing a subpopulation of MDSCs, in
ASCs and SCCs when compared to papillary ACs (Banat et al., 2015). This conceivably indicates
that the identified murine histotype-specific immunosuppressive microenvironment translates to
human disease. However, while Lkb1;Pten SCC tumors express the PD-L1 checkpoint molecule,
we found no increased expression of PD-L1 in Kras;Lkb1 ASCs or papillary ACs compared with
normal lung epithelium (data not shown). Tumor-specific mechanisms of immune regulation may
thus vary depending on tumor model or histotype. Outstanding questions are how such functional
heterogeneity is tied with expression of the Il1b cytokine, already expressed at baseline in
untransformed tracheal cells (Rock et al., 2009), and how such heterogeneity may relate to human
disease. Interestingly, polymorphisms in IL1B have been associated with increased lung cancer risk,
in particular SCC (Landvik et al., 2009). Furthermore, loss of function mutations in the HLA class I
MHC gene have been reported for human lung SCC (Cancer Genome Atlas Research, 2012),
indicating that immunosuppression may be a feature of human squamous lesions.
In conclusion, our study provides important insights in the etiology of lung cancer histotype
diversity, implying that the niche and cell-of-origin biology crucially define histopathology-specific
tumorigenesis and formation of an immune microenvironment. Our data further imply that
progenitor cell-specific tumor phenotypes are dominant over their driver genotype as Kras;Lkb1
SPC+ progenitors drive AC features similar to Kras;p53. Such phenotypic dominance possibly
relates to clinical evidence for clonal heterogeneity in the genetic makeup of tumor cells in
histopathologically indistinct lesions (Heim et al., 2014). Future approaches will need to address
16
which molecular aspects of CC10+ and SPC+ progenitors cooperate with Kras;Lkb1 drivers  to
define histopathology diversity. It will further be interesting to find how this GEMM can be used
for development of immune modulatory targets to achieve better control of ASC, an aggressive
subtype of NSCLC (Nakagawa et al., 2003). Specifically, strategies to target pro-tumorigenic
MDSC functions are under investigation, and re-priming of the anti-tumor T cell response by
epigenetic modifiers inducing Class I MHC expression could be considered. Finally, our data
suggest that the profiling of patient tumor histotype-specific functions and immune




Animal studies followed guidelines from the Finnish National Board of Animal Experimentation,
and were approved by the Experimental Animal Committee of the University of Helsinki and the
State Provincial Office of Southern Finland (Licence number ESAVI-2010-04855/Ym-23). Mice
harboring a conditional allele of mutant Kras (LSL-KrasG12D/+;  (Jackson  et  al.,  2001)  or  loss  of
function Trp53 allele (p53fl/fl; (Marino et al., 2000) were purchased from The Jackson Laboratory.
Conditional loss of function Stk11/Lkb1 mice (Lkb1fl/fl; (Bardeesy et al., 2002) were received
from  Ron  DePinho  (MD  Anderson,  Houston,  USA).  Further  details  are  explained  in  the
Supplemental Information.
Survival analysis, tissue preparation and histopathology analysis
Mice were sacrificed when showing symptoms of labored breathing and loss of weight. Kaplan-
Meier survival curves were created with GraphPad Prism (GraphPad Software, Inc. San Diego,
USA). Histopathology analysis was performed for whole slide scans of H&E-stained paraffin
sections. Details are explained in the Supplemental Information.
Immunohistochemistry
Immunistochemistry was performed on 4% formaldehyde fixed lungs and paraffin embedded lungs
using  standard  protocols.  Quantitation  of  whole  slide  scans  acquired  from  PAS  or
immunohistological stained sections was performed using the Tissue StudioTM image analysis
solution of the Definiens Developer XD 64 2.1 software (Definiens, Munich, Germany). Details are
explained in the Supplemental Information.
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Microarray gene expression profiling and quantitative PCR analysis
Total  RNA  from  snap-frozen  tumors  was  extracted  using  the  NucleoSpin  RNA  II  kit
(MACHEREY-NAGEL,  Duren,  Germany).  Expression  profiling  was  done  with  Illumina  Mouse
WT-6 version 2 expression arrays (Illumina, San Diego, CA, USA). Microarray data is made
available by GEO, accession no. GSE69552
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=yjafiucynxyftmj&acc=GSE69552).
Quantitative PCR was performed for total mRNA extracted from snap-frozen tissue using iQ™
SYBR® Green Supermix (Bio-Rad, Hercules, USA). Further details are explained in the
Supplemental Information.
Comparative gene expression analysis
Differentially expressed genes were compared to publicly available gene expression data sets made
available via the NCBI-GEO (http://www.ncbi.nlm.nih.gov/geo/) database. Details are explained in
the Supplemental Information.
Flow cytometry analysis
Tumors were dissected from moribund mice and single-cell suspensions were incubated with rat
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Figure Legends
Figure 1. Cell-of-origin defines the histopathology spectrum and associated survival
differences of Kras;Lkb1-driven lung tumors. (A) Kaplan-Meier survival curves of Kras;Lkb1
mice, showing median survival of 79 days for Ad5-CC10-Cre (1x107 pfu, black symbols) vs 120
days for Ad5-SPC-Cre infections (2.5x109 pfu, white symbols). Significance value p=0,0125 with a
Gehan-Breslow-Wilcoxon Test.  (B) Histopathology analysis for tumors harvested from moribund
Ad5-CC10-Cre and Ad5-SPC-Cre mice. Arrows indicate areas depicted in higher magnification
IHC analyses with indicated antibodies. (C) Quantification of histopathology-specific lesions from
n=5 animals per virus, showing ASC as the predominant histopathology for Ad5-CC10-Cre, and
invasive AC for Ad5-SPC-Cre treated mice. (D) Histopathology-specific quantification of Ki67
positive nuclei in lesions from animals analyzed in (C). (E) Lesion size quantification of animals
analyzed in (C) showing that ASC tumors are the largest lesions. (F) Quantification of PAS positive
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tumor areas for lung lesions infected with Ad5-CC10-Cre virus (n=4). (G) Quantification of NKX2-
1 positive nuclei on samples analyzed in (F). Error bars represent mean ± StDev. Student’s t test p
value is *p< 0.5, ***p< 0.001. Scale bars: 2000 μM for lung lobes, 50 μM for magnified images.
Figure 2. Comparative gene expression analysis indicates squamous expression profile in Ad5-
CC10-Cre derived ASC tumors. (A) Unsupervised hierarchical clustering of Ad5-CC10-Cre-
derived ASC and Ad5-SPC-Cre-derived papillary AC tumors with p<0,01 LogFC>1 as a cut-off,
showing distinct histopathology-specific gene expression signatures. (B) Venn diagram illustrating
comparative expression analyses of Ad5-CC10-Cre-derived Kras;Lkb1 ASC vs Ad5-SPC-Cre-
derived Kras;Lkb1 papillary AC, Lkb1;Pten SCC vs Kras AC (Xu et al. 2014, GSE54353) and
human SCC vs AC tumors (Kuner et al., GSE10245). Upregulated and downregulated genes are in
red and green fonts, respectively. (C) Common up- and downregulated genes of datasets shown in
figure (B) represented as a heatmap of gene expression values from Kras;Lkb1 ASC vs papillary
AC datasets. Insets in (A) and (C) show the distribution of samples within scaled expression values.
Figure 3. Distinct immune-related gene expression signatures suggest ASC vs papillary AC
histopathology-dependent tumor immune microenvironments. (A) IPA canonical pathway
analysis shows enrichment of several immune-related genes in Kras;Lkb1 Ad5-CC10-Cre-derived
ASCs compared with Ad5-SPC-Cre-derived papillary ACs. A –log(p-value) greater than 2 is used
as a cut-off. (B) Heatmap representing immune-related genes differentially expressed in Kras;Lkb1
(KL) Ad5-CC10-Cre-derived ASC and Ad5-SPC-Cre-derived papillary AC, and Kras;p53 (KP)
Ad5-CC10-Cre-derived and Ad5-SPC-Cre-derived AC tumors with p<0,01 LogFC>1 as a cut-off.
The inset shows the distribution of samples within scaled expression values. (C) qPCR validation of
Il-1 , Arg1, H2-M2 and H2-D1 gene expression in ASC (n=13 tumors) and papillary AC (PAC,
n=8 tumors) from Kras;Lkb1, and Ad5-CC10-Cre-derived (n=4 tumors) and Ad5-SPC-Cre-derived
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(n=7 tumors) PACs from Kras;p53 genotypes. Gene expression was normalized against the
housekeeping Rpl19 mRNA.  Error  bars  represent  mean  ±  StDev.  Student’s  t  test  p  value  is
**p<0.01, ***p<0.001.
Figure 4. The presence of MDSCs in ASC tumors reveals histopathology-specific tumor
immune microenvironments. (A) Representative immunohistochemical stainings for Gr-1,
CD11b, and CD3 in Ad5-CC10-Cre-derived ASC and Ad5-SPC-Cre-derived papillary AC (PAC)
from Kras;Lkb1 mice. (B) Quantification of immunostainings for Gr-1, CD11b and CD3 (n=5
mice). (C) Representative flow cytometry plots showing Gr-1 and CD11b expression in Ad5-CC10-
Cre-derived ASC and Ad5-SPC-Cre-derived papillary AC from Kras;Lkb1 mice. Plots are gated for
live cells. Percentages of Gr-1+CD11b+ cells are presented in the upper right quadrant of the plot.
(D) Quantification of Gr-1+CD11b+ MDSCs in Ad5-CC10-Cre-derived ASC (n=4) and Ad5-SPC-
Cre-derived papillary AC (PAC, n=4) from Kras;Lkb1 mice assessed by flow cytometry. (E)
Schematic representation summarizing lung progenitor cell-specific lesion etiology following
expression of oncogenic Kras concomitant with loss of Lkb1 in CC10+ or SPC+ cells. Both CC10+
and SPC+ progenitors can give rise to invasive AC, AIS, papillary AC and ASC, with ASC most
prevalent for CC10+ cells. CC10+ cells uniquely give rise to pure mucinous and acinar AC. ASCs
exhibit an immunosuppressive microenvironment, showing MDSCs recruitment and decreased T
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Figure S1, related to Figure 1
Cell-of-origin defines histopathology spectrum in Kras;Lkb1 mice. (A) Representative images of
anti-GFP stained Ad5-CC10-Cre and Ad5-SPC-Cre infected Kras;Lkb1;Rosa26mT/mG mice at two and
four weeks post infection, respectively. The majority of GFP positive cells in Ad5-CC10-Cre infected
lungs were located in bronchiolar regions (arrows), occasionally at bronchioalveolar duct junctions
(arrowhead). GFP positive cells in Ad5-SPC-Cre virus infected lungs were mainly seen in the alveolar
region (arrows). Scale bars: 100 μm. (B) Representative images of anti-LKB1 stained Ad5-CC10-Cre-
and Ad5-SPC-Cre-infected Kras;Lkb1 and Kras;p53 lungs. All Kras;Lkb1 tumors were negative for
LKB1. Arrows indicate areas depicted in higher magnification. Scale bars: 2000 μM for lung lobes,
50 μM for magnified images. (C) Tumor lesion quantification. Representative image of H&E-stained
lung sections from Ad5-CC10-Cre infected Kras;Lkb1 mice, and corresponding pseudo-colored
image depicting tumor segmentation performed with Definiens software. PAC: Papillary AC, MAC:
Mucinous AC, IAC: in situ AC. (D) Representative IHC images of KRT5 and SOX2 for Ad5-CC10-
Cre-induced ASC tumors. All ASCs showed expression of KRT5, but lacked SOX2 expression. Scale
bars: 50 μm. (E) Representative images from H&E-stained lung sections from Ad5-CC10-Cre
infected Kras;Lkb1 mice showing invasive AC histopathology class. Scale bars: 100 μm. (F)
Representative images of anti-p63 stained Ad5-CC10-Cre ASC mucinous and papillary ACs, showing
rare p63 positive nuclei. Scale bars: 50 μm. (G) Time point analysis of Kras;Lkb1 mice infected with
Ad5-CC10-Cre and Ad5-SPC-Cre viruses. Representative images of H&E, anti-NKX2-1 and anti-p63
stained lungs show papillary hyperplasias of bronchiolar epithelial cells in Ad5-CC10-Cre-infected
lungs and adenocarcinoma in situ (AIS) lesions in Ad5-SPC-Cre infected lungs at six wk post
infection (n=2). At nine wk post infection pure squamous cell carcinoma (SCC) was detected in one
out of four mice in Ad5-CC10-Cre-infected lungs, and invasive AC or invasive papillary AC in Ad5-
SPC-Cre infected lungs (n=4). Arrows indicate areas depicted in higher magnification. Scale bars:
2000 μM for lung lobes, 50 μM for magnified images.
Figure S2, related to Figure 1
Cell-of-origin defines histopathology spectrum in Kras;Lkb1 mice. (A) Ki67 IHC quantification.
Representative image of anti-Ki67 stained lung sections from Ad5-CC10-Cre-infected Kras;Lkb1
mice, and the corresponding pseudo-colored images describing Ki67 positive (yellow) and negative
(blue) nuclear detection performed with Definiens. Scale bars: 50 μm. (B) Representative images of
anti-HMGA2 stained Ad5-CC10-Cre- and Ad5-SPC-Cre-induced Kras;Lkb1 tumors. All ASCs
showed homogenous staining for HMGA2, whereas all other histopathologies showed negative
staining or pockets of positive regions. Arrows indicate areas depicted in higher magnification. Scale
bars: 1000 μM for lung lobes, 50 μM for magnified images.  (C) Representative images of PAS and
NKX2-1 immunostaining of Ad5-CC10-Cre-derived lesions. Scale bars: 100 μm. (D) PAS staining
quantification. Representative image of lung sections from Ad5-CC10-Cre infected Kras;Lkb1 mice,
and corresponding pseudo-colored images showing PAS positive (yellow) and negative (purple) area
detection performed with Definiens. Scale bars: 50 μm. (E) NKX2-1 immunohistochemistry
quantification. Representative image of anti-NKX2-1 stained lung sections from Ad5-CC10-Cre-
infected Kras;Lkb1 mice, and corresponding pseudo-colored image describing NKX2-1 low (yellow),
NKX2-1 medium (orange), NKX2-1 high (dark brown) and negative (blue) nuclear detection
performed  with  Definiens.  Scale  bars:  50  μm.  (F)  Representative  images  of  PAS and  anti-NKX2-1
immunostaining of Ad5-CC10-Cre-derived bronchiolar hyperplasia. Scale bars: 100 μm.
Figure S3, related to Figure 2
KrasG12D/+;Lkb1fl/fl tumors exhibit histotype-specific gene expression signatures (A) Workflow
describing comparative gene expression analysis of ASC and papillary AC tumors from Kras;Lkb1
mice. (B) Western blot analysis of tumors selected for microarray profiling using anti-p63 and anti-ß-
actin antibodies. (C) Comparison of Kras;Lkb1 Ad5-CC10-Cre ASC vs Ad5-SPC-Cre papillary AC
differentially expressed genes with normal airway basal cells vs epithelial differentially expressed
genes (GSE15724) and Kras;Lkb1 Ad5-CMV-Cre  ASC  vs  AC  tumors  (GSE6135).  (D)  qPCR
validation of immune-related genes in Ad5-SPC-Cre-induced ASC tumors (n=2) and Ad5-CC10-Cre-
induced papillary AC (n=1). Gene expression was normalized against the housekeeping Rpl19
mRNA. Error  bars  represent  mean  ±  StDev.  (E) Gr-1 immunohistochemistry quantification.
Representative image of anti-Gr-1 stained lung sections from Ad5-CC10-Cre-infected Kras;Lkb1
mice, and the corresponding pseudo-colored image describing Gr-1 low (yellow), Gr-1 medium
(orange), Gr-1 high (dark brown) and negative (blue) nuclear detection performed with Definiens.
Tightened filtering was performed to exclude any false positive staining detection (grey nuclei).
Identical quantification settings were used for CD11b and CD3 stainings. Scale bars: 50 μm. (F)
Representative images of anti-Gr-1, anti-CD11b and anti-CD3 stained Ad5-CC10-Cre and Ad5-SPC-
Cre-induced Kras;p53 tumors. Scale bars: 50 μm. (G) Quantification of immunostainings for Gr-
1, CD11b and CD3 in Kras;p53 mice infected with Ad5-CC10-Cre (n=2) and Ad5-SPC-Cre
(n=2). Error bars represent mean ± StDev.
Table S1, related to Figure 2 and Figure S3.
List of commonly up- and downregulated genes from the comparative gene expression analysis
represented as log fold changes and p-values from the Kras;Lkb1 Ad5-CC10-Cre ASC vs Ad5-SPC-
Cre papillary AC comparison.
Supplemental Experimental Procedures
Mouse breeding and recombinant adenovirus administration
Kras mice were crossed with Lkb1fl/fl or p53fl/fl mice to generate Kras;Lkb1 or Kras;p53 mice
on a C57Bl/6J background. Kras;Lkb1 mice were crossed with Rosa26mT/mG Cre-reporter
mice (Muzumdar et al., 2007), resulting in mixed background cohorts
(C57Bl/6J;29X1/SvJ;ICR). Eight to ten wk old mice were intranasally or intratracheally
administered with 1-20x107 pfu of Ad5-CC10-Cre or 2.5-7.5x109 pfu of Ad5-SPC-Cre
viruses (Viral Vector Core Facility, University of Iowa, USA) under isofluorane anaesthesia.
Tissue preparation and histopathology analysis
Histopathology analysis was performed for H&E-stained paraffin sections. Whole slide scans
of stained tissue sections were acquired with a Pannoramic 250 3DHISTECH digital slide
scanner. Scans were assessed for lesion numbers and sizes using the Tissue studio image
analysis solution of Definiens Developer XD 64 2.1 software (Definiens, Munich, Germany).
Histopathology diagnoses were made by an expert pathologist.
Antibodies
The following antibodies were used for immunohistochemistry and immunoblotting.
Antibody Company Catalogue no. Antigen retrieval
LKB1 Cell Signaling
Technology
D60C5F10 10mM sodium citrate pH 6.0
p63 Abcam ab53039 10mM sodium citrate pH 6.0
NKX2-1 Abcam ab133638 10mM sodium citrate pH 6.0
Ki67 Thermo Fisher
scientific






10mM sodium citrate pH 6.0
Keratin 5 Abcam ab52635 10mM sodium citrate pH 6.0
Gr-1 E-Bioscience 14-5931 Trypsin
CD11b BioSB BSB6441 10mM sodium citrate pH 6.0
CD3 Abcam ab5690 10mM sodium citrate pH 6.0
SOX2 Santa Cruz
Biotechnology
sc-17320 10mM sodium citrate pH 6.0
-actin Sigma A1978
Immunohistochemistry and quantitation
For immunistochemistry, lungs were fixed overnight at room temperature in 4%
formaldehyde, embedded in paraffin, sectioned (5 μm) from two distinct regions representing
the surface and middle regions of the lungs. Sections were dehydrated and antigenic epitopes
were exposed using an optimized antigen retrieval method (see more details in the table for
used antibodies). Tissue sections were blocked with 1% BSA and 10% Normal Goat Serum
in  1x  PBS.  Primary  antibody  staining  was  overnight  at  4°C  (SOX2)  or  1h  at  ambient
temperature or (all others). Primary antibodies were detected using secondary antibody
BrightVision  poly-HRP  anti-rabbit  (IL  ImmunoLogic,  AD  Duiven,  the  Netherlands),  or
Peroxidase-Goat Anti-Rat IgG (H+L) (Invitrogen Corporation, Camarillo, CA) for 30 min at
ambient  temperature.  Detection  was  done  with  DAB  (Bright  DAB,  IL  ImmunoLogic,
Duiven, The Netherlands). Whole slide scans of immunohistologically stained lung sections
were acquired with a Pannoramic 250 3DHISTECH (3DHISTECH Kft., Budapest, Hungary)
digital slide scanner using a 20x objective. Scans were assessed for quantitation of PAS or
immunohistological stainings using the Tissue StudioTM image analysis solution of the
Definiens Developer XD 64 2.1 software (Definiens, Munich, Germany). Inflammatory
infiltrations were diagnosed by an expert pathologist.
Microarray gene expression  data analysis
Data analysis consisted of data pre-processing, quality analysis and detection of statistically
differentially expressed genes between different samples. All methods used were
implemented in the beadarray, limma, and BioMart packages of the Bioconductor Project.
The result sheets from GenomeStudio were loaded to R, normalized, log2-transformed and
background corrected. Additional gene information was extracted from Ensembl using
BioMart. Matching was done via Ensembl gene names.
Comparative gene expression analysis
Differentially expressed genes were compared to publicly available gene expression data sets
made available via the NCBI-GEO (http://www.ncbi.nlm.nih.gov/geo/) database.
Differentially expressed genes using a p<0,01 and LogFC>1 cut-off value from the following
studies were included in the analysis: GSE54352 (2), GSE15724 (3), GSE10245 (4) and
GSE6135 (5). Venn diagrams were generated using Venny 2.0.2
(http://bioinfogp.cnb.csic.es/tools/venny/). Heatmaps were generated using the R statistical
programming language heatmap function from the Heatplus Bioconductor package. R version
2.15.3 (http://www.r-project.org/) was used to visualize genes commonly upregulated across
data sets.
Microarray gene expression profiling and quantitative PCR analysis
For gene expression analyses, two tumors per tumor-bearing mouse were excised from the
lung lobes. Each tumor was divided into three parts; one each for RNA and protein isolation,
and one as a histology reference. Total RNA from snap-frozen tumors was extracted using
the NucleoSpin RNA II kit (MACHEREY-NAGEL, Duren, Germany). Expression profiling
was done with Illumina Mouse WT-6 version 2 expression arrays (Illumina, San Diego, CA,
USA). For the quantitative PCR analysis the total RNA isolated from snap-frozen tumors was
quantified  using  the  NanoDrop  1000  (Thermo  Fisher  Scientific  Inc.,  Waltham,  USA).   A
high-capacity cDNA reverse transcription kit (Life technologies, Waltham, USA) was used to
synthesize complementary DNA (cDNA). Triplicate reactions using iQ™ SYBR® Green
Supermix (Bio-Rad, Hercules, USA) were run and analyzed on a CFX384 TouchTM Real-
Time PCR Detection System (Bio-Rad, Hercules, USA), using relative quantitation against
the housekeeping Rpl19 mRNA. The following primers flanking exon-exon boundaries were
designed and verified for specific amplification: Il-1 , fwd
5’TGCCACCTTTTGACAGTGATGAGA3’ rev 5’CCTGGAAGGTCCACGGGAA3’;
Arginase1, fwd 5’TCGTGTACATTGGCTTGCGA3’ rev
5’GCCAATCCCCAGCTTGTCTA3’; H2-D1, fwd 5’CTGAAGAACGGGAACGCGAC3’
rev 5’TGTAAGAGTCAGTGGACGGAGG3’; H2-M2, fwd
5’GTGCCTTGGATGGAACAGAT3’; rev 5’CCAGTCATCCTTTGGATGGT3’; Rpl19 fwd
5’CGGGAATCCAAGAAGATTGA3’ rev 5’TTCAGCTTGTGGATGTGCTC3’. Cycles
started with three minutes denaturation at 95 °C, followed by 40 cycles of 15s at 95°C, and
1m at 60°C. A melting curve ranging from 57°C to 95°C was included in every analysis to
confirm specific amplification. For Arginase 1, an annealing temperature of 58°C was used.
Immunoblotting analysis
Protein lysates from snap-frozen tissues were prepared using a Precellys® tissue homogenizer
(Bertin technologies, France). Cell lysates were prepared in RIPA buffer and protein
concentrations were measured using a BCA kit. Protein samples (20 μg) were analyzed by
immunoblotting.
Flow cytometry analysis
Tumors were dissected from the lungs of moribund mice and single cell suspensions were
prepared by incubating the tumor tissue in HBSS containing 2mg/ml Collagenase 1A (Sigma
Aldrich,  USA) and 0,3 mg/ml Dispase (Life Technologies,  Thermo Fisher Scientific,  USA)
for 30 minutes at 37°C, after which the tissue was disrupted using the gentle MACS
Dissociator (Miltenyi Biotec, Germany) in DMEM medium containing 20mM Hepes and
5U/ml DNAse (Promega, USA). Single cell suspensions were stained using APC conjugated
Rat anti-Gr-1 (Biolegend, USA) and FITC conjugated Rat anti-CD11b (Biolegend, USA)
antibodies. The antibodies were incubated in HBSS/2%BSA for 30 minutes at 4°C at 1:25
dilution. Dead cells were stained with 1μg/ml Propidium Iodide (Sigma Aldrich, USA).
Analysis of the cells was performed using a BD Accuri flow cytometer, and data were
analyzed with the BD Accuri C6 software (Becton, Dickinson and Company, USA).
Statistical analysis
For the statistical analysis of we used Student’s t test (two-tailed and equal variance). A p-
value < 0.05 was considered significant. Error bars indicate SD.
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Supplementary Table 1, related to Figure 2 and Supplementary Figure 3.
List of commonly up- and downregulated genes from the comparative gene expression analysis represented
as log fold changes and p-values from the Kras;Lkb1 Ad5-CC10-Cre ASC vs Ad5-SPC-Cre papillary AC
comparison.
Ad5-CC10-Cre derived Kras;Lkb1 ASC vs Ad5-SPC-Cre derived Kras;Lkb1 papillary AC; Lkb1;Pten SCC vs Kras
AC (Xu et al. 2014, GSE54353); human SCC vs AC tumors (Kuner et al., GSE10245)
Gene LogFC P.Value Adj.P.Val
Krt6b 4,064895218 2,86E-09 1,90E-06
Krt6a 2,88010548 1,11E-07 2,03E-05
Zfp750 2,586819988 1,85E-08 5,70E-06
Calml3 2,508817568 8,84E-06 0,000434838
Krt15 1,98725044 2,75E-07 3,75E-05
Sgk1 1,235556478 2,48E-06 0,000180144
Fxyd3 1,21776195 0,000465713 0,007121127
Rapgefl1 1,023115374 9,46E-07 8,78E-05
Dsg3 1,013274283 0,000186607 0,003677196
Celsr2 1,009851937 2,39E-07 3,46E-05
Krt17 6,480742841 1,23E-09 1,21E-06
Krt5 4,741898945 2,46E-10 4,61E-07
Krt14 4,729042034 1,42E-05 0,000591751
Gpr87 3,750789294 2,96E-11 8,72E-08
Clca5 3,421039565 9,55E-08 1,82E-05
Lypd3 3,091228646 3,22E-05 0,001033619
Krt16 3,038105964 4,04E-09 2,29E-06
Pkp1 2,997180129 1,01E-05 0,000477906
Vsnl1 2,656167403 1,11E-08 4,77E-06
Trp63 2,572210067 6,06E-12 3,12E-08
Snai2 2,543222344 2,73E-09 1,88E-06
Efs 2,312028751 6,14E-08 1,33E-05
P2ry1 1,814915127 3,79E-08 8,99E-06
Dapl1 1,690803978 7,50E-10 9,10E-07
Trim29 1,655666154 0,00010719 0,002449449
Fscn1 1,556296265 4,20E-06 0,000259199
Hr 1,506296829 1,47E-07 2,49E-05
2610528A11Rik 1,087798271 0,000137464 0,002927555
Dgka 1,026082285 1,31E-07 2,25E-05
Plekhb1 -1,033836655 2,36E-05 0,000833556
Ptprm -1,084496704 1,67E-06 0,000132517
Ctsh -1,135088307 0,000222835 0,004173821
St3gal5 -1,16689992 0,000713279 0,009770334
Slc34a2 -1,229963288 0,000128328 0,002793128
Slc26a9 -1,24239973 5,47E-05 0,001512401
Ahcyl2 -1,361390926 3,54E-05 0,00110697
Lpcat1 -1,441100162 8,87E-05 0,002133149
Tspan8 -1,460808859 1,76E-05 0,000690221
Ppp1r9a -2,397095416 1,30E-05 0,000562926
Napsa -2,834033514 4,24E-07 5,15E-05
Ad5-CC10-Cre derived Kras;Lkb1 ASC vs Ad5-SPC-Cre derived Kras;Lkb1 papillary AC;Pten SCC vs Kras AC (Xu
et al. 2014, GSE54353)
Gene LogFC P.Value Adj.P.Val
Ppbp 4,301742649 1,99E-07 2,99E-05
Klk8 3,28244013 1,95E-08 5,91E-06
Ifitm1 3,163843669 8,39E-08 1,68E-05
Gp2 3,095473571 1,02E-05 0,000480819
Clic6 3,029312411 8,07E-08 1,65E-05
Ltf 3,0232633 4,34E-05 0,001261855
Gabrp 2,953742698 3,29E-09 2,06E-06
Tbx1 2,941031317 5,66E-07 6,17E-05
Otx1 2,834533016 1,34E-08 5,22E-06
Scgb3a1 2,761557199 2,39E-06 0,000175119
Aqp4 2,659834182 5,01E-05 0,001412095
Slitrk6 2,268185779 3,70E-08 8,95E-06
Tiam1 2,256112596 2,35E-09 1,88E-06
Ifitm6 2,225760594 5,12E-07 5,83E-05
Casp1 2,111535318 1,28E-07 2,24E-05
Cyp27a1 2,068398574 1,16E-08 4,77E-06
Wfdc3 2,046900637 0,000388975 0,006263711
Ifitm2 1,968165166 1,12E-05 0,000514802
Tmc5 1,936153678 6,52E-08 1,38E-05
Sox21 1,879990049 9,41992E-10 1,01988E-06
Mycl 1,836297296 1,30E-05 0,000562926
Cldn23 1,725283844 7,28E-06 0,0003763
Klk10 1,673587873 3,66E-06 0,000235662
2300002M23Rik 1,651265077 1,67E-07 2,72E-05
Sprr2g 1,597072081 7,65E-07 7,41E-05
Tmprss13 1,547035273 9,90E-10 1,02E-06
Cxcl5 1,517714154 1,23E-08 4,88E-06
Ecm1 1,449986118 0,000571094 0,008319006
Adamtsl4 1,434630129 5,09E-06 0,000297819
Irf7 1,377473649 1,05E-05 0,000489333
Clec2d 1,351667467 1,77E-05 0,000690221
Gsta3 1,304378526 0,000440771 0,006820704
Tspan33 1,205872993 9,13E-05 0,002183905
Fam46b 1,203360757 3,23E-06 0,000217193
Arhgef3 1,182057533 5,92E-07 6,32E-05
Lrrc26 1,177261765 0,000184909 0,003661204
Frrs1 1,149864462 7,39E-06 0,000379877
Slc39a6 1,141665357 2,42E-05 0,000838141
Wnt7b 1,100742247 0,000282215 0,004967559
Tfap2c 1,100684979 6,38E-06 0,000346721
Pof1b 1,057734366 1,25E-07 2,22E-05
Hsd17b2 1,043678599 0,000270183 0,004797763
Cyp2b10 1,031397057 0,000614385 0,008784004
Slc7a8 1,029435891 3,78E-05 0,001157115
Gsto1 1,028154614 1,44E-05 0,000595884
Mall 1,020838641 2,57E-06 0,000184608
Msantd3 1,015503827 3,83E-06 0,000243003
Krt6b 4,064895218 2,86E-09 1,90E-06
Krt6a 2,88010548 1,11E-07 2,03E-05
Zfp750 2,586819988 1,85E-08 5,70E-06
Calml3 2,508817568 8,84E-06 0,000434838
Krt15 1,98725044 2,75E-07 3,75E-05
Sgk1 1,235556478 2,48E-06 0,000180144
Fxyd3 1,21776195 0,000465713 0,007121127
Rapgefl1 1,023115374 9,46E-07 8,78E-05
Dsg3 1,013274283 0,000186607 0,003677196
Celsr2 1,009851937 2,39E-07 3,46E-05
Krt17 6,480742841 1,23E-09 1,21E-06
Krt5 4,741898945 2,46E-10 4,61E-07
Krt14 4,729042034 1,42E-05 0,000591751
Gpr87 3,750789294 2,96E-11 8,72E-08
Clca5 3,421039565 9,55E-08 1,82E-05
Lypd3 3,091228646 3,22E-05 0,001033619
Krt16 3,038105964 4,04E-09 2,29E-06
Pkp1 2,997180129 1,01E-05 0,000477906
Vsnl1 2,656167403 1,11E-08 4,77E-06
Trp63 2,572210067 6,06E-12 3,12E-08
Snai2 2,543222344 2,73E-09 1,88E-06
Efs 2,312028751 6,14E-08 1,33E-05
P2ry1 1,814915127 3,79E-08 8,99E-06
Dapl1 1,690803978 7,50E-10 9,10E-07
Trim29 1,655666154 0,00010719 0,002449449
Fscn1 1,556296265 4,20E-06 0,000259199
Hr 1,506296829 1,47E-07 2,49E-05
2610528A11Rik 1,087798271 0,000137464 0,002927555
Dgka 1,026082285 1,31E-07 2,25E-05
Col17a1 5,025445094 8,31E-13 1,71E-08
Tmprss11g 3,612988155 1,40E-06 0,00011442
Aqp3 3,049499899 4,37E-06 0,000267141
Upk3bl 2,3645967 1,06E-05 0,000491014
Cwh43 2,255775512 3,39E-07 4,46E-05
Tpbg 2,213087982 5,11E-07 5,83E-05
Wnt10a 2,202487002 9,04E-07 8,53E-05
Lrig3 2,133480927 1,86E-09 1,59E-06
Htra1 1,9742672 5,41E-06 0,000309994
Rgs12 1,768790397 2,69E-07 3,74E-05
Evpl 1,664523823 3,18E-05 0,001024405
Apcdd1 1,564060909 3,64E-07 4,66E-05
Fbln1 1,41345374 1,76E-07 2,82E-05
Barx2 1,405121172 2,69E-07 3,74E-05
Ngfr 1,372386307 1,22E-08 4,88E-06
Cdh3 1,36896438 9,15E-09 4,15E-06
Ccdc3 1,348661482 2,38E-05 0,000836316
Kif21a 1,316708116 2,42E-05 0,000838141
Fam57a 1,305612112 3,27E-06 0,000218401
Plch2 1,298860294 6,83E-09 3,43E-06
Wnt4 1,240429909 3,14E-10 4,97E-07
Itgb4 1,225887923 1,26776E-05 0,000555194
Niacr1 1,223207012 8,65E-08 1,69E-05
Psapl1 1,191536251 0,000506668 0,007611832
Pkp3 1,104825926 3,56E-05 0,001109329
Arhgap32 1,084767013 8,35E-08 1,68E-05
Man2a1 1,02980095 0,0002011 0,003881589
Ces2g 1,012728291 1,73E-07 2,78E-05
Pcbd1 -1,01266118 2,90E-05 0,000954445
Ptgs1 -1,035525417 6,50E-05 0,001718979
Cideb -1,085190992 0,000261821 0,004676485
Kdm3a -1,098249847 3,89E-05 0,001171753
Elovl1 -1,101061635 0,000404124 0,006413027
Adk -1,105024856 1,53E-06 0,00012255
Mylk -1,118321309 3,81E-05 0,001161981
Pros1 -1,13322592 0,000646362 0,009106255
Spr -1,147862815 3,58E-06 0,000233416
Ciita -1,153590497 1,21E-10 2,58E-07
4921507P07Rik -1,154570617 1,34E-05 0,000573774
Egr2 -1,159479858 0,000361639 0,005940529
Susd2 -1,186784613 0,000538464 0,007968748
Eva1a -1,219646097 1,10E-06 9,55E-05
Acot7 -1,230953503 7,43E-05 0,001880742
Unc13d -1,232479494 3,67E-06 0,000235662
Crlf1 -1,275587664 0,000465018 0,007115781
Adssl1 -1,275843818 6,16E-07 6,41E-05
Car4 -1,320714106 0,000303357 0,005236842
Scarf2 -1,388910549 1,01E-06 9,17E-05
H2-Ab1 -1,470348395 1,43E-05 0,000593517
Lrrc8c -1,477330207 9,26E-09 4,15E-06
Ager -1,579816873 3,06E-06 0,000209391
H2-DMa -1,60921388 8,73E-09 4,15E-06
Lamp3 -1,6403467 7,30E-06 0,0003763
Chrnb1 -1,642160635 2,13E-07 3,18E-05
Bmp4 -1,673468291 3,84E-07 4,82E-05
Npw -1,688474342 0,000342705 0,005738839
Renbp -1,72252724 3,85E-08 9,02E-06
Cdh16 -1,748131739 6,95E-07 6,92E-05
Dpep2 -2,007282021 6,82E-07 6,86E-05
Cd74 -2,023164975 1,89E-07 2,91E-05
Fbp2 -2,054643897 8,94E-05 0,002146234
Chi3l1 -2,056055903 7,83E-05 0,001957923
Gata6 -2,104007907 9,80E-09 4,30E-06
Lgi3 -2,12757937 7,46E-07 7,34E-05
Hhex -2,28415459 2,17E-07 3,21E-05
Adam19 -2,318299424 2,37E-11 8,15E-08
Cldn18 -2,428907714 1,08E-06 9,40E-05
Itih4 -2,61812704 1,86E-07 2,91E-05
Vsig2 -2,8978702 2,07E-08 6,09E-06
Nrn1 -2,995940883 2,31E-05 0,000825158
Aif1l -3,164038231 1,66E-08 5,43E-06
Ctse -3,421681314 1,43E-05 0,000593517
Plekhb1 -1,033836655 2,36E-05 0,000833556
Ptprm -1,084496704 1,67E-06 0,000132517
Ctsh -1,135088307 0,000222835 0,004173821
St3gal5 -1,16689992 0,000713279 0,009770334
Slc34a2 -1,229963288 0,000128328 0,002793128
Slc26a9 -1,24239973 5,47E-05 0,001512401
Ahcyl2 -1,361390926 3,54E-05 0,00110697
Lpcat1 -1,441100162 8,87E-05 0,002133149
Tspan8 -1,460808859 1,76E-05 0,000690221
Ppp1r9a -2,397095416 1,30E-05 0,000562926
Napsa -2,834033514 4,24E-07 5,15E-05
Sftpc -1,013479428 3,18E-06 0,000214909
Lcp1 -1,023140496 1,54E-07 2,56E-05
Atp2a3 -1,349662184 1,26E-06 0,000106311
Plekhd1 -1,536838606 0,000382373 0,006196131
Pip5k1b -1,770073039 1,27E-06 0,000107061
Sftpb -1,959551374 6,01E-06 0,00033471
Cxcl15 -2,061399013 2,32E-05 0,000825158
Sftpa1 -2,11503717 0,00015855 0,003255014
Fbp1 -2,60215319 4,13E-06 0,000255393
Pla2g1b -2,642586558 4,02E-05 0,00119669
Ad5-CC10-Cre derived Kras;Lkb1 ASC vs Ad5-SPC-Cre derived Kras;Lkb1 papillary AC; human SCC vs AC
tumors (Kuner et al., GSE10245)
Gene LogFC P.Value Adj.P.Val
Car12 3,636862829 2,63E-09 1,88E-06
Pdpn 1,744004733 0,000156923 0,003235567
Igf2bp2 1,587802928 0,000222947 0,004173821
Gm684 1,429416585 6,12E-07 6,41E-05
Hspb1 1,420229376 4,98E-07 5,83E-05
Has3 1,261680584 6,23E-05 0,001667649
Ltb4r1 1,243028669 9,54E-07 8,82E-05
Fgfbp1 1,020884122 4,05E-05 0,001200011
Krt6b 4,064895218 2,86E-09 1,90E-06
Krt6a 2,88010548 1,11E-07 2,03E-05
Zfp750 2,586819988 1,85E-08 5,70E-06
Calml3 2,508817568 8,84E-06 0,000434838
Krt15 1,98725044 2,75E-07 3,75E-05
Sgk1 1,235556478 2,48E-06 0,000180144
Fxyd3 1,21776195 0,000465713 0,007121127
Rapgefl1 1,023115374 9,46E-07 8,78E-05
Dsg3 1,013274283 0,000186607 0,003677196
Celsr2 1,009851937 2,39E-07 3,46E-05
Krt17 6,480742841 1,23E-09 1,21E-06
Krt5 4,741898945 2,46E-10 4,61E-07
Krt14 4,729042034 1,42E-05 0,000591751
Gpr87 3,750789294 2,96E-11 8,72E-08
Clca5 3,421039565 9,55E-08 1,82E-05
Lypd3 3,091228646 3,22E-05 0,001033619
Krt16 3,038105964 4,04E-09 2,29E-06
Pkp1 2,997180129 1,01E-05 0,000477906
Vsnl1 2,656167403 1,11E-08 4,77E-06
Trp63 2,572210067 6,06E-12 3,12E-08
Snai2 2,543222344 2,73E-09 1,88E-06
Efs 2,312028751 6,14E-08 1,33E-05
P2ry1 1,814915127 3,79E-08 8,99E-06
Dapl1 1,690803978 7,50E-10 9,10E-07
Trim29 1,655666154 0,00010719 0,002449449
Fscn1 1,556296265 4,20E-06 0,000259199
Hr 1,506296829 1,47E-07 2,49E-05
2610528A11Rik 1,087798271 0,000137464 0,002927555
Dgka 1,026082285 1,31E-07 2,25E-05
Sostdc1 2,930147281 0,000660051 0,009223703
Pard6g 2,765215384 6,52E-10 8,91E-07
Bnc1 2,377164297 2,71E-09 1,88E-06
Sfn 2,251581488 3,08E-09 1,98E-06
S100a8 1,889118575 0,000116966 0,002614854
Pthlh 1,459110393 0,000165801 0,0033703
Clip4 1,409097502 0,000130502 0,002819601
Col7a1 1,329498769 3,78E-07 4,81E-05
Amotl1 1,179282851 1,05E-06 9,31E-05
Trim59 1,046473677 7,29E-05 0,001863426
Gdf15 -1,065481026 0,000247593 0,004489287
Gprc5a -1,066873106 2,18E-05 0,000792638
Errfi1 -1,232325325 7,52E-06 0,000385737
Cpm -1,251867026 0,000693469 0,009593146
Hkdc1 -2,155174339 2,36E-06 0,000174026
Plekhb1 -1,033836655 2,36E-05 0,000833556
Ptprm -1,084496704 1,67E-06 0,000132517
Ctsh -1,135088307 0,000222835 0,004173821
St3gal5 -1,16689992 0,000713279 0,009770334
Slc34a2 -1,229963288 0,000128328 0,002793128
Slc26a9 -1,24239973 5,47E-05 0,001512401
Ahcyl2 -1,361390926 3,54E-05 0,00110697
Lpcat1 -1,441100162 8,87E-05 0,002133149
Tspan8 -1,460808859 1,76E-05 0,000690221
Ppp1r9a -2,397095416 1,30E-05 0,000562926
Napsa -2,834033514 4,24E-07 5,15E-05
Cmtm8 -1,032511879 0,000238502 0,004369773
Cd55 -1,446457341 0,000102306 0,002385451
Acox2 -1,64064951 9,63E-07 8,86E-05
Ad5-CC10-Cre derived Kras;Lkb1 ASC vs Ad5-SPC-Cre derived Kras;Lkb1 papillary AC; mouse lung basal cells
vs epithelial cells (Rock et al. 2009, GSE15724)
Gene LogFC P.Value Adj.P.Val
Sncg 1,839855318 5,87E-06 0,000327761
Scin 1,674641271 2,95E-05 0,000964679
Nxn 1,57921197 9,10E-06 0,000444586
Il1r2 1,433847403 0,000233918 0,004328114
Il1b 1,410776466 2,63E-05 0,000884856
Cib2 1,286434757 1,32E-06 0,000110423
Cav1 1,279630393 9,97E-05 0,002334545
Notch1 1,26558021 7,18E-07 7,11E-05
Fads1 1,206201817 0,000263389 0,004696351
Sytl1 1,19770372 1,90E-05 0,00073062
B3gnt8 1,166292081 4,15E-07 5,09E-05
Pcdhb22 1,164517777 0,000134662 0,002894312
Dlk2 1,152847829 2,42E-06 0,000176611
Fam101b 1,106656825 3,33E-07 4,43E-05
Tacstd2 1,092475614 3,58E-05 0,001112435
Enho 1,055377066 0,000521062 0,007792835
Ptk7 1,04865216 1,71E-06 0,00013465
Def6 1,007300675 5,06E-07 5,83E-05
Sostdc1 2,930147281 0,000660051 0,009223703
Pard6g 2,765215384 6,52E-10 8,91E-07
Bnc1 2,377164297 2,71E-09 1,88E-06
Sfn 2,251581488 3,08E-09 1,98E-06
S100a8 1,889118575 0,000116966 0,002614854
Pthlh 1,459110393 0,000165801 0,0033703
Clip4 1,409097502 0,000130502 0,002819601
Col7a1 1,329498769 3,78E-07 4,81E-05
Amotl1 1,179282851 1,05E-06 9,31E-05
Trim59 1,046473677 7,29E-05 0,001863426
Krt17 6,480742841 1,23E-09 1,21E-06
Krt5 4,741898945 2,46E-10 4,61E-07
Krt14 4,729042034 1,42E-05 0,000591751
Gpr87 3,750789294 2,96E-11 8,72E-08
Clca5 3,421039565 9,55E-08 1,82E-05
Lypd3 3,091228646 3,22E-05 0,001033619
Krt16 3,038105964 4,04E-09 2,29E-06
Pkp1 2,997180129 1,01E-05 0,000477906
Vsnl1 2,656167403 1,11E-08 4,77E-06
Trp63 2,572210067 6,06E-12 3,12E-08
Snai2 2,543222344 2,73E-09 1,88E-06
Efs 2,312028751 6,14E-08 1,33E-05
P2ry1 1,814915127 3,79E-08 8,99E-06
Dapl1 1,690803978 7,50E-10 9,10E-07
Trim29 1,655666154 0,00010719 0,002449449
Fscn1 1,556296265 4,20E-06 0,000259199
Hr 1,506296829 1,47E-07 2,49E-05
2610528A11Rik 1,087798271 0,000137464 0,002927555
Dgka 1,026082285 1,31E-07 2,25E-05
Col17a1 5,025445094 8,31E-13 1,71E-08
Tmprss11g 3,612988155 1,40E-06 0,00011442
Aqp3 3,049499899 4,37E-06 0,000267141
Upk3bl 2,3645967 1,06E-05 0,000491014
Cwh43 2,255775512 3,39E-07 4,46E-05
Tpbg 2,213087982 5,11E-07 5,83E-05
Wnt10a 2,202487002 9,04E-07 8,53E-05
Lrig3 2,133480927 1,86E-09 1,59E-06
Htra1 1,9742672 5,41E-06 0,000309994
Rgs12 1,768790397 2,69E-07 3,74E-05
Evpl 1,664523823 3,18E-05 0,001024405
Apcdd1 1,564060909 3,64E-07 4,66E-05
Fbln1 1,41345374 1,76E-07 2,82E-05
Barx2 1,405121172 2,69E-07 3,74E-05
Ngfr 1,372386307 1,22E-08 4,88E-06
Cdh3 1,36896438 9,15E-09 4,15E-06
Ccdc3 1,348661482 2,38E-05 0,000836316
Kif21a 1,316708116 2,42E-05 0,000838141
Fam57a 1,305612112 3,27E-06 0,000218401
Plch2 1,298860294 6,83E-09 3,43E-06
Wnt4 1,240429909 3,14E-10 4,97E-07
Itgb4 1,225887923 1,26776E-05 0,000555194
Niacr1 1,223207012 8,65E-08 1,69E-05
Psapl1 1,191536251 0,000506668 0,007611832
Pkp3 1,104825926 3,56E-05 0,001109329
Arhgap32 1,084767013 8,35E-08 1,68E-05
Man2a1 1,02980095 0,0002011 0,003881589
Ces2g 1,012728291 1,73E-07 2,78E-05
Slc17a9 -1,034249167 1,07E-05 0,000494843
Atp6v0e2 -1,054769326 5,79E-05 0,00156945
Trim30a -1,095484355 0,0003617 0,005940529
Lgals3bp -1,109622465 8,25E-05 0,002035775
Gstk1 -1,166952407 1,92E-05 0,00073299
Sdcbp2 -1,18348163 0,000548512 0,008081441
Fam174b -1,189204298 6,26E-05 0,001672841
Plaur -1,233099763 3,57E-05 0,001109329
Tmem8 -1,270742422 4,05E-06 0,000253829
Degs2 -1,310245338 0,000549681 0,008092879
Cacna1h -1,392371714 1,48E-05 0,000607006
Hdc -1,488481365 0,000108002 0,002457095
Foxa3 -1,821006491 5,37E-06 0,000308658
Fcna -1,99503127 0,000524527 0,00782879
Tmem54 -2,004014539 6,25E-06 0,000342662
Cmtm8 -1,032511879 0,000238502 0,004369773
Cd55 -1,446457341 0,000102306 0,002385451
Acox2 -1,64064951 9,63E-07 8,86E-05
Plekhb1 -1,033836655 2,36E-05 0,000833556
St3gal5 -1,16689992 0,000713279 0,009770334
Slc34a2 -1,229963288 0,000128328 0,002793128
Ahcyl2 -1,361390926 3,54E-05 0,00110697
Ppp1r9a -2,397095416 1,30E-05 0,000562926
Sftpc -1,013479428 3,18E-06 0,000214909
Lcp1 -1,023140496 1,54E-07 2,56E-05
Atp2a3 -1,349662184 1,26E-06 0,000106311
Plekhd1 -1,536838606 0,000382373 0,006196131
Pip5k1b -1,770073039 1,27E-06 0,000107061
Sftpb -1,959551374 6,01E-06 0,00033471
Cxcl15 -2,061399013 2,32E-05 0,000825158
Sftpa1 -2,11503717 0,00015855 0,003255014
Fbp1 -2,60215319 4,13E-06 0,000255393
Pla2g1b -2,642586558 4,02E-05 0,00119669
Ad5-CC10-Cre derived Kras;Lkb1 ASC vs Ad5-SPC-Cre derived Kras;Lkb1 papillary AC; Ad5-CMV-Cre derived
Kras;Lkb1 ASC vs AC (Ji et al. 2015, GSE6135)
Gene LogFC P.Value Adj.P.Val
Wfdc1 2,432883241 1,34E-07 2,28E-05
Hspa2 1,247619569 2,68E-07 3,74E-05
Hsph1 1,243515918 5,41E-07 6,02E-05
Car12 3,636862829 2,63E-09 1,88E-06
Bnc1 2,377164297 2,71E-09 1,88E-06
Sfn 2,251581488 3,08E-09 1,98E-06
Has3 1,261680584 6,23E-05 0,001667649
Krt5 4,741898945 2,46E-10 4,61E-07
Gpr87 3,750789294 2,96E-11 8,72E-08
Lypd3 3,091228646 3,22E-05 0,001033619
Krt6a 2,88010548 1,11E-07 2,03E-05
Trp63 2,572210067 6,06E-12 3,12E-08
Krt15 1,98725044 2,75E-07 3,75E-05
Col17a1 5,025445094 8,31E-13 1,71E-08
Aqp3 3,049499899 4,37E-06 0,000267141
Aqp4 2,659834182 5,01E-05 0,001412095
Tiam1 2,256112596 2,35E-09 1,88E-06
Cyp27a1 2,068398574 1,16E-08 4,77E-06
Psapl1 1,191536251 0,000506668 0,007611832
Pkp3 1,104825926 3,56E-05 0,001109329
Ces2g 1,012728291 1,73E-07 2,78E-05
Ccl6 -1,238072525 1,56E-05 0,000629781
Hkdc1 -2,155174339 2,36E-06 0,000174026
